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Abstract 
The eukaryotic cell cycle is driven by a set of kinases called the cyclin-dependent 
kinases (CDKs). During G1, CDK2/cyclin E phosphorylates the CDK inhibitor, p27, 
leading to its ubiquitination by the SCFSkp2 complex and subsequent degradation. 
Skp2 is the substrate recognition component of the SCFSkp2 complex and has been 
found to be up-regulated in many cancers. High levels of Skp2 indicate poor 
prognosis. Its overexpression often correlates with low p27 levels. Skp2 was first 
identified in a complex with CDK2, cyclin A, Cks1 and Skp1. CDK2/cyclin A binds to 
SCFSkp2 and is required for the recruitment of p27 to the SCFSkp2 complex.  
The aims of this project were to structurally characterize the CDK2/cyclin 
A/Skp1/Skp2 complex and to identify the functional significance of the Skp2/cyclin A 
interaction. In the absence of a crystal structure, site-directed mutagenesis was used 
to identify the regions on cyclin A and Skp2 which mediate this interaction. Mutation 
of residues 244-247 of cyclin A blocked its interaction with Skp2. Mutation of this 
region did not interfere with binding to CDK2, or p27, and CDK2/cyclin A kinase 
activity did not appear to be affected. CDK2 was found not to have a role in binding 
to Skp2. 
Cyclin A binds to an extended region within the N-terminus of Skp2. Residues 
Leu32, Leu33, Ser39 and Leu41 of Skp2 have been reported to comprise the cyclin 
A binding region (Ji et al., 2006). This site was confirmed and a further two residues 
were identified as contributing to the interaction. The Skp2 N-terminal region is 
involved in binding many regulatory proteins and is heavily post-translationally 
modified. The binding of cyclin A to this sequence may therefore affect the structure 
and/or accessibility to modifying enzymes. The characterisation of these mutants has 
shown that they are potentially useful tool mutants for studying Skp2 function and 
regulation in human cell-based assays. 
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Chapter	1:	Introduction	
1.1	The	eukaryotic	cell	cycle	
1.1.1	The	eukaryotic	cell	division	cycle	
The normal cell division of somatic cells exists to renew tissues. For proliferating cells, 
cell division occurs about every 24 hours (Bernard and Herzel, 2006). The cell cycle 
is properly executed through a tightly regulated orchestration of events that allows a 
cell to grow, replicate its DNA, separate the sister chromatids and form two daughter 
cells. The division event is initiated by both intra- and extracellular signals. The 
external signalling molecules are known as mitogens. When these signals aberrantly 
trigger cell division or when the signalling pathways they initiate become constitutively 
activated this can lead to tumour development.  
One of the hallmarks of cancer is the ability of cells to proliferate uncontrollably 
(Hanahan and Weinberg, 2011). The cell cycle occurs in four main stages comprising 
two growth phases (G1 and G2 phases) separated by DNA replication (S phase) and 
mitosis (M phase). During the cell cycle, a series of checkpoints are passed before 
mitotic cell division and distribution of genetic material to the daughter cells. For 
example, in response to genotoxic stress, the cell initiates the DNA damage response 
(DDR) and delays cell cycle progression, halting the cell at the so-called checkpoints 
until the damage is repaired (Jackson and Bartek, 2009, Bartek and Lukas, 2007). 
After a cell division cycle the cell can enter into the quiescent, G0 phase. The cell can 
then either re-enter the cell cycle in response to mitogenic signals or remain in this 
quiescent stage. 
Progression through the cell cycle in higher eukaryotes is governed by a set of serine-
threonine protein kinases called the cyclin-dependent kinases (CDKs), whose levels 
and activities are tightly regulated to ensure proper progression. As the name 
suggests, CDKs require a cyclin protein for full activity (Desai et al., 1992). The cyclins 
act as regulatory subunits with the levels of these proteins changing during the cell 
cycle, as a result of increased transcriptional activity, and decreasing due to ubiquitin-
mediated proteasomal degradation (Pines, 2006, Pines, 1995, Pines, 1996, Reed, 
2003). CDKs act as the catalytic subunits catalysing a phosphorylation reaction when 
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in their active cyclin-bound form. Protein phosphorylation is a post-translational 
modification which performs an essential role in the control of cell cycle events. The 
transient nature of this modification lends itself to the timely regulation that is required 
for the cell cycle. Kinases form a large superfamily of about 600 structurally similar 
proteins, of which the CDKs make up a sub-branch of circa 20 kinases (Cao et al., 
2014). As CDKs are the master regulators of the cell cycle it is not surprising that 
dysregulation of their activity is strongly implicated in carcinogenesis. 
1.1.2	Cyclin-dependent	kinases	(CDKs)	
Protein phosphorylation is catalysed by kinases. The CDKs belong to the CMGC 
(cyclin-dependent kinase [CDK], mitogen-activated protein kinase [MAPK], glycogen 
synthase kinase [GSK3], CDC-like protein kinase [CLK]) family of protein kinases. 
The first identified CDK protein was CDK1 in Saccharomyces cerevisiae and 
Schizosaccharomyces pombe, at the time called Cdc28 or Cdc2 respectively. It was 
found that mutations to the Cdc28 gene caused the cell cycle to stop (Pines, 1993). 
The next CDK protein to be identified was CDK2, which shares 65% sequence 
homology with CDK1 (Elledge and Spottswood, 1991). Subsequently additional family 
members were cloned and classified as CDKs (Matsushime et al., 1992, Bates et al., 
1994, Meyerson et al., 1992). CDK1, CDK2, CDK4 and CDK6 have the most 
significant roles in control of the cell cycle (Figure 1.1) and  CDK3, CDK7 and CDK11 
are also required (Satyanarayana and Kaldis, 2009). CDK1 is the only essential CDK 
protein, with knockout of CDK1 leading to embryonic lethality at around embryonic 
day two (Malumbres and Barbacid, 2009, Satyanarayana and Kaldis, 2009). This 
result can be explained by the ability of CDK1 to bind all of the cell cycle cyclins (A, 
B, D and E). In the absence of other interphase CDKs such as CDK2, -4 and -6, CDK1 
can take over their role (Santamaria et al., 2007). Surprisingly, it was found that CDK2-
/- mice are viable, with the only significant defect being sterility in both male and female 
mice (Berthet et al., 2003, Ortega et al., 2003). Certain CDKs, such as CDK9 and 
CDK11, have been found to have a role in transcription and other processes, but for 
the purpose of this thesis I will focus on the cell cycle CDKs. 
CDKs are subject to regulation by phosphorylation. Full activity of CDKs is achieved 
upon phosphorylation of a conserved threonine residue within the activation segment 
also known as the T-loop, for example Thr160 in CDK2 (Gu et al., 1992). By 
comparing the structures of the non-phosphorylated and phosphorylated CDK2/cyclin 
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A structures, it was determined that a conformational change occurs upon 
phosphorylation. The T-loop moves by as much as 7 Å after phosphorylation, so that 
the phosphate group is stabilised by three arginine residues (Russo et al., 1996b). 
	
 
 
 
 
In addition to the activating phosphorylation, cell cycle CDKs are inhibited by 
phosphorylation. The importance of this event in regulating CDK1 activity at G2/M 
was recognised following the identification of Cdc25 and Wee1 as cell division cycle 
genes in S. cerevisiae and S. pombe (Aligue et al., 1997, Russell et al., 1989) Cdc25 
phosphatase and Wee1 kinase antagonistically regulate the phosphorylation status 
of CDK1 Thr14 and Tyr15 within the CDK active site. Subsequently, other members 
of the CDK family were also shown to be subject to inhibitory phosphorylation events 
within the active site. For example, CDK2 can be inactivated by phosphorylation of 
Thr14 and Tyr15 by Wee1 and Myt1, respectively, to maintain genome integrity 
(Hughes et al., 2013).  
Figure 1.1: The cell cycle is driven forward by CDK/cyclin complexes. Four 
CDKs are responsible for driving the cell cycle, CDK1, CDK2, CDK4 and CDK6. 
The levels of CDKs are fairly constant throughout the cell cycle, but the levels of 
cyclins A, B and E rise and fall at various stages of the cell cycle (Figure 1.3) leading 
to particular CDK/cyclin complexes being active at particular phases of the cell 
cycle. 
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CDK2 exhibits the classical kinase fold (Morgan, 1997), which consists of an N-
terminal lobe which primarily comprises β-strands and a C-terminal lobe which is 
primarily α- helical (Figure 1.2, (De Bondt et al., 1993)). CDKs are catalytically inactive 
on their own requiring their cognate cyclins for activity. Cyclin A binding to CDK2 alters 
the conformation of the PSTAIRE helix of CDK2, T-loop conformation and the relative 
orientation of the N- and C-terminal lobes (Jeffrey et al., 1995). The T-loop moves out 
of the active site entrance and no longer blocks the substrate binding site. Extensive 
hydrogen bonding to cyclin A induces a conformational change to the loop 
immediately preceding the PSTAIRE helix. This moves the helix into the catalytic cleft 
towards the ATP. The PSTAIRE contains Glu51 which is important for positioning the 
ATP phosphates (Jeffrey et al., 1995). 
 
Figure 1.2: The structure of CDK2. The CDK2 structure is bi-lobate with an N-
terminal lobe rich in β-sheets with a single helix, and a C-terminal lobe comprised 
predominantly of α-helices (De Bondt et al. 1993). The PSTAIRE helix of the N-
terminal lobe (in blue) contains a catalytic glutamate residue. The ATP-binding site 
lies in a cleft between the two lobes (Brown et al., 1999). 
Chapter 1: Introduction 
 
5 
 
1.1.3	Cyclins	
The levels of cyclins involved in the cell cycle oscillate throughout the cell cycle 
(Figure 1.3). Their periodic accumulation and disappearance are carefully timed for 
accurate progression through the cell cycle. Four major classes of cell-cycle 
regulating cyclins exist classified into the A-, B-, D- and E- type cyclins. Each class 
consists of a small number of closely related sequences that are not functionally 
equivalent but do exhibit redundancy. For example, CCNE1 or CCNE2 knockout mice 
are viable, but double CCNE1/CCNE2 knockout mice die at embryonic day 11.5 
(Satyanarayana and Kaldis, 2009). Cyclin A2 and B1 appear, however, to be the least 
redundant of the cyclins and knockout of these genes encoding either cyclin is 
embryonic lethal (Satyanarayana and Kaldis, 2009, Brandeis et al., 1998, Murphy et 
al., 1997). However, like the cyclins, CDKs also exhibit high levels of redundancy in 
that in the absence of the appropriate cognate partner, CDKs can be activated by 
pairing with non-cognate partners (Sherr and Roberts, 2004).  
	
 
 
The levels of cyclins A, B and E rise and fall due to changes in expression and 
degradation (Figure 1.3, (Vermeulen et al., 2003)). Cyclin D however is not expressed 
periodically, but rather is synthesised upon growth factor stimulation (Sherr, 1993). 
Cyclins exhibit diverse sequences, but all share homology in the cyclin box, which is 
Figure 1.3: Protein levels of cyclins oscillate during the cell cycle. 
Cyclin D is present throughout the cell cycle, however the other cell cycle 
cyclins are expressed and degraded periodically. 
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a region of about 100 amino acids comprising five α helices that bind to CDKs (Brown 
et al., 1995, Gibson et al., 1994). The cell cycle cyclins share the tandem cyclin box 
fold (CBF), but differ in the sequences which surround this core fold (Figure 1.4). 
Cyclins were originally named due to their concentration changes during the cell cycle 
(Evans et al., 1983), however they were later classified based on their CBF, and many 
other cyclins not involved in the cell cycle have been identified (Morgan, 2007). 
Although a large conformational change occurs in the CDK when it binds to its cyclin 
partner, the cyclin is unchanged between its free and bound states (De Bondt et al., 
1993, Brown et al., 1995, Jeffrey et al., 1995). 
	
1.1.3.1	Cyclin	A	
Cyclin A isoforms partner to both CDK1 and CDK2 during the mitotic and meiotic cell 
cycles. There are two forms of cyclin A, an embryonic and a somatic form, called 
cyclin A1 and A2 respectively. Cyclin A1 is expressed during spermatogenesis, 
whereas cyclin A2 is expressed in proliferating somatic cells (Yang et al., 1997, Liu et 
al., 1998). Targeted deletion of the cyclin A2 gene, Ccna2, in mice causes embryonic 
lethality (Murphy et al., 1997). In contrast, deletion of Ccna1 (encoding cyclin A1) 
produces a sterile male mouse due to a block of spermatogenesis before the first 
Figure 1.4: Phylogenetic tree of cell cycle cyclins. Principle structural domains 
are shown. Figure is adapted from Malumbres and Barbacid (2005). 
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meiotic division, whereas female mice are phenotypically normal (Liu et al., 1998). 
For the purpose of this thesis cyclin A will be used to refer to cyclin A2.  
Cyclin A levels are mainly controlled at the transcriptional level. Cyclin A mRNA 
accumulates during S-phase and declines at mitosis (Evans et al., 1983). The protein 
is required at two points in the cell cycle: for the initiation of DNA replication, and 
hence, the successful completion of S-phase (Girard et al., 1991) and for the 
completion of mitosis, respectively (Pagano et al., 1992, Walker and Maller, 1991). 
The role of E2F transcription factors are well characterised in the regulation of cyclin 
A transcription. Reporter gene assays have revealed that mutation of the cell-cycle-
responsive element (CCRE) or cell-cycle-dependent element (CDE) of the cyclin A 
gene, located at chromosome 4p27, results in deregulation of the gene in G0/G1 (Huet 
et al., 1996). This observation led to the hypothesis that the CCRE/CDE region is a 
repressor binding site (Huet et al., 1996, Schulze et al., 1995).  It was subsequently 
found that this region contains an E2F-binding site (Schulze et al., 1995). E2F is a 
transcription factor family which are involved in transactivation of several genes 
whose products are involved in cell cycle regulation or DNA replication, of which some 
are transcriptional activators and some are transcriptional repressors. Binding of p107 
to E2F at the cyclin A promoter represses transcription (Devoto et al., 1992). Cyclins 
synthesised during G1 can stimulate the expression of cyclin A. CDK2/cyclin E can 
directly bind to E2F/p107 complexes and activate transcription of cyclin A (Zerfass-
Thome et al., 1997). Similarly, cyclin D can activate cyclin A transcription (Schulze et 
al., 1995). Cyclin A can interact with E2F and inhibit its own expression by 
CDK2/cyclin A-mediated phosphorylation of E2F (Krek et al., 1995, Xu et al., 1994) 
completing a negative feedback loop to limit cyclin A expression. 
The structure of CDK2/cyclin A was solved in 1995 (Jeffrey et al., 1995), shortly 
followed by the bovine cyclin A structure (Brown et al., 1995). This CDK2/cyclin A 
structure does not include the N-terminal region of cyclin A, but does include residues 
173-432 that encode the CBF. The N-terminal region is predicted to be unstructured 
but does contain sequence elements that regulate cyclin A activity that include sites 
of post-translational modification and destruction boxes (D-boxes) that are recognised 
by the anaphase-promoting complex/cyclosome (APC/C) and are required for cyclin 
destruction (Glotzer et al., 1991).  
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The CBF is common to members of the cyclin family, and includes the CDK2 binding 
site (Figure 1.5) (Jeffrey et al., 1995). The structure revealed two sequential 
subdomains of 90 amino acids with identical folds (residues 208-306 and 310-397). 
This fold comprises a compact five-helical domain termed the cyclin box. Although 
the two domains have very similar structure, their sequence homology is only 12% 
(Jeffrey et al., 1995). The CDK2/cyclin A interface consists of many interlocking CDK2 
and cyclin A elements, including the conserved PSTAIRE motif of CDK2 (Noble et al., 
1997).  
A 
 
B 
 
 
 
 
 
Figure 1.5: Human cyclin A2 structural domains. A) The structure of cyclin A 
(173-432) is shown. The N-terminal 172 amino acids have not been structurally 
characterised. B) Schematic of cyclin A. The positions of the D-box and CBFs 
are shown. The numbers represent amino acid positions. Adapted from (Yam et 
al., 2002). 
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The role of cyclin A within the CDK2/cyclin A complex is not simply activation of CDK2. 
Cyclin A also has a role in substrate recruitment through a hydrophobic patch which 
binds to substrates via their RXL (arginine, any amino acid, leucine) motif (Adams et 
al., 1996). Interestingly, the CDK2/cyclin A complex has a wide range of substrates, 
whereas the CDK2/cyclin E complex has fewer substrates. The two complexes share 
only a small subset of substrates such as Rb and p27 (Sarcevic et al., 1997). This 
shows that the cyclin plays a significant role in substrate selection. 
It remains poorly understood how specificity for substrates is determined by the cyclin. 
It might be argued that cyclins are interchangeable and that their substrate specificity 
arises from their accumulation rather than binding capabilities (Murray, 2004). 
However, there are some differences in substrate specificity between the cyclins as 
there are differences in cell cycle events when one cyclin is substituted for another by 
expression at an adjusted time (Cross et al., 1999).  
1.1.4	CDK	activation	by	cyclin	binding	
CDK2 activation has been extensively studied at the structural level. Binding of cyclin 
A induces structural changes in the activation loop and the ATP-binding site causing 
partial activation of CDK2 (Jeffrey et al., 1995). Phosphorylation of Thr160 of CDK2 
by CDK-activating kinase (CAK (composed of CDK7, cyclin H and Mat1 in most 
eukaryotes)) leads to its full activation (Russo et al., 1996b, Stevenson et al., 2002). 
These events were believed at the time to represent a general mechanism of 
activation for all CDKs. However, many examples of alternate mechanisms of CDK 
activation and regulation have emerged since the CDK2/cyclin A structure was 
published. The discovery of a CDK-binding protein which is not a cyclin, 
Speedy/Spy1, showed that Thr160 phosphorylation is not always required for full 
activation of CDK2 as Spy1 can fully activate CDK2 upon binding (Cheng et al., 2005).  
Two CDK4/cyclin D structures were published in 2009 and revealed the differences 
between cyclin D binding to CDK4, and cyclin A binding to CDK2 (Figure 1.6) (Takaki 
et al., 2009, Day et al., 2009). Cyclin D binds in a more elevated position with a much 
smaller interface between CDK4 and cyclin D (Figure 1.6B) and binding is not 
sufficient to drive CDK4 into an active conformation. Even when phosphorylated and 
bound to cyclin D, the CDK4 active site remains in a conformation which appears to 
be unable to support catalysis. It is thought that activation occurs when 
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phosphorylated CDK4/cyclin D forms a Michaelis complex with ATP and protein 
substrates (Takaki et al., 2009). Determination of the CDK9/cyclin T1 (positive 
transcription elongation factor b (P-TEFb)) structure also revealed a buried interface 
that is smaller further than that of CDK4/cyclin D (Baumli et al., 2008). In contrast, the 
structure of CDK1/cyclin B (Figure 1.6C) is most reminiscent of that of CDK2/cyclin A 
but again has a slightly enlarged cleft between the CDK1 and cyclin B subunits that 
suggests it might be subject to additional regulation in this region (Brown et al., 2015). 
Taken together, the structures of various CDK/cyclin complexes suggest that though 
there are many common elements to CDK activation by cyclin binding, important 
differences exist. 
A 
 
B 
 
C 
 
 CDK2/cyclin A  CDK4/cyclin D3  CDK1/cyclin B/Cks1 
 
Positive and negative regulators of P-TEFb such as human immunodeficiency virus 
(HIV1) transactivator of transcription (Tat) protein, hexamethylene bisacetamide-
inducible protein 1 (HEXIM1) and BRD4 were found to bind to a site on the C-terminal 
CBF of cyclin T1 (Baumli et al., 2008, Bigalke et al., 2011, Tahirov et al., 2010, 
Barboric et al., 2007). Adjacent to this binding site is the binding site of AFF4, a key 
component of the super elongation complex (Gu et al., 2014). This suggests this 
cyclin T1 site is somewhat analogous to the N-terminal CBF recruitment site of cyclins 
A, B, D and E with exceptions being that a specific binding motif is not required and 
Figure 1.6: Comparison of CDK2/cyclin A structure with that of CDK4/cyclin 
D3 and CDK1/cyclin B/Cks1. CDK2/cyclin A (A), CDK4/cyclin D3 (B) and 
CDK1/cyclin B/Cks1 (C). The CDK is coloured in white (N-terminal lobe) and coral 
(C-terminal lobe) with the C-helix and activation segment coloured red and cyan, 
respectively. The cyclin is coloured lawn green and Cks1 in ice-blue. 
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the binding surface is extended with some interactions being mutually exclusive and 
others being cooperative. 
CDK2/cyclin A regulators bind to the cyclin recruitment site which recognises RXL 
motifs. No other sites on cyclin A involved in binding regulators have been identified, 
and therefore the cyclin A and cyclin T1 regulatory/substrate binding site appear to 
be very different. With further investigation, however, the cyclin A recruitment site 
could be identified as being a larger area of the cyclin A surface than identified thus 
far with other substrates and regulators not requiring an RXL motif. For example, S-
phase kinase-associated protein 2 (Skp2) has been identified as a cyclin A-binding 
protein, but does not have an RXL motif and therefore is expected to not bind to the 
cyclin recruitment site (Ji et al., 2006). 
The cyclin can confer inhibitor specificity as well as substrate specificity. Interestingly, 
it was determined that p27 and p21 act as inhibitors of CDK1- and CDK2/cyclin 
complexes, but they act as activators for CDK4 and CDK6/cyclin D complexes (Sherr 
and Roberts, 1999, Soos et al., 1996, Blain et al., 1997, LaBaer et al., 1997). 
However, recently it was reported that p21 and p27 exert their major effects on 
CDK4/6 as inhibitors, rather than as activators (Cerqueira et al., 2014). It is believed 
that CDK/cyclin D complexes are able to sequester p21 and p27 thereby facilitating 
CDK2/cyclin E activation, and allowing the cell cycle to continue to move forward 
(Sherr, 2000). 
1.1.5	Initiation	and	control	of	the	G1/S	transition	
Two major events occur in G1 phase, the restriction point and the G1 checkpoint. The 
restriction point is the point at which the cell is committed to a new division cycle 
(Pardee, 1989). In a normal cell, growth factors are required to progress the cell into 
G1 phase. After the restriction point, no further growth factor stimulation is required 
(Zetterberg et al., 1995, Johnson and Skotheim, 2013). The G1 checkpoint is the point 
at which the cell ‘checks’ for DNA damage before beginning DNA synthesis (Bartek 
and Lukas, 2001).  
A new round of the cell cycle occurs upon reception of an external mitogenic signal 
which starts a signalling cascade with propagation of the signal until it has reached 
the effector molecule. Effector molecules include transcription factors which are 
involved in inducing the expression of cyclin D (Shichiri et al., 1993, Sherr, 1995). 
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Cyclin D binds to and activates CDK4 and CDK6 and these complexes localise to the 
nucleus due to the nuclear localisation signal (NLS) on cyclin D. In the nucleus CDK4/- 
and CDK6/cyclin D then mono-phosphorylate retinoblastoma (Rb) (Narasimha et al., 
2014). Before phosphorylation by CDKs, Rb binds strongly to E2F transcription factor 
family members and acts as an inhibitor preventing them from inducing the expression 
of their target genes (Helin et al., 1992, Dyson, 1998). Phosphorylation by CDK4- and 
CDK6/cyclin D causes a large change in the molecular shape and dimensions of Rb 
(Lamber et al., 2013) and leads to its dissociation from E2F, releasing it from 
repression and switching on transcription of target genes such as cyclin E (Figure 
1.7). As the cell progresses through G1, Rb is hyper-phosphorylated by CDK2/cyclin 
E and this is required for full inactivation of Rb (Harbour et al., 1999, Zarkowska and 
Mittnacht, 1997). There are 16 potential CDK phosphorylation sites on Rb (Martinsson 
et al., 2005).The release of E2F from repression by Rb and the expression of cyclin 
E leads to a positive feedback loop resulting in fully active E2F target genes and 
expression of proteins required for synthesis and replication (Harbour et al., 1999). 
	
 
 
 
Figure 1.7: Schematic of G1 progression by Rb phosphorylation. Mitogenic 
signalling activate CDK4/- and CDK6/cyclin D complexes which then 
phosphorylate Rb. As the cell moves through G1 phase, CDK2/cyclin E complexes 
become active and also phosphorylate Rb. In a hyperphosphorylated state, Rb no 
longer binds to E2F which is then released from repression of its transcriptional 
activity.  
Chapter 1: Introduction 
 
13 
 
Several proteins have been hypothesised to be responsible for transition to post 
restriction point, referred to at times as the ‘R-factor’ (Blagosklonny and Pardee, 2002, 
Foster et al., 2010). Phosphorylation of Rb was also thought to be the key event 
causing the restriction point to be overcome (Weinberg, 1995). Cyclin D is also 
postulated to be the R-factor since it acts as a readout of growth factor stimulation 
(Blagosklonny and Pardee, 2002). Therefore, perhaps it is the integrity of the whole 
signalling system that is required for passing through the restriction point rather than 
any one factor alone. 
If there is DNA damage at the G1 checkpoint, the cell triggers the DNA damage 
response (DDR) in an attempt to repair the damage. When the damage is detected, 
there is a delay in cell cycle progression brought about by the activation of p53 
(Kuerbitz et al., 1992, Kastan et al., 1991, Sakaguchi et al., 1998). If the damage is 
excessive, the cell undergoes apoptosis (Levine, 1997, Evan and Littlewood, 1998). 
DNA damage can occur due to errors in DNA replication and/or genotoxic damage 
caused by reactive metabolic toxins or by exogenous radiation such as ultraviolet 
light. Two protein kinases, ataxia-telangiectasia mutated (ATM) and ataxia-
telangiectasia (ATR) are recruited to DNA upon damage. ATM is recruited to DNA 
double-strand breaks by the Mre11-Rad50-Nbs1 (MRN) complex (Lee and Paull, 
2005). ATR is recruited to DNA single-strand breaks via replication protein A (RPA) 
(Zou and Elledge, 2003). ATM and ATR initiate a signal transduction pathway 
involving as many as hundreds of proteins involved in the DDR (Matsuoka et al., 
2007). When these pathways are defective, cancers can develop. For example, the 
BRCA1 and BRCA2 genes which encode proteins involved in the repair of double 
strand breaks through homologous recombination, are the most prevalent mutations 
linked to hereditary breast and ovarian cancer (Fackenthal and Olopade, 2007, 
Moynahan and Jasin, 2010). Mutation of p53 is another common occurrence in many 
cancers as p53 is involved in determining whether or not the cell will undergo cell 
cycle arrest or apoptosis after DNA damage (Nigro et al., 1989, Riley et al., 2008).  
1.1.6	 Control	 of	 the	 cell	 cycle	 through	 ubiquitin-mediated	 proteasomal	
degradation	
Cell cycle transitions are often actioned by ubiquitin-mediated degradation of cell 
cycle regulators. Proteolysis is particularly advantageous due to its irreversibility, thus 
allowing for directionality. The timing of cell cycle events is co-ordinated by the levels 
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of various cyclins. Certain cyclins and proteins that regulate CDK/cyclin complexes 
are subject to ubiquitin-mediated degradation (Teixeira and Reed, 2013, Sudakin et 
al., 1995). Ubiquitination is the process by which one or several ubiquitin molecules 
are covalently attached to lysine residues of a protein as a post-translational 
modification and this can act to target the protein to the 26S proteasome for 
degradation (Chau et al., 1989, Hochstrasser, 1995).  
Ubiquitin chains can be linked through different lysine residues of ubiquitin, or 
methionine 1, and the nature of the linking determines the response to modification. 
The residues of ubiquitin that can be used to link to another ubiquitin molecule are 
Met1, Lys6, Lys11, Lys27, Lys29, Lys33, Lys48 and Lys63 (Komander and Rape, 
2012). The linkage type defines the chain conformation, and these chain types can 
then be specifically recognised. For example, Lys48-linked ubiquitin chains adopt a 
compact conformation, whereas Lys63-linked ubiquitin chains form an open 
conformation resembling beads on a string (Tenno et al., 2004, Varadan et al., 2004). 
Lys48-linked chains lead to proteolysis of the ubiquitinated protein; the polyubiquitin 
chain is recognised by the ATPase subunit of the proteasome (Lam et al., 2002, Dikic 
et al., 2009). Other ubiquitin linkages lead to a range of molecular signals in the cell 
(Ikeda and Dikic, 2008). Similar to the process of phosphorylation, ubiquitination is 
reversible, and the removal of ubiquitin chains is carried out by specific de-
ubiquitinating enzymes (DUBs; (Hochstrasser, 1995, Komander et al., 2009)). 
The ubiquitin-proteasome pathway consists of two distinct stages. The first is the 
covalent attachment of ubiquitin to a protein, and the second is the degradation of the 
ubiquitinated protein by the 26S proteasome (Figure 1.8). The first stage is mediated 
by at least three enzymes. First, ubiquitin is transferred to an E1 ubiquitin-activating 
enzyme in an ATP-dependent manner. This activated ubiquitin is then transferred to 
an E2 ubiquitin-conjugating enzyme. Finally the ubiquitin is conjugated to the 
substrate protein by an E3 ubiquitin-ligase (Hershko, 1983, Hershko, 2005). The E3 
ubiquitin ligase confers substrate specificity.  Multiple ubiquitin molecules can be 
added, leading to the formation of a polyubiquitin chain, which in the case of Lys48-
linked ubiquitin chains and possibly other linkages, is recognised by the 26S 
proteasome (Finley, 2009). The protein is then destroyed in an ATP-dependent 
manner.  
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In humans, there are two E1 proteins, 38 E2 proteins and over 600 E3 ubiquitin 
ligases (Ye and Rape, 2009). No evidence links the E1 enzymes to cancer, and there 
have been few reports of E2 dysregulation in cancer (Okamoto et al., 2003). E3 
enzymes, on the other hand, are widely reported to be deregulated in cancer 
(Nakayama and Nakayama, 2006) as are the deubiquitinating enzymes (DUBs) that 
selectively remove ubiquitin moieties (Hussain et al., 2009).  
E3 ubiquitin ligases are grouped into one of three classes based on their conserved 
structural domains and the mechanism by which the ubiquitin is transferred from the 
E2. The Really Interesting New Gene (RING) family catalyses the transfer of ubiquitin 
from the E2 onto a lysine residue of the substrate (Deshaies and Joazeiro, 2009). 
Whereas, the homology to E6AP C-terminus (HECT) and RING-between-RING 
(RBR) family of E3s play a more direct role in catalysis of ubiquitin transfer by forming 
a catalytic thioester intermediate between an active site cysteine and the C-terminus 
of the ubiquitin before the ubiquitin is transferred onto the substrate (Berndsen and 
Wolberger, 2014).  
 
 
 
 
 
Figure 1.8: Schematic of the ubiquitin-proteasome cascade. Three 
enzymes are required for ubiquitination of protein substrates, an E1 ubiquitin-
activating enzyme, an E2 ubiquitin-conjugating enzyme and an E3 ubiquitin 
ligase. Shown here is the mechanism of transfer used by the RING family of 
ubiquitin ligases. Lys48-linked ubiquitin chains are recognised by the 26S 
proteasome and the substrate is degraded. 
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The levels of cell cycle regulators are controlled through ubiquitination by two key E3 
ubiquitin ligases, the Skp1/Cul1/F-box (SCF) and anaphase promoting complex/ 
cyclosome (APC/C) complexes. SCF complexes belong to the RING-type E3 ubiquitin 
ligase family (Joazeiro and Weissman, 2000). Each SCF complex includes an F-box 
protein, a cullin subunit, an adaptor protein which bridges the cullin and F-box protein 
and a zinc finger RING protein. F-box proteins share a conserved F-box region which 
is required for binding to the adaptor protein Skp1 (Schulman et al., 2000). In humans 
there are 69 known F-box proteins (Jin et al., 2004). These F- box proteins (FBPs) 
can be classified into three classes: those with WD40 repeats (FBXWs), those with 
leucine rich repeats (FBXLs) and those with diverse domains (FBXOs) (Frescas and 
Pagano, 2008). Many FBPs have been reported to require phosphorylation of a 
substrate before binding can occur (Ganoth et al., 2001, Orlicky et al., 2003). The 
extent of phosphorylation has been found to differ between substrates. Cyclin E is 
required to be phosphorylated at multiple sites for recognition by the Fbw7 complex 
(Hao et al., 2007). In contrast, p27 requires mono-phosphorylation for recognition by 
the SCFSkp2 complex (Hao et al., 2005, Ganoth et al., 2001). Dimerisation of the FBP 
has also been reported for Fbw7 for the ubiquitination of cyclin E (Welcker et al., 
2013). The requirement of an accessory protein for ubiquitination of one and possibly 
more substrate(s) has been reported for the FBXL, Skp2 (Ganoth et al., 2001, Spruck 
et al., 2001) The difference in binding requirements might be due to the FBP needing 
to bind many biologically diverse proteins thus dimerisation, varying levels of 
phosphorylation and accessory proteins may facilitate the vast amount of substrates 
required to bind. 
The SCF and APC/C complexes control the proteolysis of many key regulators of the 
cell cycle such as the cyclins and CDK inhibitors. It is believed that the SCF and 
APC/C complexes play a large role in cancer progression (Nakayama and Nakayama, 
2006), however only the dysregulated activity of some of the substrate recognition 
subunits has been shown to result in tumourigenesis. 
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1.2	The	SCF	complex	
1.2.1	The	SCFSkp2	ubiquitin	ligase	
SCF complexes are involved in the degradation of hundreds of proteins. SCF 
substrate specificity is conferred by F-box proteins which are the variable units. These 
proteins share an F-box domain which mediates binding to Skp1 (Figure 1.9). The 
name F-box comes from the first protein identified as having this domain; cyclin F (Bai 
et al., 1996). There are 69 F-box proteins, of which only three (Skp2, β-TrCP and 
Fbxw7) have been extensively studied due to their roles in regulating the activities of 
tumour suppressor and activator proteins that regulate cancer progression (Skaar and 
Pagano, 2009, Jia and Sun, 2011).  
 
 
 
 
Many Skp2 targets, such as E2F1, do not accumulate in Skp2 knockout mice 
suggesting that there is redundancy in the ubiquitination of these proteins (Nakayama 
and Nakayama, 2006). Levels of p27, however, do increase in Skp2 -/- mouse 
embryonic fibroblasts (MEFs) and the Skp2 knockout phenotype can be rescued by 
deletion of p27, showing that the Skp2/p27 axis is non-redundant and p27 is a key 
substrate of Skp2 in vivo (Nakayama et al., 2000, Nakayama et al., 2004). Skp2 
knockout mice display reduced organ size and markedly larger, polyploid nuclei 
(Nakayama et al., 2004). 
Figure 1.9: Functional domains of Skp2. The N-terminus of Skp2 is disordered 
and contains multiple binding sites including the Cdh1 binding site, as well as 
phosphorylation sites and an NLS.  
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1.2.2	SCFSkp2	substrates	
There are many targets of the SCFSkp2 complex including p21 (Bornstein et al., 2003), 
p27 (Tsvetkov et al., 1999), p57 (Kamura et al., 2003), p130 (Tedesco et al., 2002), 
cyclin E (Nakayama et al., 2004) and E2F1 (Marti et al., 1999). p21 was the first CDK 
inhibitor (CKI) to be discovered, and is a universal inhibitor of CDKs (Xiong et al., 
1993a). p130 is a member of the retinoblastoma family of proteins, also known as 
pocket proteins (Mulligan and Jacks, 1998), which associate with and inhibit the E2F 
family of transcription factors. Like p27, p130 can also inhibit CDK2/cyclin E and 
CDK2/cyclin A complexes, and p130 is also down-regulated at the G1-S boundary 
(Bhattacharya et al., 2003). Cyclin E is ubiquitinated by SCFSkp2 during late G1 and S 
phases of the cell cycle. Binding to CDK2 was found to protect cyclin E from 
ubiquitination by SCFSkp2 (Clurman et al., 1996, Nakayama et al., 2000). The reason 
for this is unclear, however it could function to ensure prompt switching of CDK2/cyclin 
E complexes for CDK2/cyclin A complexes as cyclin A levels rise toward the end of 
G1-phase. Auto-phosphorylation of cyclin E by CDK2/cyclin E on Thr380 is required 
for recognition by the SCFSkp2 complex (Yeh et al., 2001).  
1.2.3	The	SCFSkp2	accessory	factor,	Cks1	
Cks1 was originally identified in 1986 in fission yeast through a genetic screen to 
identify multicopy suppressors of a Cdc2 temperature-sensitive mutation (Hayles et 
al., 1986). It was subsequently shown to be an essential gene producing a mitotic 
arrest in S. pombe cells (Hadwiger et al., 1989). The human homologue was identified 
in 1987 in complex with CDK1 (Draetta et al., 1987, Lee and Nurse, 1987). Cks1 is a 
member of the Cdc kinase subunit (Cks)/ suppressor of Cdc 1 (Suc1) family of small 
proteins which interact with CDKs. The structure of Cks1 bound to CDK2 was 
published in 1996 where its location bound to the CDK2 C-terminal domain suggested 
that it might be in a position to increase CDK2 activity towards phosphorylated 
substrates through phospho-amino acid binding to its anion-binding pocket (Bourne 
et al., 1996). Cks1 was then identified as an essential phosphomotif-binding 
component of the SCFSkp2 complex for degradation of p27. Together with Skp2 it 
forms the substrate recognition site that binds to the phosphorylated Thr187 of p27 
and mediates the majority of the interaction of the SCFSkp2 complex with p27 (Ganoth 
et al., 2001). p57 and p21 have been shown to be ubiquitinated in vitro by the SCFSkp2-
Cks1 complex (Bornstein et al., 2003, Kamura et al., 2003). This role of Cks1 in SCF-
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mediated ubiquitination is believed to be specific to Skp2 as no other F-box proteins 
have been found to bind to Cks1 (Hao et al., 2005). 
Mammalian cells contain two Cks paralogues, Cks1 and Cks2 sharing 80% sequence 
identity (Figure 1.10). Cks1 and Cks2 both contain a four-stranded β-sheet surface, 
which is involved in binding CDKs. They also both have an anion-binding site which 
can bind to phosphate, sulphate or acidic residues (Arvai et al., 1995, Parge et al., 
1993). It was initially surprising when it was found that Cks2 cannot substitute for 
Cks1 in the ubiquitination of p27 (Ganoth et al., 2001, Spruck et al., 2001), an 
observation explained by the finding that Skp2 binds to Cks1 but not Cks2 (Ganoth et 
al., 2001, Spruck et al., 2001). However, both Cks1 and Cks2 bind to CDK2 (Bourne 
et al., 1996) and it was therefore proposed that the binding sites of Skp2 and CDK2 
on Cks1 are mutually exclusive. When the structure of Cks1 bound to Skp2 was 
published (Hao et al., 2005), it was indeed shown that these sites do not in fact overlap 
and that the Cks1/CDK2 interaction could remain intact while Cks1 is bound to the 
SCFSkp2 complex (Hao et al., 2005). The Pagano and Hershko groups used site-
directed mutagenesis to confirm where Skp2, CDK2 and p27 bind on the Cks1 surface 
and subsequently demonstrated using these mutant proteins that all three interactions 
are required for Cks1 to promote p27 ubiquitination (Sitry et al., 2002).  
 
Until recently, the major roles of Cks1 were thought to be the control of cell cycle 
progression and facilitating the degradation of p27. However, emerging evidence 
suggest Cks1 also plays a role in growth signalling pathways, apoptosis and the DNA 
Figure 1.10: Sequence alignment of Cks1 and Cks2. Sequence homology 
is high, but despite this, only Cks1 binds to Skp2. Clustal W was used for 
sequence alignment (Larkin et al., 2007). An asterisk indicates positions that 
are fully conserved. A colon indicates conservation between groups of strongly 
similar properties, scoring >0.5 in the Gonnet PAM 250 matrix. A full stop 
indicates conservation between groups of weakly similar properties, scoring 
=<0.5 in the Gonnet PAM 250 matrix. 
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damage response. A few studies have suggested a role for Cks1 in MAPK, JAK-STAT 
and NF-κB pathways. The role of Cks1 in these signalling pathways appears to be 
independent of Skp2 and p27 (Shi et al., 2010). The DNA repair pathway involves 
inactivation of CDK2 by degradation of its activating phosphatase, Cdc25A. Cks1 
binding to CDK2 can override Tyr15 phosphorylation of CDK2 activating it (Liberal et 
al., 2012). Therefore Cks1 may contribute to oncogenesis following aberrant 
execution of DNA repair.  
Similar to the Skp2 knockout mice, Cks1-/- mice are smaller than wild type (WT) 
littermates and have increased levels of p27 and cyclin E (Spruck et al., 2001). This 
accumulation of p27 occurs despite phosphorylation of Thr187, showing that Cks1 is 
required for p27 binding to the SCFSkp2 complex. Parallel experiments showed that 
Cks1 is required for the in vitro ubiquitination of p27 (Ganoth et al. 2001). Cells derived 
from Cks1-/- mice proliferate slowly probably due to the increase in p27 levels (Spruck 
et al., 2001). Similarly, Cks2-/- mice are viable with no major defects apart from 
sterility. However, Cks1 and Cks2 double knockout mice are not viable indicating that 
they have a redundant function (Spruck et al., 2003, Martinsson-Ahlzen et al., 2008).  
Silencing of Cks1 and Cks2 in MEFs leads to cell cycle arrest in G2, replication and 
polyploidy, signifying their essential role in recruiting substrates to CDK1/cyclin B 
during mitosis (Martinsson-Ahlzen et al., 2008).  
1.3	The	APC/C	
The APC/C is a high molecular weight complex of 1.2 MDa composed of 13 subunits 
(Schreiber et al., 2011), which has specific degradative activity for cell cycle regulatory 
proteins (Chang et al., 2014). Substrate recognition by the APC/C is mediated by 
substrate binding to one of two co-activator proteins, Cdc20 or Cdh1 (also known as 
fizzy and fizzy-related 1, respectively). In contrast to the way in which FBPs commonly 
recognise phosphodegron motifs, APC/C ubiquitin ligases recognise specific degron 
sequences. Substrates that are targeted to the APC/C for ubiquitination encode a 
destruction box (D-box), the canonical sequence of which is RXXL (Glotzer et al., 
1991, Pfleger and Kirschner, 2000). Most substrates also have a conserved KEN 
(lysine, glutamate, asparagine) box motif (Chan et al., 2013, Pfleger and Kirschner, 
2000). Other motifs that are less well conserved motifs are the A box and the GEN 
box (Littlepage and Ruderman, 2002, Castro et al., 2003). These motifs are 
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degenerate and the presence of one or more motifs varies from substrate to substrate 
(Pines, 2011). APC/C substrates include mitotic cyclins (cyclin A and B), mitotic 
kinases and their regulators (Aurora A, survivin, Plk1); a protein involved in 
coordination of anaphase (securin); proteins involved in replication (such as geminin); 
and proteins involved in ubiquitin-mediated degradation (such as Skp2) (García-
Higuera et al., 2008). Many of the substrates of the APC/C complex are 
overexpressed in cancer and are associated with poor prognosis. It is unsurprising 
therefore that Cdh1+/- mice develop a range of tumours in later life including tumours 
of the lungs, liver, kidneys, testes and sebaceous gland (García-Higuera et al., 2008). 
There is a multitude of interplay between the APC/C and its substrates. For example, 
the APC/CCdh1 degrades Cdc20 ensuring that only Cdh1 is active during this period. 
Additionally, the APC/C is activated by CDK1/cyclin B and cyclin B is degraded by the 
APC/CCdh1 complex therefore ensuring that once cyclin B levels reach a certain point, 
cyclin B undergoes proteolysis (Harper et al., 2002). CDK2 is involved in the removal 
of Cdh1 from the APC/C complex through phosphorylation, and CDK2 is involved in 
protecting Skp2 from degradation through phosphorylation of Skp2 (Fukushima et al., 
2013, Yam et al., 1999, Rodier et al., 2008). There is also much crosstalk between 
the APC/C and SCF complexes. The SCF scaffold with the F-box substrate receptor 
β-TrCP is responsible for ubiquitination of Cdh1 leading to its degradation and the 
APC/CCdh1 complex is responsible for degradation of Skp2 (Fukushima et al., 2013). 
Use of mouse genetic models have shown that Cdh1 functions as a haploinsufficient 
tumour suppressor. Complete inactivation of Cdh1 leads to embryonic lethality due to 
placental defects. Knockout of Cdh1 in MEFs causes defects in proliferation and 
accumulation of chromosomal aberrations (García-Higuera et al., 2008). Cdh1 is also 
involved in the degradation of many other cell cycle regulators such as cyclin A, cyclin 
B and Cdc6 (cell division cycle 6) and therefore the detrimental effect of Cdh1 loss on 
cells is not only due to dysregulation of Skp2 (García-Higuera et al., 2008). Cdh1 is 
required to keep Skp2 levels, and other substrate levels, in check during G1 phase in 
order to control for proper G1/S transition (Figure 1.11) as Cdh1 ablation not only 
accelerates S-phase entry, but it also lowers the requirement for cyclin E1 for 
progression through G1 phase (Yuan et al., 2014). The APC/C is regulated by early 
mitotic inhibitor 1 (Emi1), which binds to the substrate binding regions of Cdh1 and 
Cdc20 blocking substrate interaction (Miller et al., 2006). 
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1.4	Skp2	gene	expression	
The Skp2 gene is found on chromosome 5p13. The expression of Skp2 changes 
periodically throughout the cell cycle, however, it is believed that Skp2 protein levels 
are mainly determined by the rate of Skp2 degradation (Bashir et al., 2004, Wei et al., 
2004). Skp2 expression is regulated by multiple transcription factors. These include 
MYC, FOXO3a, E2F1 and many others (Bretones et al., 2011, Wu et al., 2013, Zhang 
and Wang, 2006, Schneider et al., 2006). Skp2 expression increases at the mRNA 
level in human myeloid leukaemia K562 cells with conditional c-Myc expression. c-
Myc binds to the E-box region of the Skp2 promoter (Figure 1.13) and c-Myc-induced 
Skp2 expression leads to reduced p27 levels, demonstrating another mechanism for 
Figure 1.11: Cell cycle transitions are controlled in part by ubiquitin-
mediated degradation. During early G1 phase, the APC/C Cdh1 complex 
is active leading to degradation of Skp2. During mid and late G1, Cdh1 
becomes inactive and levels of Skp2 rise leading to degradation of p21 and 
p27 allowing the cell to progress through to S phase. Skp2 remains active 
during S- and G2-phases.  
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c-Myc-dependent transformation (Bretones et al., 2011). Another member of the Myc 
family of transcription factors, MYCN was also found to be a positive regulator of Skp2 
expression (Evans et al., 2015). MYCN amplification is strongly associated with 
advanced-stage aggressive neuroblastoma and the relationship of MYCN with Skp2 
has been suggested as a likely oncogenic pathway leading to the observed correlation 
with advanced disease (Bell et al., 2007, Westermann et al., 2007). 
In 2012, Wu and colleagues identified FOXO3a as a negative regulator of the Skp2 
gene (Figure 1.13) (Wu et al., 2013). Overexpression of FOXO3a causes cell cycle 
arrest and apoptosis (Dansen and Burgering, 2008), and loss of FOXO3a expression 
or cytoplasmic relocalisation has been reported for many human cancers (Yang and 
Hung, 2009). Interestingly, Wu and colleagues have found that FOXO3a also interacts 
directly with the SCF complex and inhibits its ubiquitin ligase activity. Further studies 
will be required to investigate the mechanism by which FOXO3a is inhibiting the 
SCFSkp2 complex. 
E2F1 is another key driver of Skp2 expression (Figure 1.12 and 1.13) (Zhang and 
Wang, 2006). CDK2/cyclin E activates E2F1 indirectly through inactivation of Rb, 
Skp2 is therefore able to positively affect its own expression through promotion of the 
degradation of the CDK2/cyclin E inhibitor, p27 (Figure 1.12). Shortly after the 
discovery of E2F1 as a key inducer of Skp2 expression, Yung and co-workers 
investigated whether Skp2 creates an autoinduction loop resulting in high levels of 
Skp2, low p27 levels and inactivated Rb (Yung et al., 2007). They found that when 
Skp2 is ectopically overexpressed, there was increased activity on the Skp2 promoter. 
Conversely, Skp2 knockdown reduced Skp2 promoter activity. They also looked at 
the rate of S-phase entry and the time to mitogen independence (restriction point), 
using MEFs derived from a knock-in mouse with a p27 mutation of Thr187 to alanine. 
They found that MEFs with mutated p27, which would be expected to have a defective 
autoinduction loop, took much longer than WT MEFs to reach mitogen independence. 
However, this did not result in a general decrease in the rate of cell cycling, as the 
time taken to reach S-phase was similar between WT and p27 mutated MEFs when 
continuously exposed to mitogenic stimuli (Yung et al., 2007). 
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Schneider and colleagues found that the Skp2 gene is also regulated by the non-
canonical NF-κB pathway upon stimulation by IKKα. They showed that IKKα siRNA 
treatment leads to down-regulation of Skp2. Increased p27 levels also followed IKKα 
treatment. They determined that the relB/p52 dimer of the NF-κB family is involved in 
binding and activating the Skp2 gene (Schneider et al., 2006). 
The mammalian target of Rapamycin (mTOR) has also been found to be involved in 
Skp2 gene regulation (Figure 1.13). mTOR is a downstream mediator or the PI3K/Akt 
pathway. Rapamycin was found to decrease Skp2 both at the transcript and protein 
levels suggesting that mTOR regulates Skp2 gene expression. Rapamycin was also 
found to stabilise p27 levels in breast cancer (Shapira et al., 2006). Consistent with 
this finding, increased PI3K/Akt pathway activity leads to reduced p27 protein levels 
(Liang et al., 2002, Yakes et al., 2002). 
Figure 1.12: The Skp2 autoinduction loop. Skp2 is able to stimulate its own 
expression without the requirement of exogenous mitogens. Adapted from 
(Yung et al., 2007) 
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1.5	Regulation	of	Skp2	by	post-translational	modification	and	effects	
of	modification	on	Skp2	activities	
Unlike other subunits of the SCFSkp2 complex such as Skp1 and Cul1, the levels of 
Skp2 change throughout the cell cycle. The most established cause of changes in 
Skp2 levels is due to ubiquitin-mediated degradation of Skp2. Skp2 is targeted to the 
APCCdh1 complex during early G1 and mitosis (Lin and Diehl, 2004). However, recent 
studies have revealed that the phosphorylation state, acetylation state and perhaps 
even cyclin A-bound state of Skp2 has an effect on its recruitment to the APCCdh1 
complex (Rodier et al., 2008, Inuzuka et al., 2012, Gao et al., 2009). Cdh1 binds to 
two regions within the N-terminal regulatory region of Skp2. The first region is the D-
box motif, a motif commonly found in Cdh1 substrates. The consensus sequence for 
this motif is RXXLXXXXN/D/E (Li and Zhang, 2009). The second region encompasses 
the NLS (Figure 1.9).  
Skp2 is phosphorylated by CDK2/cyclin A on residues 64 and 72 and these 
phosphorylation events block the association of Skp2 with Cdh1 (Rodier et al., 2008). 
This modification does not affect the activity of the SCFSkp2 complex. However, 
phosphorylation of Ser64 and to a lesser extent, Ser72, affects the stability of Skp2 
by directly affecting Cdh1 binding and subsequent ubiquitination. Consistent with this 
model, they found that Ser64 phosphorylation occurs in G1 phase when Skp2 is 
known to be most stable. They then investigated whether a dephosphorylation event 
is required in order to trigger Skp2 degradation. They found that the phosphatase 
Cdc14B is responsible for dephosphorylating Skp2 on Ser64 and thus inducing Skp2 
Figure 1.13: Summary of Skp2 gene expression. E2F1, NF-κB and c-Myc are 
transcription factors which have been found to positively regulate Skp2. mTOR 
and FOXO3a are negative regulators of Skp2. 
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ubiquitination and subsequent degradation (Rodier et al., 2008). Therefore, the 
opposing activities of CDK2 and Cdc14B are crucial for regulating entry into S-phase. 
Akt is also able to phosphorylate Skp2 on Ser72 (Gao et al., 2009) Sequence analysis 
of Skp2 revealed an Akt phosphorylation consensus sequence around Ser72, and 
phosphorylation of Ser72 was confirmed through an in vitro kinase assay. The Akt 
pathway functions to promote cell growth and cell survival (Song et al., 2005). For 
many Akt substrates such as p27, p21 and FOXO1, phosphorylation results in 
masking of their NLS combined with 14-3-3 binding leading to cytoplasmic 
localisation. Phosphorylation of Skp2 by Akt also leads to masking of its NLS and 
subsequent nuclear export (Gao et al., 2009). There have been many reports of 
increased cytoplasmic Skp2 levels in cancers and this study provided a molecular 
mechanism for this phenomenon (Drobnjak et al., 2003, Radke et al., 2005, Dowen 
et al., 2003). A concurrent publication with similar findings was that of Lin and co-
workers (Lin et al., 2009). They too found that Akt-mediated phosphorylation of Skp2 
leads to nuclear export and stabilisation via direct blocking of the Skp2/Cdh1 
interaction. The cytoplasmic localisation is stabilised by 14-3-3β binding and this 
interaction requires phosphorylation of Skp2 at Ser72. Interestingly, Lin and co-
workers found that Skp2 binds more tightly to the SCF complex when phosphorylated, 
suggesting that Akt might mediate SCF complex assembly. In contrast, Bashir et al. 
(2010) showed that SCF assembly is not affected by either Ser64 or Ser72 
phosphorylation.  
In 2012, Inuzuka and colleagues identified acetylation sites within the Skp2 
NLS/Cdh1-binding site (Inuzuka et al., 2012). They reported that p300 can acetylate 
Skp2 on residues K68 and K71, and hypothesised that this modification can affect the 
interaction of Skp2 with Cdh1. Depletion of p300 led to a decrease in Skp2 levels, 
particularly during G1-phase (Inuzuka et al., 2012). SIRT3 (a deacetylase) was able 
to deacetylate residues K68 and K71. Members of the Sirtuin family are involved in 
tumourigenesis and cellular metabolism, and SIRT3 specifically has a tumour 
suppressive function (Kim et al., 2010, Zhu et al., 2014). In support of this tumour 
suppressive function, Inuzuka and colleagues found an inverse correlation between 
Skp2 and SIRT3 immunohistochemical staining in breast cancer samples. They 
hypothesised that acetylation of residues 68 and 71 might have an effect on the sub-
cellular localisation of Skp2 as acetylation of lysines within an NLS often leads to 
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cytoplasmic accumulation (di Bari et al., 2006, Dietschy et al., 2009). High levels of 
cytoplasmic Skp2 have been reported in many clinical samples, and is correlated with 
aggressive malignancy and poor prognosis (Radke et al., 2005, Signoretti et al., 
2002).  
Akt phosphorylation, but not Akt abundance, fluctuates throughout the cell cycle. Akt1 
is a CDK2/cyclin A substrate and its level of phosphorylation mirrors the expression 
pattern of cyclin A. Phosphorylation of Akt on Ser477 and Thr479 leads to Ser72 
phosphorylation of Skp2 by Akt, and subsequent stabilisation of Skp2 (Liu et al., 
2014). Phosphorylation of Akt on Ser477 and Thr479 also triggers Ser473 and Thr308 
phosphorylation by mTORC2 and PDK1 respectively leading to full activation of Akt 
(Liu et al., 2014). Therefore CDK2/cyclin A activity indirectly increases Skp2 levels as 
well as directly affecting Skp2 levels by Ser64 phosphorylation (Rodier et al., 2008). 
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In summary, Skp2 is regulated through modifications and protein-protein interactions 
within its N-terminus (Figure 1.14). The NLS, 14-3-3β binding and acetylation by p300 
regulate Skp2 cellular localisation; phosphorylation of residues around and within the 
Cdh1 binding site regulate the stability of Skp2 and might also regulate SCFSkp2 
formation; and cyclin A binding within this region may have a regulatory role or may 
be required for SCFSkp2 complex formation. Ser48 and Ser57 phosphorylation has 
Figure 1.14: The N-terminus of Skp2 is highly modified and involved in many 
protein-protein interactions. A) Proteins which interact with Skp2. Lines indicate 
the approximate interaction site. Ser48 and Ser57 phosphorylation have been 
identified only by mass spectrometry (Dephoure et al., 2008). B) Kinases and 
acetylases that modify the Skp2 N-terminus.  
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been identified by MS analysis (Dephoure et al., 2008), however the kinases 
responsible and the effect, if any, on Skp2 activity have not been determined. 
1.6	Skp2B	
A splice variant of Skp2 was identified in 2001 (Ganiatsas et al., 2001) originally called 
Skp2 C-terminal variant (Skp2-CTV), it was later renamed Skp2B. Since its discovery, 
our knowledge of Skp2B has increased slowly and the majority of the work done on 
this variant has been carried out by a single group led by Doris Germain. This group 
have found that Skp2B lacks the last three leucine-rich repeats (LRRs) and the C-
terminal tail (Figure 1.15), and is not involved in the degradation of p27 (Radke et al., 
2005, Ganiatsas et al., 2001).  
 
 
Figure 1.15: Structure of residues 95-424 of Skp2. Skp2 comprises an F-box 
domain, ten LRRs and a long C-terminal tail. Some of the LRRs are involved in 
substrate binding (Kobe and Kajava, 2001, Hao et al., 2005).  
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Skp2B is predominantly cytoplasmic, whereas Skp2 is predominantly nuclear 
(Ganiatsas et al., 2001). A number of studies have used antibodies that recognise 
both variants of Skp2 for cellular staining and have reported enriched levels of 
cytoplasmic Skp2 (Radke et al., 2005).  These studies might therefore be measuring 
Skp2B rather than Skp2. Many studies have reported that high Skp2 levels do not 
always correlate with low p27 levels in cell lines and primary tissue cultures. This 
finding might again be due to a high level of Skp2B rather than Skp2, as discussed 
by Radke and co-workers (Radke et al., 2005). 
The levels of Skp2B compared to Skp2 can be quantitated on Western blots due to 
its lower molecular weight and hence faster migration on SDS-PAGE. When probing 
for Skp2 there are often two bands; the top band corresponding to Skp2 and the lower 
one to Skp2B. By identifying this lower band as Skp2B the Germain group were able 
to show that Skp2B is less stable than Skp2. Using cycloheximide treatment, they 
determined the half-life of Skp2B to be 30 minutes compared to 90 minutes for Skp2 
(Radke et al., 2005).  
1.7	The	cell	cycle	inhibitor,	p27	
p27 (also known as KIP1) is encoded by the CDKN1B gene, and belongs to the 
Cip/Kip family of CDK inhibitor proteins (Polyak et al., 1994a, Polyak et al., 1994b, 
Toyoshima and Hunter, 1994). p27 inhibits CDK2-, CDK4-, CDK6-, and CDK1/cyclin 
complexes. The level of p27 oscillates throughout the cell cycle being greatest as the 
cell moves into G1-phase and then steadily decreases as the cell progresses through 
G1-phase into S-phase (Pagano et al., 1995). Levels of p27 are high in cells exposed 
to certain anti-mitogenic signals or differentiation signals such as contact inhibition, 
TGF-β and serum deprivation (Reynisdottir et al., 1995, Polyak et al., 1994b). The 
importance of p27 in limiting proliferation is illustrated by the p27 knockout mouse 
which displayed increased body size, organ hyperplasia and, similar to the Rb 
knockout mice, these mice developed pituitary gland tumours (Fero et al., 1996). 
Haploinsufficiency of p27 predisposes to tumours in multiple tissues when challenged 
with γ-radiation or chemical carcinogens (Fero et al., 1998). 
p27 is an intrinsically unstructured protein (IUP, (Lacy et al., 2004)) meaning that it 
lacks any highly ordered three-dimensional structure (Yoon et al., 2012) and is 
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proposed to undergo a folding upon binding transition upon incorporation into 
CDK/cyclin complexes (Wang et al., 2011). The structure of p27 bound to CDK2/cyclin 
A revealed that p27 binds to CDK/cyclin complexes as an extended structure 
interacting with both CDK2 and cyclin A (Figure 1.16) (Russo et al., 1996a). It was 
hypothesised that the disordered structure of p27 provides the opportunity to make 
diverse interactions (Lacy et al., 2004). Indeed, the regions of p27 that include many 
sites of post-translational modification lie within these disordered regions allowing for 
them to be flexible enough to bind diverse partners. For example, within the 
CDK/cyclin binding region also known as the kinase inhibitory domain (KID), p27 can 
lose its inhibitory capability through tyrosine phosphorylation (Grimmler et al., 2007). 
This mechanism of binding is common to IUPs and is believed to increase flexibility 
in binding and allow access to proteins that introduce modifications (van der Lee et 
al., 2014). 
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1.7.1	p27	mislocalisation	in	cancer	
CDK inhibitors (CKIs) are potent negative regulators of the cell cycle. The INK family 
of CKIs are frequently mutated or deleted in cancers (Ortega et al., 2002, Asghar et 
al., 2015). p27, however, is rarely mutated in cancers, and therefore does not behave 
as a traditional tumour suppressor. Despite this, reduced p27 expression has been 
associated with development of lung, breast, colon, ovarian, thyroid, prostate and 
many other cancers (Chu et al., 2008). Hence, the role of p27 in cancer is 
controversial, and it has been described as a haploinsufficient tumour suppressor 
Figure 1.16: The structure of the p27 KID bound to CDK2/cyclin A. p27 KID 
can be divided into subdomains (labelled by bars above the p27 sequence) 
based on structure and sequence in the region which contacts CDK2/cyclin A. 
The D1 domain contains the RXL motif, the LH domain is an amphipathic α-
helix and the D2 domain binds to the active site of CDK2. Adapted from (Lacy 
et al., 2004). 
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(Fero et al., 1998). This phenotype is demonstrated by the p27 knockout mouse which 
is not as tumour prone as would be expected, with tumours only occurring in the 
pituitary gland (Nakayama et al., 1996). In different contexts, p27 can be transferred 
to alternative complexes or its cellular localisation may be altered. For example, in 
some cancers which exhibit high p27 levels, p27 is sequestered in CDK4/cyclin D 
complexes reducing its ability to inhibit CDK2/cyclin E complexes. Her2 
overexpression has been reported to upregulate cyclin D and promote CDK4/cyclin 
D/p27 complex formation (Lane et al., 2000). In contrast, high levels of cytoplasmic 
p27 are a marker of poor prognosis in many cancers and has been associated with 
Protein kinase B (Akt) activation (Liang et al., 2002, Viglietto et al., 2002). For 
example, altered p27 localisation has been reported in prostate (Tsihlias et al., 1998), 
oesophagus (Singh et al., 1998), thyroid (Baldassarre et al., 1999), ovarian (Duncan 
et al., 2010, Masciullo et al., 2000) and breast cancers (Catzavelos et al., 1997).  
Akt phosphorylates p27 on Ser10, Thr157 and Thr198 and phosphorylation of these 
residues alone or in combination leads to cytoplasmic accumulation of p27 (Rodier et 
al., 2001, Fujita et al., 2003, Sekimoto et al., 2004). Phosphorylation of Ser10 occurs 
during G1 phase in response to growth factor stimulation, perhaps contributing to the 
inactivation of p27 (Lee and Kay, 2007). This modification creates a binding site for 
CRM1/Exportin1 suggesting that it may indirectly affect p27 sub-cellular localisation 
(Rodier et al., 2001). This phosphorylation event was found by Besson and co-
workers to be a mechanism of tumourigenesis (Besson et al., 2006). p27S10A/S10A mice 
are less prone to tumours induced by urethane than WT mice. As p27S10A is unable 
to undergo Ser10 phosphorylation-induced nuclear export, a larger proportion of 
p27S10A was found to localise in the nucleus compared to p27WT. A possible 
mechanism of protection from tumour development would be the increased 
occupation of p27 on CDK2/cyclin complexes within the nucleus (Besson et al., 2006).  
Phosphorylation of Thr157 leads to binding of 14-3-3β which blocks binding to 
importin α and prevents p27 from being imported into the nucleus (Viglietto et al., 
2002, Sekimoto et al., 2004). Thr198 of p27 is also phosphorylated by p90 ribosomal 
S6 kinase (RSK1), which is activated through the MEK/ERK pathway, and 5’ AMP 
activated protein kinase (AMPK) which has a role in energy homeostasis within the 
cell (Fujita et al., 2003, Liang et al., 2007, Short et al., 2010). When in the cytoplasm, 
p27 has a role in regulation of the actin cytoskeleton and cell migration through 
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modulation of RhoA and through this role has been implicated in many cancers (Hsu 
et al., 2014, Roy et al., 2013).  In renal cell carcinoma (RCC), levels of cytoplasmic 
p27 correlate with tumour grade, and in RCC cell lines PI3K/Akt signalling correlated 
with Thr157 phosphorylation and cytoplasmic mislocalization (Kim et al., 2009). 
Phosphorylation of p27 on Thr157 and localisation to the cytoplasm has also been 
observed to be increased in breast cancer (Viglietto et al., 2002). As a result of the 
oncogenic nature of cytoplasmic p27, inhibition of its nuclear export has been 
proposed as a target for therapeutic intervention (Wang et al., 2014, Gravina et al., 
2014). 
1.7.2	p27	phosphorylation	by	oncogenic	tyrosine	kinases	
During G1 phase of the cell cycle, p27 is phosphorylated on Tyr74 by Src, and Tyr88 
by Src, Abl (and BCR-ABL) and Lyn (a Src family kinase) (Grimmler et al., 2007, Chu 
et al., 2007). These phosphorylations weaken p27 binding to CDK2/cyclin E. Tyr88 
lies in the 310 helix of p27 (Figure 1.16) which occupies the ATP-binding site of CDK2 
(Russo et al., 1996b). Phosphorylation of Tyr74 also serves to disrupt hydrophobic 
interactions and leads to weakening of the CDK2/cyclin E/p27 interaction. Tyr74 and 
Tyr88 phosphorylated p27 is still able to bind CDK2/cyclin E, but CDK2/cyclin E is 
partially active in this state and can phosphorylate p27 on Thr187 (Grimmler et al., 
2007, Chu et al., 2007). Increase levels of tyrosine-phosphorylated p27 have been 
reported in leukaemic cells, indicating that increased activity of these tyrosine kinases 
on p27 might contribute to progression of leukaemia (Kardinal et al., 2006, Grimmler 
et al., 2007). The Src family kinase inhibitor, AZD0530, and imatinib have been shown 
to reduce Tyr88 phosphorylation and increase the stability of p27 (Chu et al., 2007). 
1.7.3	Transcriptional	and	translational	control	of	p27	
The levels of Cdkn1b (the gene encoding p27) transcription remain fairly constant 
throughout the cell cycle (Hengst and Reed, 1996). Levels of translation of p27 do 
however change during the cell cycle, with increased translation correlating with exit 
from the cell cycle. A U-rich region in the 5’-UTR of p27 has been identified that is 
necessary for efficient translation, and human antigen R (HuR) is a protein which 
binds to the p27 5’ UTR (Millard et al., 2000). The HuR binding site is part of the 
internal ribosome entry site (IRES). Binding of HuR is therefore inhibitory as it blocks 
ribosome binding (Kullmann et al., 2002, Coleman and Miskimins, 2009). HuR is 
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predominantly nuclear in early and mid G1 and then moves out of the nucleus during 
late G1, S and G2 (Wang et al., 2000). Consistent with this, translation of p27 is 
regulated during the cell cycle with a decrease at the G1/S transition (Hengst and 
Reed, 1996). Other factors which bind the p27 5’-UTR are the heterogeneous nuclear 
ribonuclearproteins (hnRNPs) C1 and C2. C1 and C2 bind to the 5’-UTR of p27 during 
G2 and M (Millard et al., 2000). hnRNPs C1 and C2 were shown to also bind to the 
IRES element, however, they are enhancers of p27 translation in contrast to HuR 
(Cho et al., 2005). Recently, other factors which bind to the 5’-UTR have been 
identified, such as, Far Upstream Element (FUSE) Binding Protein 1 (FBP1) and 
urothelial carcinoma-associated 1 (UCA1) (Zheng and Miskimins, 2011, Huang et al., 
2014). Recently it has been reported that p27 mRNA is regulated by the miRNA let-7 
(Liu et al., 2015). This might in part explain why let-7 is found to be dysregulated in 
many cancers (Boyerinas et al., 2010). Control of p27 translation is thus emerging as 
a very complex process, involving multiple proteins which compete to bind to the IRES 
element and other regions of the 5’-UTR. 
1.8	Structures	of	Skp2-containing	complexes	
p27 is recognised as a substrate by SCFSkp2 when bound to CDK2/cyclin A. Unusually 
Skp2 requires Cks1 as an accessory protein to bind p27. 
1.8.1	The	SCFSkp2	structure	
In 2000, the first structure of the F-box, LRRs and C-terminal tail of Skp2 (residues 
97-424) was published (PDB: 1FQV). The structure revealed the F-box region of Skp2 
binding tightly to Skp1 through interlocking helices mediated predominantly by 
hydrophobic interactions (Figure 1.17) (Schulman et al., 2000). The LRRs of Skp2, 
which are involved in substrate binding, have a concave structure resembling a sickle.  
The ~30 amino acid C-terminal tail of Skp2 extends back towards the F-box region 
packing loosely against its concave LRR region (Schulman et al., 2000). 
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Not long after the Skp1/Skp2 structure was solved, the same group published the 
structure of the Cul1-Rbx1-Skp1-Skp2 complex (PDB: 1LDK). Only the F-box of Skp2 
was included in this complex (Zheng et al., 2002). Superimposition of their structure 
onto the LRR-containing structure revealed the F-box region of Skp2 to be about 100 
Å from the zinc-RING finger protein, Rbx1. Docking the structure of an E2 enzyme 
onto Rbx1, c-Cbl-UbcH7,  suggested that the LRRs of Skp2 are orientated toward the 
catalytic cysteine of the E2, from which they are separated by ~50 Å (Figure 1.18). 
This distance is determined by the Cul1 scaffold protein. Zheng and co-workers argue 
that Cul1 serves to separate SCFskp2 substrates from their E2 ligase component so 
as to accommodate substrates of differing sizes and with varying spacing between 
their ubiquitinated lysines (Zheng et al., 2002). The SCF complex appears to be 
relatively rigid and therefore this gap opens up new questions concerning the 
Figure 1.17: The Skp1/Skp2 interface. Skp1 is shown in blue and Skp2 in 
magenta. Tryptophans, tyrosines and phenylalanines which are oriented toward 
the core of the Skp1/Skp2 interface are shown in ball and stick conformation. Other 
hydrophobic residues which contribute to this interaction are not shown for clarity.  
PDB: 1FQV 
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mechanism of ubiquitination. The structure also revealed that Skp2 does not directly 
interact with Cul1 (Schulman et al., 2000, Zheng et al., 2002). 
	
 
 
 
1.8.2	Skp1/Skp2/Cks1	structure	
The structure of Skp1/Skp2/Cks1 bound to a p27 peptide was unexpected in that it 
showed that Cks1 makes a significant contribution to the p27 binding site and the 
Skp2 C-terminal tail is only involved in binding substrates indirectly through contacts 
it makes with Cks1 (Hao et al., 2005). It had been suggested that the Skp2 C-terminal 
tail might undergo a conformational change in order to accommodate Cks1 (Reed, 
2005). However, binding of Cks1 does not cause any significant changes to the Skp2 
structure and the structure of Cks1 bound to Skp2 is nearly identical to the structure 
of unbound Cks1 (Hao et al., 2005).  
Figure 1.18: Model of the SCFSkp2-E2 complex. A model of the SCFSkp2-
E2 complex reveals a circa 50 Å gap between Skp2 and the catalytic E2 
molecule. The structure appears to be rigid and therefore this gap between 
Skp2 and the E2 enzyme opens up new questions into the mechanism of 
ubiquitination. From Zheng et al. (2002). 
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The Skp1/Skp2/Cks1/p27 peptide structure also confirmed the importance of the 
phosphorylation at Thr187 to its binding to the SCFSkp2 complex, in particular to Cks1. 
Modelling CDK2/cyclin A into the SCF structure using the CDK2/Cks1 and 
CDK2/cyclin A structures, showed that CDK2/cyclin A could be accommodated in the 
SCF complex (Figure 1.19). Therefore this structure provided additional evidence to 
support a model in which CDK2/cyclin A aids the ubiquitination of p27 independently 
of its role in Thr187 phosphorylation (Zhu et al., 2004). Within the p27 sequence 
Glu185 and pThr187 were shown to make a significant contribution to p27 peptide 
binding (Figure 1.19, (Hao et al., 2005)). The structure of the Skp1/Skp2/Cks1/p27 
complex and supporting mutagenesis experiments show that only Glu185 and 
pThr187 of p27 contribute significantly to the interaction with the SCFSkp2 complex 
(Hao et al., 2005). This result suggests that additional interactions stabilise the 
complex, for example, Cks1 binding to CDK2. In support of this model, the 
concentration of Cks1 required to bind a p27 phosphopeptide to the SCFSkp2 complex 
is about tenfold higher than the concentration needed to bind full-length 
phosphorylated p27 to Cks1 in the presence of CDK2/cyclin E (Hao et al., 2005) and 
CDK2 binding to Cks1 enhances ubiquitination of p27 (Sitry et al., 2002).  
Unexpectedly, the Skp1/Skp2/Cks1/p27 structure showed that Cks1 contributes 
much of the interface for p27 (Figure 1.19). Only two residues of Skp2, Arg294 and 
Tyr346, appear to contribute to the interaction with p27. The phosphorylated threonine 
of p27 (pThr187) binds into an anion binding pocket on Cks1 (Figure 1.19). Cks1 in 
turn, binds to the concave surface of the LRRs of Skp2 (Hao et al., 2005). 
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Figure 1.19 shows that a ten amino acid segment of p27 (181-190) binds Skp2/Cks1 
in a bipartite manner. Residues 181-184 bind Skp2, residue 185 binds to both Skp2, 
and Cks1 and residues 186 to 190 bind Cks1. p57 has considerable homology to p27 
in the C-terminal region with eight out of ten of the residues equivalent to those 
contained in the Skp1/Skp2/Cks1/p27 structure being identical to those in p27. It is 
likely, therefore, that p57 makes similar interactions with Skp2/Cks1 (Hao et al., 
2005). p21 has lower sequence homology to p27, however, both p57 and p21 have a 
glutamate residue at position -2 relative to the phosphorylated residue which, for p27, 
binds to the anion-binding pocket of Cks1. 
Figure 1.19: Residues Glu185 and pThr187 of p27 form key interactions 
with Skp2/Cks1. A) Structure of Skp2/Cks1/p27. Skp2 is shown in magenta, 
Cks1 is in gold and p27 is in cyan. Some of the interacting residues are shown 
as cylinders. B)  Crucial residues of p27, such as Glu185 and a phosphorylated 
residue at position 187 of p27, involved in its interaction with Skp2/Cks1 are 
conserved between the Cip/Kip family of CDK inhibitors (conserved residues are 
coloured). PDB: 1AST. 
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1.8.3	The	Skp1/Skp2/Cks1/CDK2/cyclin	A	complex	
Skp2 was first identified in a complex with Skp1, Cks1, CDK2 and cyclin A  and shown 
to form a pentameric complex with CDK2/cyclin A (Zhang et al., 1995). CDK2/cyclin 
A can be docked into the structure of the SCF complex through the interaction of 
CDK2 with Cks1 (Figure 1.20, (Hao et al., 2005)). The N-terminus of Skp2 interacts 
with cyclin A through residues 32, 33, 39 and 41 of Skp2 (Ji et al., 2006). Mutating 
these residues to alanine (termed Skp2 4A) disrupts the Skp2/cyclin A interaction and 
overexpressing Skp2 4A in U2OS cells leads to p21/p53-mediated cell cycle arrest (Ji 
et al., 2006). 
 
	
 
 
There has been conflicting evidence as to whether CDK2/cyclin A is required for p27 
ubiquitination, which might reflect non-overlapping roles for different CDK/cyclin 
complexes in mediating p27 degradation.  It is known that CDK2/cyclin E is required 
for p27 phosphorylation at Thr187 leading to its degradation, but that there is no 
significant effect on p27 ubiquitination when CDK2/cyclin E is absent (Spruck et al., 
2001). p27 can also be phosphorylated by CDK1/cyclin B, but this does not stimulate 
its ubiquitination (Montagnoli et al., 1999). The requirement for a direct Cks1/CDK2 
interaction for p27 ubiquitination is also controversial. Using a Cks1 mutant which was 
Figure 1.20: Model of the SCFSkp2-Cks1-p27-CDK2-cyclin A structure. 
Residues 95-424 of Skp2 are shown in ribbon representation. Residues 94-180 
of p27 for which no structural information exists is shown as a dashed line. From 
Hao et al. (2005). 
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shown by biophysical and yeast two-hybrid analyses to be incapable of binding CDK2 
(Bourne et al., 1996), one group demonstrated in vitro that the Cks1/CDK2 interaction 
may be redundant for ubiquitination of p27 (Spruck et al., 2001). Whereas, another 
(Sitry et al., 2002) demonstrated that when Cks1 is mutated, such that it cannot bind 
CDK2, the ubiquitination of p27 is greatly reduced. This latter study was followed up 
by another suggesting that CDK2/cyclin A has a non-catalytic role in the turnover of 
p27 (Zhu et al., 2004). A catalytically inactive CDK2/cyclin A complex was shown to 
stimulate ubiquitination of phosphorylated p27. In support of the earlier observations 
(Spruck et al., 2001), CDK2/cyclin E could not promote p27 ubiquitination after 
phosphorylation. Another study found that CDK2/cyclin E is required for p27 
ubiquitination (Ungermannova et al., 2005). However, a comparison of whether 
CDK2/cyclin A stimulates p27 ubiquitination more effectively than CDK2/cyclin E in 
their assay was not undertaken. 
The structure of the Skp1/Skp2/Cks1/p27 peptide complex supports a model in which 
CDK2/cyclin A binding to the SCFSkp2 complex is mediated by Cks1 as the CDK2-
binding interface of Cks1 is accessible, and CDK2/cyclin A can be docked onto the 
complex without requiring any conformational changes (Figure 1.20). The authors of 
this paper also showed that a complex assembled from sub-complexes of Cul1/Rbx1, 
Skp1/Skp2Δ88/Cks1, and CDK2/cyclin A/pThr187p27 is stable to size-exclusion 
chromatography (SEC) (Hao et al., 2005). As the recombinant Skp2 encoded only the 
F-box and LRRs and lacked the N-terminal sequence, the Skp2/cyclin A interaction 
would not be expected to be intact, and therefore, the interaction via the CDK2/Cks1 
interaction must be sufficient for complex stability (Hao et al., 2005). The authors 
suggest that CDK2/cyclin A could strengthen the interaction of p27 with the SCFSkp2 
complex as the affinity of p27 for Skp2/Cks1 is 10-20 fold lower than that observed 
for other substrates of the SCFSkp2 complex (Nash et al., 2001, Wu et al., 2003). 
1.9	The	role	of	Skp2	in	cancer	
Skp2 has been well-characterised as the substrate recognition component of the 
SCFSkp2 complex, however, it has other functions which often also contribute to cancer 
progression. In this section, functions of Skp2 involving its role within the E3 ligase 
will be discussed as well as its other oncogenic functions. 
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1.9.1	The	Skp2/p27	axis	
Given the role of Skp2 in promoting cell cycle progression, it is not surprising that it is 
overexpressed in many cancers such as breast, prostate, non-small cell lung cancer 
(NSCLC), ovarian and many more (Hershko, 2008). In many of these cancer types, 
high Skp2 levels correlate with low p27 levels heavily implicating the Skp2/p27 axis 
in tumourigenesis and/or tumour progression. Counter-intuitively, p27 down-
regulation with antisense oligonucleotides has been shown to sensitise cancer cells 
to chemotherapeutic drugs, for example, flavopiridol and 4-
hydroperoxycyclophosphamide (St Croix et al., 1996, Achenbach et al., 2000). In 
retrospective studies, however, reduced p27 levels correlated with reduced survival 
after platinum-based chemotherapy for NSCLC and ovarian cancers (Oshita et al., 
2000, Masciullo et al., 2000, Korkolopoulou et al., 2002, Hershko, 2010). This is 
perhaps due to the change in roles of p27 depending on its sub-cellular localisation 
(see Section 1.7.1). Further investigation is required to evaluate p27 as a predictor of 
response to chemotherapy and whether attenuation of the Skp2/p27 axis would be 
beneficial in these patients.  
1.9.2	Role	of	Skp2	in	tumourigenesis	upon	BCR-ABL	overexpression		
Recent reports have suggested that Skp2 promotes tumourigenesis upon BCR-ABL 
overexpression and Skp2 loss is also able to counter the effects of BCR-ABL  
overexpression (Agarwal et al., 2008). Treatment of a leukaemic cell line with Imatinib 
caused an increase in p27 levels. This was not due to decreased phosphorylation of 
p27 on Thr187 by CDK2/cyclin E, which would be expected to target p27 for 
ubiquitination by the SCFSkp2 complex. Skp2 mRNA and protein levels on the other 
hand were reduced following Imatinib treatment, consistent with transcriptional 
regulation of Skp2 by BCR-ABL (Agarwal et al., 2008).  Further investigation into this 
effect of BRC-ABL on Skp2 suggests that the stability of Skp2 is affected by Imatinib. 
It was found that BCR-ABL phosphorylates and inactivates Emi1 which leads to 
increased activity of the APC/C complex (Chen et al., 2011). 
1.9.3	Potential	for	targeting	Skp2	in	TP53-	and	Rb1-deficient	tumours	
Rb and p53 are tumour suppressors frequently lost or mutated in cancers. Combined 
deletion of Rb1 (encoding Rb) and TP53 (encoding p53) is effective at inducing 
tumours in a wide range of tissues in mice. Skp2 loss in Rb-deficient mice blocks 
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pituitary tumourigenesis (Wang et al., 2010). Skp2 was found to suppress apoptosis 
in Rb-deficient tumours. These effects are mediated through E2F1-mediated gene 
expression. The widely accepted mechanism for induction of tumorigenesis by Rb 
loss is through E2F1 activation. The loss of Skp2 in this context leads to altered E2F1 
target gene activation, which switches the E2F1 output from pro-proliferative to pro-
apoptotic (Lu et al., 2014). In p53-deficient tumours, Skp2 inactivation can lead to 
p53-independent senescence when the p19Arf-p53 pathway is impaired (Lin et al., 
2010a). p53 is activated by oncogenic stress such as the loss of Rb (Sherr, 2012). 
The activation of the p53 pathway leads to cell cycle arrest, and possibly senescence, 
or apoptosis. Zhao and co-workers investigated the effect of combined loss of Skp2, 
Rb and p53 (Zhao et al., 2013). They reported that upon deletion of Skp2 following 
p53 and Rb loss, p27 levels are increased and safeguard against tumorigenesis. 
Therefore, inhibition of Skp2 in the context of Rb and p53 loss could be beneficial in 
cancer therapy. 
1.9.4	Skp2	activation	of	Akt	
Skp2 has a role in proliferation through its ubiquitination of many cell cycle regulatory 
proteins. However, it has also been shown to be involved in many other oncogenic 
pathways. In the cytoplasm, Skp2 is involved in the ubiquitination of Akt after 
epidermal growth factor (EGF) stimulation (Chan et al., 2012). This ubiquitination 
activates Akt through the attachment of Lys63-linked ubiquitin chains. Cytoplasmic 
Skp2 was also found to have a role in increasing glycolysis through Akt signalling 
(Chan et al., 2012). Cancer cells develop a mechanism of increasing ATP levels 
through increased glucose uptake and glycolysis called the Warburg effect (Vander 
Heiden et al., 2009). This increased ATP synthesis is believed to facilitate increased 
uptake and synthesis of cellular building blocks (Vander Heiden et al., 2009). Akt has 
been shown to be a key regulator of the Warburg effect and Akt is often highly active 
in cancers (Elstrom et al., 2004, Plas and Thompson, 2005). Investigation into the 
effects of Skp2 activation of Akt on the levels of glucose uptake and tumour size 
showed that Skp2 does regulate in vivo glycolysis, and that knockdown of Skp2 
decreases tumour size in a xenograft mouse model bearing Her2-overexpressing 
breast tumours (Chan et al., 2012). 
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1.9.5	Role	of	Skp2	in	prostate	cancer	
Androgens are the primary drivers of prostate cancer cell growth. When androgens 
are ablated or withdrawn, a proportion of cells undergo apoptosis and the remainder 
arrest in G1 of the cell cycle. Androgen ablation therapy is the primary treatment for 
metastatic prostate cancer (Huggins and Hodges, 1941, Katsogiannou et al., 2015), 
however, 80-90% of patients develop castration-resistant prostate cancer (CRPC) 
after 12-33 months (Attard et al., 2006). Skp2 has a well-established role in prostate 
cancer. Expression of Skp2 was found to increase with androgen addition leading to 
increased degradation of p27 and increased proliferation (Lu et al., 2002, Waltregny 
et al., 2001). This suggests that Skp2 is involved in a cell’s mechanism of overcoming 
androgen deprivation.  
Kokontis and co-workers found that treatment of CRPC cells with an androgen 
analogue decreased the protein levels of Skp2, CDK2 and cyclin A amongst others 
(Kokontis et al., 2014). Levels of p27 were found to be significantly increased. As 
predicted from these findings, they also observed a G1 cell-cycle arrest in response 
to androgen treatment. This suggests that the Skp2/p27 axis is heavily involved in the 
anti-proliferative effect of androgen therapy in CRPC (Kokontis et al., 2014).  
1.9.6	Role	of	Skp2	in	breast	cancer	
Skp2 has been reported to be overexpressed in a subset of breast carcinomas with 
low levels of p27 expression (Signoretti et al., 2002). Emerging evidence suggests 
that Skp2 plays a key role in cell growth, apoptotic cell death, invasion and metastasis 
in human breast cancer (Sonoda et al., 2006, Zhang et al., 2005). Furthermore, Skp2 
knockdown by RNAi significantly inhibited cell proliferation in MCF-7 breast cancer 
cells (Sun et al., 2007). 
It was found in 2014 that the SCFSkp2 complex is one of several E3 ligases which 
mediate ERα degradation upon oestrogen stimulation (Zhou et al., 2014). 
CDK2/cyclin E phosphorylation of oestrogen receptor α (ERα) on Ser341 is required 
for ERα recognition by the SCFSkp2 complex. ERα activation by a ligand rapidly 
stimulates its interaction with Skp2 which leads to its transcriptional activation and 
subsequent proteasomal degradation of ERα. This coupled process is common 
among transcription factors (Nawaz and O'Malley, 2004). E2F1 was identified as a 
late ERα-activated gene regulated by Skp2. As E2F1 is a transactivator of Skp2, 
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Skp2/ERα-mediated gene expression would be expected to form a feed-forward 
mechanism to drive S-phase entry. Attenuation of this feed-forward loop perhaps 
through inhibition of CDK2-mediated phosphorylation of ERα might serve to block 
proliferation of ERα-positive cancers (Zhou et al., 2014). 
1.9.7	Skp2	mediates	RhoA	expression	
Skp2 is also known to be a transcription cofactor. Skp2 cooperates with Miz1, Myc 
and p300 to induce RhoA expression. RhoA is a member of the Rho family of small 
GTPases, and has a role in cancer metastasis. Upregulation of RhoA has been 
documented in many human cancers (Chan et al., 2010, Bellizzi et al., 2008, Horiuchi 
et al., 2003). Although Skp2 is able to ubiquitinate c-Myc, this ubiquitination is not 
required for RhoA expression, so this is a novel ubiquitination-independent function 
of Skp2 (Chan et al., 2010). Skp2 may also act as a cofactor for other Myc target 
genes (von der Lehr et al., 2003). 
1.9.8	Role	of	Skp2	in	migration	and	metastasis	
Skp2 has been found to have a role in migration. Skp2-/- MEFs exhibit decreased 
ability to migrate to chemoattractants in a transwell assay; and in wound scratch 
assays, loss of Skp2 severely decreased the wound healing (Lin et al., 2009, Inuzuka 
et al., 2012). Skp2 was found to be involved in the ubiquitin-mediated degradation of 
E-cadherin, a transmembrane protein involved in maintaining cell-cell contacts. Upon 
treatment with the proteasome inhibitor, MG132, E-cadherin levels are increased 
(Inuzuka et al., 2012).  
1.9.9	Summary	of	the	roles	of	Skp2	in	cancer	
As Skp2 inactivation is not embryonic lethal in a knockout mouse model, and its 
oncogenic activity is far-reaching, Skp2 is an attractive target for small-molecule 
inhibition. An increasing body of data suggests that Skp2 plays essential roles in 
tumourigenesis induced by loss of PTEN and Rb or by overexpression of BCR-ABL, 
all of which are common events in human cancers. The role of cytoplasmic Skp2 in 
migration and metastasis provides further motivation to identify molecules for 
therapeutic intervention to inactivate Skp2 (Figure 1.21). One well-established 
mechanism of oncogenesis is the Skp2/ p27 axis, and this appears to be the most 
penetrative and functionally significant role of Skp2. High Skp2 levels are often 
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correlated with low p27 levels and p27 is the SCFSkp2 substrate which is most 
increased after Skp2 ablation (Nakayama et al., 2000, Hershko, 2008). However, 
there are also many tumour types where Skp2 overexpression is not accompanied by 
decreased p27 levels. Therefore, the role of Skp2 is likely to be tissue, tumour and 
cell-compartment specific.  
 
 
 
 
The role of Skp2 in tumourigenesis and tumour progression appears to be dependent 
on acetylation and phosphorylation status, subcellular localisation, and various 
binding partners (Figure 1.21). A more complete understanding of the roles of Skp2 
in cancer would benefit not only basic science, diagnosis and prognosis, but might 
also highlight pathways and protein targets suitable for drug discovery efforts. 
Figure 1.21: Oncogenic roles of Skp2. Skp2 has been implicated in many pro-
oncogenic pathways in the nucleus as well as in the cytoplasm to which Skp2 
localises after phosphorylation by Akt or acetylation by p300 within the NLS. 
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1.10 Targeting	 the	 Skp2/p27	 interaction	 for	 chemotherapeutic	
intervention	
1.10.1	Indirect	inhibition	of	Skp2	activity	
Skp2 has emerged as an attractive drug target due to its involvement in cell cycle 
control, apoptosis and metastasis; as well as emerging roles in the integration of cell 
signaling pathways involved in oncogenesis. The finding that Skp2 is nonessential for 
life, but required for cancer progression, has increased expectations of the therapeutic 
potential of Skp2 (Nakayama et al., 2000). Inhibitors have been developed which 
indirectly down-regulate Skp2 by targeting the ubiquitin-proteasome system (UPS) or 
affect Skp2 activity. The Food and Drug Administration (FDA) have approved the use 
of bortezomib (Velcade) for treatment of multiple myeloma and mantle cell lymphoma 
(Bross et al., 2004, Kane et al., 2007). Bortezomib is a 26S proteasome inhibitor which 
prevents degradation of all proteins carrying Lys48-linked ubiquitin chains. Therefore 
it is unlikely that specifically targeting Skp2 would have a similar effect in multiple 
myeloma or mantle cell lymphoma. There have been many side effects reported with 
clinical use of Bortezomib with peripheral neuropathy being one of the most significant 
(Argyriou et al., 2008, Orlowski and Kuhn, 2008, Swords et al., 2015). This might be 
due to the wide range of pathways affected by the inhibition of the proteasome. 
Another inhibitor which has broad effects is the neddylation activating enzyme (NAE) 
inhibitor, MLN4924 (Pevonedistat). Pevonedistat was the first reported neddylation 
inhibitor (Soucy et al., 2009). It blocks the neddylation of cullin proteins, thus 
preventing their activation. There are seven cullin proteins which make up the cullin-
RING E3 ubiquitin ligase (CRL) family and Pevonedistat inhibits the degradation of all 
CRL substrates, including p27 (Soucy et al., 2009), although much of the activity of 
Pevonedistat has been attributed to inhibition of SCF- and/or CRL4-mediated 
ubiquitination of Cdt1 (Soucy et al., 2009, Lin et al., 2010b). Clinical trials of 
Pevonedistat as a single agent in lymphoma, myeloma and melanoma are ongoing. 
Results from a recent clinical trial indicate that Pevonedistat has modest clinical 
activity in patients with acute myeloid leukaemia (AML) and myelodysplastic 
syndromes (MDS) (Swords et al., 2015). Notably, emergence of resistance to 
Pevonedistat has been observed in vitro (Toth et al., 2012, Milhollen et al., 2012). In 
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cell lines and xenograft mouse models, mutations in the ATP-binding pocket of NAE 
were identified as the primary mechanism of resistance to Pevonedistat (Milhollen et 
al., 2012). 
1.10.2	Direct	inhibition	of	Skp2	activity	
A number of groups have identified compounds that target Skp2 directly (summarised 
in Table 1.1 and Figure 1.22). The first compound of this type was reported in 2008, 
when Chen and co-workers identified a set of inhibitors which were able to disrupt the 
Skp1/Skp2 complex (Chen et al., 2008). Inhibitors were screened using in vitro 
translated 35S-labeled p27 and an in vitro reconstituted system consisting of CDK2, 
cyclin E, Skp1, Skp2, Cul1, Roc1 and a HeLa cell extract. Their lead compound, 
compound A (CpdA), was found to decrease p27 ubiquitination in this system. They 
showed that CpdA induced G1 cell cycle arrest and caspase-independent apoptosis 
(Chen et al., 2008). No further investigations on CpdA have been published since this 
initial report. 
Other inhibitors have been developed which are reported to disrupt the Skp1/Skp2 
interaction (Chan et al., 2013). Using the Skp1/Skp2 crystal structure, two potential 
pockets where small molecule inhibitors might bind were identified and virtual 
screening was used to identify hit compounds. The lead compound, compound 25, 
was hypothesized to bind to a pocket on Skp2 at the interface which contacts Skp1. 
Compound 25 was found to selectively bind Skp2 without affecting the interaction of 
Skp1 with the F-box proteins Fbw7 and β-TrCP. Compound 25 is able to prevent 
complex assembly in an in vitro system, however, the Skp1/Skp2 complex could not 
be disrupted after it had been formed.  
Comparing these two studies which identified CpdA and compound 25, there were 
differences in the mechanisms of action of the compounds, for example, CpdA was 
found to induce autophagic cell death, whereas compound 25 induced cellular 
senescence. These differences may be due to where the putative binding sites of the 
two molecules are located, as compound 25 is believed to bind to Skp2, whilst the 
CpdA binding site has not been determined. Neither compound has been co-
crystallised with Skp1 or Skp2 to confirm their binding sites and as Skp2 requires 
Skp1 for stability (Li et al., 2005), a structure of compound 25 with Skp2 might be 
challenging to obtain. Chan and colleagues also investigated the effect of compounds 
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on glycolysis, as the group had shown in an earlier publication that Skp2 deficiency 
impairs Glut1 expression, glucose uptake and glycolysis (Chan et al., 2012). They did 
indeed find that Skp2 inhibition by compound 25 suppressed glycolysis in two prostate 
cancer cell lines as determined by decreased expression of the glucose transporter 1 
(Glut1) (Chan et al., 2013).  
The interaction of p27 with Skp2/Cks1 has also been targeted for inhibition with small 
molecules (Ooi et al., 2013). A high-throughput screening system was used to identify 
small molecule inhibitors which would displace p27 from the Skp2/Cks1 interface. 
Skp2 was tagged with a fluorophore and Skp1, Skp2 and Cks1 were co-expressed in 
insect cells. The complex of Skp1/Skp2/Cks1 was added to a 96 well plate coated 
with covalently attached p27 phosphopeptide in the presence of small molecules. Two 
compounds, linichlorin A and gentian violet, were identified as inhibitors of p27 binding 
to Skp2/Cks1. The compounds have anti-proliferative activity against cancer cells and 
transformed cells, with IC50 values in the µM range (Ooi et al., 2013). A similar screen 
was developed in the Liu lab to find inhibitors of the Skp2/Cks1 interaction 
(Ungermannova et al., 2013). An AlphaScreen assay was used, which is a bead-
based proximity assay. With a hit rate of 2.8%, 45 compounds were identified which 
disrupt the interaction of Skp2 with Cks1. An in vitro ubiquitination counterscreen 
identified two compounds, NSC689857 and NSC681152 which inhibit p27 
ubiquitination (Ungermannova et al., 2013). 
Another set of inhibitors believed to inhibit the interaction of p27 with Skp2/Cks1 
came from the Pagano and Cardozo group (Wu et al., 2012). Using the Skp1/Cks1 
crystal structure, a pocket formed by both Skp2 and Cks1 was identified, which is 
flanked by residues important for the binding of p27. A virtual screen of 315,000 
compounds was carried out and mutagenesis was subsequently used to check that 
the lead compounds bound in the desired pocket. The authors identified four lead 
compounds, C1, C2, C16 and C20, but were unable to confirm their potential binding 
modes by co-crystallisation with Skp1/Skp2/Cks1 (Wu et al., 2012). They showed that 
p27 levels increase upon addition of the compounds, whilst p130 and Cdt1 (which are 
Cks1-independent substrates) were not affected, suggesting that the compounds 
might be specific for p27, p21 and possibly also p57. Following on from this initial 
study, the Cardozo group showed that their inhibitors increase nuclear p27 levels and 
decrease cytoplasmic levels over time in endometrial carcinoma (ECA) cell lines. 
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They also tested their compounds in vivo. Ovariectomised mice were injected with 
several doses of estradiol (E2) to induce p27 degradation. The mice were then treated 
with the C-series inhibitors, and this blocked p27 degradation and inhibited 
proliferation (Pavlides et al., 2013). 
Name of inhibitor Interaction 
targeted 
Cellular response to 
inhibitor 
Reference 
CpdA Skp1-Skp2  Decreased p27 
ubiquitination. G1 
arrest and caspase-
independent apoptosis 
observed in myeloma 
cell lines 
(Chen et al., 
2008) 
Compound #25 Skp1-Skp2  Induces cellular 
senescence, inhibits 
proliferation and 
reduces cancer 
glycolysis in prostate 
cancer cell lines.  
(Chan et al., 
2013) 
Linichlorin A and 
gentian violet 
p27 to Skp2/Cks1  Anti-proliferative in 
HeLa and tsFT210 
cells. 
(Ooi et al., 
2013) 
C1, C2, C20, 
C16 
p27 to Skp2/Cks1  Induce p27 
accumulation, G1 and 
G2/M arrest in breast 
and prostate cancer 
cell lines. Anti-
proliferative in vivo. 
(Wu et al., 
2012, Pavlides 
et al., 2013) 
NSC689857 and 
NSC681152 
Skp2-Cks1 Inhibition of p27 
ubiquitination. 
(Ungermannova 
et al., 2013) 
 
 
1.10.3	Can	structural	studies	guide	development	of	small-molecule	inhibitors	of	
Skp2?	
Structural studies over the past decade and a half have identified a number of 
potential pockets on Skp2 within the Skp2/Cks1 complex, which appear to be 
amenable to small-molecule inhibition (Figure 1.22). The most successful inhibitor of 
the SCFSkp2 complex is MLN4924 or Pevonedistat, which is a pan-Cullin inhibitor. The 
Pagano and Cardozo groups identified novel inhibitors specific to the degradation of 
Table 1.1: Published small-molecule inhibitors of the SCFSkp2complex.  
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a subset of CKIs. They were able to show that these compounds induced cell cycle 
arrest (Wu et al., 2012). However, they were unable to obtain a crystal structure of 
their inhibitors bound to Skp2/Cks1 (Wu et al., 2012). Skp2 on its own is very unstable 
and therefore compounds which disrupt the Skp1/Skp2 interaction would be expected 
to render Skp2 unlikely to crystallise. This makes it difficult to define structure-activity 
relationships for any compounds, and is perhaps the reason for the stalling of SCFSkp2 
drug discovery efforts over the past few years. 
	
 
 
 
 
Figure 1.22: Interactions of the SCFSkp2 complex which have been targeted for 
small-molecule inhibitor development. 1) Cul1 activation has been targeted 
through inhibition of neddylation by MLN4924 (Pavonedistat) (Soucy et al., 2009). 2) 
The Cdc34 inhibitor, CC0651, has been shown to inhibit the ability of Cdc34 to 
ubiquitinate substrates (Ceccarelli et al., 2011). 3) Compound A and compound 25 
are believed to inhibit the Skp1/Skp2 interaction (Chen et al., 2008, Chan et al., 
2013). 4) Compounds have been identified which directly block the interaction of p27 
with Skp2/Cks1 (Wu et al., 2012). Figure adapted from Hao et al. (2005). 
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Overview	and	aims	of	thesis	
Skp2 was first identified as a component of a CDK2/cyclin A/Skp1/Skp2/Cks1 
complex with unknown function (Zhang et al., 1995). Skp2 was later found to be the 
substrate recognition component of the SCF E3 ubiquitin ligase complex involved in 
the degradation of a range of substrates that include p27, p21, p57 and cyclin E. Over 
the past decade, further roles for Skp2 have been reported in areas such as cell cycle 
control through the indirect inactivation of Rb; metastasis through RhoA gene 
transactivation; activation of Akt through Lys63-linked ubiquitination; and cell 
migration through enhanced degradation of E-cadherin.  
There is controversy both over the role of cyclin A in both p27 ubiquitination and Skp2 
regulation. A number of investigations have shown that the Skp2/cyclin A interaction 
is required for optimal p27 ubiquitination (Zhu et al., 2004, Montagnoli et al., 1999, 
Sitry et al., 2002) and others have suggested that this interaction is required for 
regulation of Skp2 or CDK2/cyclin A kinase activity (Ji et al., 2006, Gao et al., 2009). 
This investigation first sought to identify the regions of Skp2 that interact with cyclin A 
and Cdh1. This knowledge would provide novel insights into the binding mechanism 
of Skp2 to cyclin A, identify potential overlapping sites of Skp2 protein interaction and 
help to explain how post-translational modifications in the N-terminal region of Skp2 
may regulate alternative Skp2 complex assembly. This knowledge might also help to 
guide the development of small molecules to inhibit Skp2 activity. This work would 
build on compounds reported in the literature and that are currently in preclinical trials 
that block Skp2 function. Compound development has been hindered by a lack of 
appropriate Skp2-containing crystal structures. Despite this drawback, Skp2 remains 
a key potential target to treat many cancers and other Skp2-protein interactions might 
offer a better approach to targeting Skp2. 
At the start of this project, it was known that Skp2 and p27 compete for binding to 
CDK2/cyclin A and Skp2 does not bind to CDK2/cyclin E. Although an RXL motif of 
Skp2 was identified as the putative cyclin A binding site (Sutterluty et al., 1999), it was 
later determined that Skp2 binds to a separate region of cyclin A as Skp2 binds 
independently of a RXL-containing short peptide (Ji et al., 2007). Therefore, the Skp2 
and p27 binding sites are believed to overlap on the cyclin A surface, but at a site 
distinct from the RXL recruitment site. 
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Chapter 3 describes an investigation to identify cyclin A residues that mediate its 
interaction with Skp2. The Skp2 binding site on cyclin A is a novel site. Mutations at 
this site do not affect the catalytic activity of CDK2/cyclin A or disturb the cyclin A 
structure. The binding site of cyclin A on Skp2 is described in Chapter 4. The Skp2 
mutant that is unable to bind to cyclin A is a useful tool to study the functional 
significance of this interaction and to develop further inhibitors that block Skp2 
function. Studies to determine the crystal structure of Skp2 bound to CDK2/cyclin A 
are also described in Chapter 4. The validation of the Skp2 and cyclin A interaction 
sites in cellulo is described in Chapter 5, as well as the potential use of this mutant as 
a tool for investigating the function of the Skp1/Skp2/CDK2/cyclin A complex.
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Chapter	2:	Experimental	procedures	
2.1	Protein	expression	and	purification	
2.1.1	Expression	of	human	pThr160	CDK2	
The pGEX-6P-1-GST-CDK2-GST-CAK1 DNA construct (Brown et al., 1999) was 
transformed into chemically competent E. coli BL21 (DE3) pLysS cells (Agilent 
Technologies) according to the manufacturer’s instructions. A single colony was 
picked to grow an overnight culture in 5-10 mL of Luria-Bertani (LB) medium. 
Ampicillin (Amp, 50 mg/L) and chloramphenicol (Cam, 34 mg/L) were added to 
maintain the pGEX-6P-1 and pLysS vectors, respectively. The saturated overnight 
culture was used to inoculate between 1 and 6 litres LB medium supplemented with 
antibiotics (Amp and Cam), which was incubated at 37°C with vigorous shaking. Once 
the culture reached an OD600 of between 0.8 and 0.9, the temperature was dropped 
to 18°C and the cells were left to equilibrate to this temperature for one hour. Isopropyl 
β-D-1-thiogalactopyranoside (IPTG) was then added to a final concentration of 80 µM. 
The cells were then incubated for 20 hours at 18°C with shaking. The cells were 
harvested by centrifugation at 4000 rpm (Beckman JLA, 8.1000) at 4°C for 20 
minutes. The cell pellet was resuspended in 35 mL ice-cold modified HEPES-buffered 
saline (mHBS) buffer (Appendix A, Table A1.1) supplemented with a cOmplete™ 
EDTA-free protease inhibitor cocktail tablet (Roche) and stored at -20°C until use. 
2.1.2	Expression	of	human	cyclin	A	
The pET21d human cyclin A DNA construct (residues 174-432 with a C-terminal 
hexahistidine tail (Brown et al., 1999)) was transformed into chemically competent E. 
coli BL21 (DE3) pLysS cells (Agilent Technologies) according to the manufacturer’s 
instructions. A single colony was picked to grow an overnight culture in 5-10 mL of LB 
medium. Amp (50 mg/L) and Cam (34 mg/L) were added to maintain the pET21d and 
pLysS vectors, respectively. The saturated overnight culture was used to inoculate 
between 1 and 6 litres of LB medium supplemented with antibiotics (Amp and Cam), 
which was incubated at 37°C with vigorous shaking. Once the culture reached an 
OD600 of between 0.5 and 0.6, the temperature was dropped to 30°C and the cells 
were left to equilibrate to this temperature for 15 minutes. IPTG was then added to a 
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final concentration of 100 µM. The cells were then incubated for 3 hours at 30°C with 
shaking. The cells were harvested by centrifugation at 4000 rpm (Beckman JLA 
8.1000) at 4°C for 20 minutes. The cell pellet was resuspended in 35 mL ice-cold 
mHBS buffer supplemented with a cOmplete™ EDTA-free protease inhibitor cocktail 
tablet (Roche) and stored at -20°C until use. 
2.1.3	Expression	of	Skp1/Skp2-N	
The pGEX-6P-1-GST-Skp2-Skp1 construct (Figure 2.1) was transformed into 
chemically competent E. coli BL21 (DE3) pLysS cells (Agilent Technologies) 
according to the manufacturer’s instructions. In this expression strategy the GST-
Skp2 and Skp1 sequences are transcribed as a single mRNA that includes a second 
ribosome binding site downstream of the Skp2 stop codon. This construct encodes 
Skp2 residues 1-140 (Skp2-N) and full-length Skp1 (residues 1-163, Appendix A, 
Table A1.4). The GST-Skp2 fusion and Skp1 are translated from a single RNA 
transcript which encodes an internal ribosome binding site (RBS) 3’ to the Skp2 stop 
codon to initiate Skp1 translation (Figure 2.1). A single colony was picked to grow an 
overnight culture in 5-10 mL of LB medium. Amp (50 mg/L) was added to maintain 
the pGEX-6P-1 vector. The saturated overnight culture was used to inoculate 
between 1 and 6 litres of LB medium supplemented with Amp (50 mg/L), which was 
incubated at 37°C with vigorous shaking. Once the culture reached an OD600 of 
between 0.5 and 0.6, the temperature was dropped to 30°C and the cells were left to 
equilibrate to this temperature for 15 minutes. IPTG was then added to a final 
concentration of 100 µM. The cells were then incubated for 3 hours at 30°C with 
shaking. The cells were harvested by centrifugation at 4000 rpm (Beckman JLA 
8.1000) at 4°C for 20 minutes. The cell pellet was then resuspended in 35 mL ice-
cold mHBS buffer supplemented with a cOmplete™ EDTA-free protease inhibitor 
cocktail tablet (Roche) and stored at -20°C until use. 
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2.1.4	Expression	of	Rb	
GST-tagged Rb C-terminal construct encoding Rb residues 792-928 in the pGEX-2T 
backbone (Adams et al., 1999, Brown et al., 1999) (RbCT) was expressed in 
chemically competent E. coli BL21 (DE3) and purified by glutathione-Sepharose 
affinity chromatography as described (Brown et al., 1999). The GST-tag was not 
cleaved. Glycerol was added to the glutathione-Sepharose column eluate to a 
concentration of 50% and protein was stored at -20°C. 
2.1.5	Other	proteins	required	
Monomeric CDK2 was kindly provided by Mathew P. Martin, and p27 proteins were 
kindly provided by Martyna W. Pastok. All site-directed mutants and truncated 
versions of the above proteins were prepared using the same protocols as described 
above. The Skp2-C plasmid construct was a gift from Bing Hao (University of 
Connecticut). Judith Reeks expressed and purified Skp2-C for experiments described 
in Chapter 5, Section 4.3. 
2.1.6	Lysis	of	E.	coli	cells	
Lysozyme, DNase I and RNase were added to the resuspended cells (0.25 mg/mL, 
10 µg/mL and 50 µg/mL final concentrations, respectively). The cells were lysed on 
ice by sonication, using pulses of 15 seconds on, separated by 15 seconds rest for a 
Figure 2.1: GST-Skp2/Skp1 construct. The GST-Skp2 and Skp1 gene 
sequences are transcribed into a bicistronic mRNA and then translated using 
separate ribosome binding sites. The GST tag is attached to the Skp2 N-
terminus. Figure is from (Schueller, 2001). 
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total of five minutes. Lysates were then spun at 20,000 rpm for 1 hour at 4°C 
(Beckman Coulter Avanti, JA 25.5). The cleared supernatant was recovered and kept 
on ice.  
2.1.7	GST-affinity	purification	
The GST-tagged protein complexes were purified by glutathione-Sepharose (GE 
Healthcare) affinity purification. The gravity-flow column (typically of bed volume 1-5 
mls) was equilibrated in mHBS before the lysates were loaded onto the column.  The 
column was run by gravity flow, allowing sufficient time for the GST to bind sufficiently. 
The column was washed with 10 column volumes (cv) of mHBS and then the complex 
was eluted with 20 mM glutathione in mHBS pH 7.0. The protein concentration of the 
eluate was determined using a Nanodrop 2000 (Thermo Scientific™) and GST-3C 
protease was added at a ratio of 1:50 w/w, protein of interest:3C protease, where 
cleavage of the GST-tag was required. Cleavage reactions were allowed to proceed 
overnight at 4°C. 
2.1.8	Nickel-affinity	purification	
His-tagged bovine cyclin A was purified by nickel-affinity purification. The cleared 
lysate was loaded onto a 5 ml Ni-NTA column (GE Healthcare) pre-equilibrated in 
mHBS. The column was washed with 5 cv of 15 mM imidazole in mHBS. Elution was 
then performed with an imidazole gradient up to 300 mM imidazole in mHBS. Eluted 
fractions were analysed by SDS-PAGE for the protein of interest. 
2.1.9	Size-exclusion	chromatography	
All proteins/ protein complexes were further purified using size-exclusion 
chromatography (SEC). 2-5 mL of concentrated protein (typically between 1-10 
mg/ml) was loaded onto a Superdex 75 (26/60) column (GE Healthcare) which had 
been pre-equilibrated in mHBS. 2-4 mL fractions were collected and then analysed 
by SDS-PAGE to identify fractions containing the protein(s) of interest and determine 
their purity. 
2.1.10	Subtractive	affinity	purification	
A second glutathione-Sepharose purification was done in order to eliminate residual 
cleaved GST, as CDK2/cyclin A and Skp1/Skp2-N elute at the same volume on SEC 
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columns as GST. The column was again run under gravity-flow. Proteins were 
recovered in the unbound fraction and concentrated for subsequent experiments in 
10, 000 kDa molecular weight cut off (MWCO) VivaSpin filter concentrators 
(Sartorius), spun at 5,000 rpm (Beckman Coulter Allegra 25R, TA-10-250) and at 4°C. 
2.1.11	SDS-PAGE		
Unless otherwise stated 12% SDS-PAGE gels were used (Expedeon). LDS sample 
buffer (Expedeon) was mixed with samples with a ratio of 1:4, before boiling at 100°C 
for two minutes. InstantBlue gel stain (Expedeon) was used to visualise protein bands. 
2.2	Site-directed	mutagenesis	
2.2.1	Overview	
Site-directed mutagenesis (SDM) is a method of creating targeted base changes in 
double-stranded plasmid DNA. There are several applications of SDM, such as the 
study of the effect of amino acid changes on protein function, or to remove or insert 
restriction endonuclease sites. Two synthetic oligonucleotides are designed, both 
containing the desired mutation. The strands are complementary to each other and 
the respective strands of the template. These oligonucleotides hybridise with the 
template after denaturation of the double-stranded DNA (dsDNA). The 
oligonucleotide primers are extended during incubation at an optimal temperature for 
the DNA polymerase. Multiple cycles of denaturation, hybridisation and extension 
generate plasmids with the desired mutations. Following temperature cycling, the 
product is treated with DpnI endonuclease. DpnI digests methylated and 
hemimethylated DNA, and thus digests the parental plasmid as DNA from most E. 
coli strains is Deoxyadenosine methylase (dam) methylated. The mutated plasmid 
can then be transformed into competent cells. 
2.2.2	Primer	Design	
Primers were designed according to the Stratagene Quickchange SDM user 
manual and purchased from Integrated DNA Technologies (purified using standard 
desalting methods). The following equation was used to calculate the optimal 
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sequence of a primer. Primers were designed such that the melting temperature 
(Tm) was greater than 78°C, when possible. 
 
                      Tm = 81.5 + 0.41(%GC) – 675/N - % mismatch             (Equation 2.1) 
 
Where N is the number of bases and %GC is the percentage of guanines and 
cytosines in the primer sequence. 
2.2.3	Reaction	compositions	
Primers were designed with desired mutations (see Appendix A, Table A1.2 for a list 
of primers used). Mutagenesis was carried out using WT and mutants of human cyclin 
A (residues 174-432) in pET21d as templates (Ruddick, 2010) according the 
manufacturer’s instructions (Stratagene). The three mutated cyclin A sequences used 
as templates contained the following mutations: Mutant 5= M246Q, S247EN; Mutant 
9= R293T and Mutant 10= T303K, D305R. Cyclin A mutants were subsequently 
verified by sequencing (Source Bioscience) and transformed into chemically 
competent E. coli BL21 (DE3) pLysS cells for expression.  
All other mutagenesis reactions were carried out using Phusion polymerase 
according to the Phusion PCR manual (NEB). GC buffer was used, DMSO was added 
to a concentration of 3% and MgCl2 was added to a final concentration of 2 mM. 
Primer anneal temperatures and elongation times were altered depending on the 
primers and templates used, respectively. Reactions were run in an Applied 
Biosystems GeneAmp PCR system 2700. Methylated template DNA was digested 
with DpnI (10 units at 37°C for 1 hour) and the reactions were transformed into 
chemically competent E. coli DH5α cells (NEB). The plasmids were amplified in 5 mL 
overnight cultures of DH5α cells in LB medium supplemented with 50 µg/mL Amp. 
Plasmids were then purified using the Qiagen Miniprep kit according to the 
manufacturer’s instructions. Sanger sequencing was used to verify the mutations had 
been correctly created, performed by Source Bioscience or Eurofins MWG. 
2.3	DNA,	RNA	and	protein	quantitation	
DNA, RNA and protein concentrations were determined using a Nanodrop 
Spectrophotometer 2000 (Thermo Scientific). Extinction co-efficients for proteins and 
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protein complexes were calculated using the Expasy Protparam program 
(http://web.expasy.org/protparam/). The extinction co-efficient is related to the residue 
composition of a protein. Only tryptophans (W), tyrosines (Y) and to a lesser extent 
cysteines (C) contribute to absorbance at 280 nM. Phenylalanine (F) absorbs at lower 
wavelengths (240-265). 
2.4	Subcloning	and	plasmid	preparation	
Unless otherwise stated, InFusion cloning (Clontech) was used to subclone 
sequences. Primers for InFusion cloning are given in Appendix A, Table A1.3. The 
InFusion protocol from Clontech was followed throughout. Digested plasmids and 
PCR products were cleaned up using a PCR clean-up kit (Qiagen) prior to InFusion 
reaction. Reactions were initially transformed into chemically competent E. coli Stellar 
cells (Clontech) and plasmids purified from overnight cultures using a Miniprep kit 
(Qiagen).  
2.5	Enzyme	kinetic	analysis	of	CDK2/cyclin	A	complexes	
2.5.1	Rb	phosphorylation	assay	
9 µL of 1 mg/mL RbCT stock, 6 µL 10x kinase buffer (5 mM ATP, 2 mM MgCl2, 0.5 M 
Tris-HCl pH 7.5) and 39 µL ddH2O were mixed in microcentrifuge tubes. Reactions 
were started with the addition of 6 µL CDK2/cyclin A WT or mutant. Reactions were 
incubated for 0-10 minutes. The reaction was stopped after each time point by 
removing a 20 µL aliquot, adding it to a tube containing 4x LDS loading buffer and 
boiling. Samples were analysed on an 8% gel, which provided a good separation of 
the variously hyperphosphorylated Rb proteins. 
2.5.2	Histone	H1	phosphorylation	assay	using	radioisotope-labelled	ATP	
10 µg of CDK2/cyclin A was mixed in buffer 2 (10 mM Tris, 80 mM NaCl pH 7.5, 20% 
v/v glycerol, final assay concentration was 10 µg/mL) and 750 µg of Histone H1 was 
dissolved in buffer 2 (final assay concentration was 883 µg/mL). The reaction was 
started with the addition of [32P] ATP to a final concentration of 12.5 µM, vortexing 
and placing in a waterbath at 30ºC. At each time interval, an aliquot of the reaction 
mix was taken out and spotted onto filter paper. The filter papers were then dried for 
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20 seconds and transferred to 1% phosphoric acid. [32P] incorporation into histone H1 
was measured by liquid scintillation counting. Reactions were carried out by Dr Lan 
Wang. 
2.6	Isothermal	titration	calorimetry	
2.6.1	Isothermal	titration	calorimetry	theory	
Isothermal titration calorimetry (ITC) is a biophysical technique used to quantitatively 
determine properties of bi-molecular interactions (Ladbury and Chowdhry, 1996). It is 
a useful complementary technique to structural biology as it allows a biochemist to 
define molecular mechanism in great detail. Every bi-molecular interaction has either 
an uptake or release of heat associated with it, and ITC is a universal indicator of 
binding (Ladbury, 2004). The equilibrium binding constant Kb (this is the reciprocal of 
the dissociation constant, Kd, commonly used as a measure of protein interactions) 
can be determined by direct measurement of heat exchanged as one component is 
titrated into the other. Unlike many other techniques, ITC allows the analysis of 
interactions between proteins in their native forms free from labelling and 
immobilisation (Cooper, 2003). 
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A calorimeter has two cells, the reference cell and the sample cell (Figure 2.2). They 
are in an enclosed adiabatic jacket which stops heat being lost into the surroundings. 
Constant energy is applied to both cells to keep a constant temperature. As the titrant 
is injected into the sample cell, this causes heat to either be taken up or be evolved. 
The change in the input energy to the sample cell to keep a constant temperature with 
respect to the reference cell is measured. The energy applied to the sample cell is 
plotted in µcal/sec. Each injection produces a change in the heat applied to the 
sample cell and then a return to baseline. Integration of these heat pulses gives the 
total heat exchanged per injection. Thermodynamic parameters can be derived from 
the heat exchanged. Using the equation below, the entropy of binding  (ΔS), Gibbs 
free energy (ΔG), enthalpy upon binding (ΔH) and the association constant (K) can 
be calculated (Equation 2.2). The stoichiometry of the interaction (n) can also be 
determined from the molar ratio of the reactants (protein A/protein B) at the 
equivalence point of the titration (ITC-200 MicroCalorimeter User’s Manual, GE 
Healthcare). 
 
Figure 2.2: Schematic of an isothermal titration calorimeter. The 
microcalorimeter consists of two cells, the sample cell and the reference cell. One 
protein is loaded into the cell, the other is titrated into the cell from the syringe, and 
the heat exchanged upon binding is measured. 
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                                      ΔG = -RT lnKa = ΔH – TΔS                             (Equation 2.2) 
R is the gas constant (8.314 JK-1mol-1) and T is the absolute temperature. Enthalpy 
(ΔH) provides an indication of changes in hydrogen and van der Waal’s bonding, 
whereas TΔS provides an indication of changes in hydrophobic interactions and 
conformational changes. ΔS is positive for entropically driven reactions. 
Another parameter which can be determined by ITC is the stoichiometry (n-value) of 
the interaction. This is the average number of binding sites per mole of protein. The 
value for a 1:1 interaction is 1, however this can differ from 1 in an experiment due to 
many factors. These include miscalculation of protein or ligand concentration; having 
impurities in the protein or ligand solutions; having binding sites which are not all 
equally accessible or identical; or the proteins or ligands not being properly folded or 
active (ITC-200 MicroCalorimeter User’s Manual, GE Healthcare). 
In order to design an ITC experiment, a unitless c-value is used to describe the 
practical window over which the instrument can accurately determine the binding 
constants (Equation 2.3). A working c-value of 10-500 is preferable (Wiseman et al., 
1989). It is recommended that the molar concentration of protein A (syringe) is 10 
times greater than the molar concentration of protein B (cell). Given the volume of the 
cell (200 µl) and the syringe (40 µl), these starting conditions will ensure that at the 
end of the titration, there is a 2-fold molar excess of the titrant.  
                                 c = [M]/KD                                             (Equation 2.3) 
[M] is the molar concentration of the protein in the cell (protein B in Figure 2.2). 
2.6.2	ITC	experiments	
Protein concentration was determined using a Nanodrop 2000 spectrophotometer 
(see Section 2.3). CDK2/cyclin A could not be concentrated to as high a concentration 
as Skp1/Skp2, so Skp1/Skp2 or p27 peptides were injected from the syringe into 
CDK2/cyclin A in the cell. Proteins were adjusted to the correct concentration using 
mHBS. To avoid buffer mismatch, proteins were purified using the same SEC column 
in the same buffer. The temperature was kept at 25°C. There was an initial delay of 
60 seconds. The titrations consisted of 18 injections, an initial injection of 0.5 µL and 
then 17 injections of 2 µL with 180 seconds between injections. The stirring speed in 
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the reaction cell was 1000 rpm. Heats of Skp1/Skp2 or p27 dilution were determined 
in independent control experiments by diluting the syringe content into buffer. 
2.6.3	ITC	data	analysis	
The ITC data were analysed using non-linear least squares regression in the Origin® 
software (OriginLab®). Drifts in the baseline were corrected during data analysis. The 
heats of dilution caused by the addition of the syringe content into buffer in the cell 
were subtracted from the addition of the syringe contents into the sample in the cell 
for all sets of data apart from the initial cyclin A mutant data (Figure 3.14).  Origin 7.0 
(OriginLab Corp.) was used for all data analysis, including ligand dilution subtractions 
and data fitting to the one-set-of-sites model. 
2.7	Skp1/Skp2	pull-down	assay	
Compounds were dissolved in DMSO to a concentration of 100 mM and 10 mM. 200 
µL of IgG-binding magnetic beads (Novex, Life Technologies) were washed twice with 
200 µL IP lysis buffer (Pierce). 20 µL of magnetic IgG binding bead suspension were 
added to microcentrifuge tubes (1.8 mL) followed by 200 µL of lysis buffer containing 
5 µg of anti-Skp2 antibody (8D9, 32-3300 Life Technologies) and this mixture was 
then rotated gently for 30 minutes. 20 µg of purified, untagged Skp1/Skp2 was added 
and a 2 µg sample was taken for the 10% inputs. The microcentrifuge tubes were 
rotated at 4ºC for one hour. The tubes were placed on a magnet to sediment the 
beads. The supernatant was removed, and 198 µL lysis buffer with 2 µL inhibitor was 
added. The final concentrations of inhibitor were 1 mM and 100 µM. The tubes were 
then left rotating overnight at 4ºC. The following morning, the magnetic beads were 
washed twice with 200 µL IP lysis buffer. 30 µL of Laemmli buffer (6.25 mM Tris/HCl, 
2% w/v SDS, 10% v/v glycerol, 5% v/v β-mercaptoethanol, 0.0025% w/v bromophenol 
blue, pH 6.8) was then added. The sample was split to run two SDS-PAGE gels 
followed by Western blot in order to probe for Skp1 and Skp2-N separately as they 
have similar molecular weights. 
2.8	Circular	dichroism	
The integrity of the CDK2/cyclin A mutant folds were assessed by circular dichroism 
(CD). CDK2/cyclin A complexes were buffer exchanged using a PD-10 column (GE 
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Healthcare) into 10 mM potassium phosphate pH 7.0. The final concentration of 
protein was 0.1 mg/mL. All CD experiments were taken on a Jasco J-810 
spectropolarimeter at 20°C. A buffer base-line was subtracted from the protein 
spectrum for each experiment. The far-UV CD spectra (190-250 nm), was measured 
using a 0.2 mm Hellma quartz cuvette, a 2nm bandwidth, and a scan speed of 20 
nm/min with a response time of 4s. The spectra were recorded as three averaged 
accumulations, and displayed as Δε (M-1cm-1) calculated using the mean residue 
concentration. In order to test the stability of the proteins, the melting temperature 
was calculated following the CD experiments. The CDK2/cyclin A complexes were 
slowly heated from 20ºC to 80 ºC causing the proteins to denature. When proteins 
unfold, they lose their highly ordered structures and the CD spectra is changed 
(Greenfield, 2006). Thereby, the melting temperature is given by the temperature at 
which there is a change in the CD spectra to one characteristic of an unfolded protein. 
2.9	Analytical	SEC	and	SEC-MALLS	
When light passes through a solvent, interaction with molecules in the solvent leads 
to scattering of the light. This scattered light is detected at many angles to the beam. 
Changes in solute lead to changes in the scattering and these are dependent on the 
concentration and molar mass of the solute. In a suitably calibrated system, this 
information can be used to determine the molar mass of the solute. For large proteins 
of greater than 200 kDa, this method can be used to determine protein size by deriving 
the radius of gyration. The SEC-MALLS instrument typically consists of a size-
exclusion column followed by a scattering detector and refractive index monitor. 
The SEC-MALLS instrument was calibrated with BSA immediately prior to this 
experiment. The instrument was run at 0.5 ml/minute in mHBS pH 7.0, 1 mM DTT 
which had been filtered twice to remove any small particles. Protein samples (100 µl) 
were loaded onto a Superdex 200 10/300 GL SEC column (GE Healthcare). The 
column output was analysed by a DAWN HELEOS II MALLS detector (Wyatt 
Technology), in which light scattered from a polarized laser source of 664 nm is 
detected by eight fixed angle detectors. The sample is then analysed by an Optilab 
T-rEX differential refractometer (Wyatt Technology), which measures absolute and 
differential refractive index using a 664 nm LED light source at 25°C. Data were 
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collected and analysed using ASTRA 6 software (Wyatt Technology). Data analysis 
was performed by Dr Owen R. Davies. 
2.10	X-ray	crystallography	
2.10.1	Introduction	to	X-ray	crystallographic	methods	
X-ray crystallography is a technique for obtaining atomic resolution structures of 
proteins. To obtain X-ray diffraction data, the molecules must be in an ordered 
crystalline array. One commonly used method of crystallisation is vapour diffusion, in 
which the protein solution is allowed to equilibrate in a closed container with a larger 
aqueous reservoir (Figure 2.3). Crystallisation requires high protein purity, usually 
greater than 95%. Commercial sparse matrix screens of various precipitants and 
conditions are generally used for initial screens. If crystallisation is successful, 
resulting crystals are tested for diffraction using X-rays. 
 
 
	
 
 
 
Figure 2.3: Protein crystallisation phase diagram. The protein solution 
increases in precipitant due to vapour diffusion. Crystal formation is initiated 
when the protein and precipitants are optimal within the nucleation zone window. 
The process of crystallisation decreases the concentration of the protein in the 
solution leading to crystal growth in the metastable zone. 
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2.10.2	The	unit	cell	
The simplest repeating unit of a crystal, which is repeated to form the crystal lattice, 
is called the unit cell. The translations in a three-dimensional lattice may be described 
in terms of three vectors a, b and c; and angles α, β and γ between them (Figure 2.4). 
A crystal is assigned a space group, which is classed based on the operations which 
described the crystalline periodicity. 
 
	
2.10.3	Bragg’s	Law	
Exposure of a protein crystal to X-ray radiation leads to diffraction of the X-ray by the 
lattice planes which satisfy Bragg’s Law (Equation 2.4). 
                                             2dsinθ = nλ                                            (Equation 2.4) 
Where d is the interplanar distance, θ is the scattering angle, n is the order of the 
reflection and λ is the wavelength of the incident wave. 
2.10.4	Structure	factors	
Each reflected wave can be described by a structure factor, which is a mathematical 
function describing the amplitude (!) and phase of a wave (") diffracted from crystal 
lattice planes. The structure factor equation (Equation 2.5) describes how structure 
factors can be calculated from the distribution of atoms in the unit cell. 
                                      # ℎ%& = ! ℎ%& . )*+[-"	 ℎ%& ]  
                          =	 01. exp	(61. exp	[28-	(ℎ*191 + %;1 + &<1)]                 (Equation 2.5) 
Figure 2.4: The unit cell of a crystal lattice. A primitive unit cell and 
parameters are illustrated. The dimensions of the unit cell are described with 
the vectors a, b and c and angles α, β and γ. 
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Where # ℎ%&  is the structure factor for the reflections of Miller indices ℎ	%	&; ! ℎ%&  is 
the structure factor amplitude; "	 ℎ%&  is the phase; 0 is the atomic scattering factor; 6 is the temperature factor (or B-factor); and *, ; and < are the fractional coordinates 
of atoms ? giving rise to the scattering. 
The structure factors can then be used to derive the electron density @ *;<  using 
Fourier Transform (Equation 2.6). 
        @ *;< = AB 	CDCECF	! ℎ%& . exp	[28-	 ℎ*1 + %;1 + &<1 ]                  (Equation 2.6) 
Where G is the unit cell volume. 
2.10.5	Molecular	Replacement	
As X-ray detectors can only record intensities but not phases, the phase information 
is lost. This is known as the ‘phase problem’. This phase problem can be solved using 
a number of methods. When a highly homologous molecule has been structurally 
characterised, the phases of the known structure can be used in order to solve the 
unknown structure. In order to solve the CDK2/cyclin A mut 7 structure, the method 
of molecular replacement was used starting from a high resolution CDK2/cyclin A WT 
structure (PDB code 2C5O) as the search model. 
Molecular replacement uses the Patterson method (Equation 2.7), which consists of 
three steps, a search for the rotation function [H]; a search for the translation t and 
finally a refinement of the position molecule(s). 
                                               IJ ≈ H IA + L                                      (Equation 2.7) 
First, the Patterson function, Pc, calculated from the model is compared to the 
observed data, Po, for all orientations of the data. This gives a rotation function, R 
which is a statistical quantity of the correctness of the molecular replacement solution.  
The Patterson function (Equation 2.8) is a Fourier transform of the square of the 
structure factor amplitudes, and can therefore be used to produce a density map. 
Peaks in the Patterson function indicate interatomic vectors. 
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   M N = 	CO@ * . @ * + N 	PG = 	 JB 	CDCECF	!(ℎ%&)J. cos 28	 ℎN + %T + &U ] 
  and         !DJ = V(ℎ%&)                                                                             (Equation 2.8) 
Where	M N  is the value of the Patterson function at a point specified by the vector N(N, T, U); @ * +	N  is the electron density at positions * and * +	N; and V is the unit 
cell volume. 
2.10.6	Crystallisation	and	structure	determination	of	CDK2/cyclin	A	mutant	7	
CDK2/cyclin A mut 7 was concentrated to 5.6 mg/mL in mHBS. As the mutant 
complex did not crystallise in conditions previously shown to support crystal growth 
of the CDK2/cyclin A WT complex, the mutant complex was re-screened in sitting 
drop 96-well trays (MRC two-well plate, Hampton Research) using a Mosquito liquid 
handler (TTP Labtech). Drops were 300 + 300 nL and 300 + 600 nL (protein + mother 
liquor). Crystals were first obtained from a Morpheus (Molecular Dimensions) 
commercial screen. A hit was obtained from condition H11, which corresponds to 0.1 
M Tris/Bicine pH 8.5, 0.1 M amino acids, 20% v/v glycerol, 10% w/v PEG 4K at 4°C. 
An optimisation screen was designed based on this condition. The optimisation 
screen was set up using a Biomek NXP automated workstation (Beckman Coulter). 
Stock solutions were 1 M Buffer 3 (Tris/bicine), 1 M amino acids, 100% glycerol and 
60% PEG 4K. Due to the high glycerol concentration, cryoprotectant was not required. 
Conditions which yielded crystals were Morpheus buffer 3 (Tris/bicine) pH 9.0, 20% 
v/v glycerol, 10% w/v PEG 4K, drop ratio 2:1; and Morpheus buffer 3 (Tris/bicine) pH 
9.0, 22.7% v/v glycerol, 11.3% w/v PEG 4K, 50 mM amino acids, drop ratio 1:1. 
Crystals were harvested using fibre loops and flash-cooled in liquid nitrogen. X-ray 
diffraction data were collected at the Diamond Light Source (Didcot, UK) on the I-24 
microfocus beamline. The automatic molecular replacement program MOLREP 
(CCP4 suite (Vagin and Teplyakov, 1997)) was used to calculate molecular 
replacement solutions and the correlation coefficients (the agreement between 
observed and calculated Patterson functions). Model building was done using Coot 
(CCP4 suite (Emsley et al., 2010)). 
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2.11	Cell	based	assays	
2.11.1	Maintenance	of	HeLa	and	HEK293T	cell	lines	
Human HeLa and HEK293T cells were grown in RPMI 1640 media (Gibco ®, Thermo 
Fisher Scientific) supplemented with 10% v/v foetal calf serum (FCS). Cells were 
grown at 37°C in 5% CO2 in a humidified incubator and passaged when confluency 
reached around 80%. Cell lines used in this study were routinely confirmed to be 
mycoplasma negative using the Mycoalert detection kit (Lonza) by Elizabeth 
Matheson.  
2.11.2	Transfection	of	HeLa	and	HEK293T	cells	
Cells were seeded onto 6-well plates or 10 cm dishes 18-20 hours prior to transfection 
at a density of about 5 x 104 cells/mL so that they achieved 60-70% confluency at the 
time of transfection. Transfection was carried out using LT1 (Mirius Bioscience) 
transfection reagent according to manufacturer’s instructions. Briefly, 0.75 µg (for 6-
well plates) or 4.5 µg (for 10 cm dishes) of each of the pcDNA3 Myc-Skp2 and 
pcDNA5/FRT/TO Flag-cyclin A vectors (prepared using an EndoFree Plasmid Maxi 
Kit, vector maps are shown in Figure 2.5) was added to Opti-MEM reduced serum 
media (ThermoFisher Scientific). 3 µL of LT1 was added for every 1µg of DNA. The 
mixture was swirled gently and incubated at room temperature for 20 to 30 minutes 
before adding dropwise to different areas of the wells or plate to evenly distribute the 
LT1:DNA complexes. Cells were placed in the 37°C incubator for 24 hours before 
harvesting (Section 2.11.3). For the IP experiments, two 10 cm dishes were used for 
every co-transfection (plasmid combination) in order to have excess amounts of 
protein for the IP experiments. 
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2.11.3	Lysis	of	HeLa	and	HEK293T	cells	
HeLa and HEK293T cells in 6-well plates were lysed by addition of 30 µL 6.25 mM 
Tris-HCl pH 6.8, 10% glycerol 2% SDS for the expression tests using the BCA assay 
(Section 2.11.4). For the immunoprecipitation experiments (Section 2.11.5) cells were 
scraped off the 10 cm dishes in ice-cold PBS and then spun down at 500 rpm 
(Eppendorf microcentrifuge) for five minutes. The supernatant was discarded and the 
cell pellet was resuspended in IP lysis buffer (Pierce). After lysis buffers were added, 
samples were stored at -20°C until use. 
2.11.4	BCA	assay	
A BCA assay kit (Pierce ThermoFisher) was used according to the manufacturer’s 
instructions to determine protein concentrations of whole cell lysates for measurement 
of expression levels of transfected proteins. Briefly, cells were thawed and sonicated 
for 15 seconds on ice. 2.5 µL were taken and mixed with 22.5 µL MilliQ water and 
added to wells of a flat-bottom 96-well plate. Reagent A and B were mixed according 
to the Manufacturer’s instructions and 200 µL was added to each diluted lysate in the 
96-well plate. The plate was incubated at 37°C for 30 minutes and then absorbance 
was measured at 570 nm using a Model 680 Microplate Reader (BioRad). Standard 
BSA concentrations were measured for every separate reading. 
Figure 2.5: Plasmid maps of pcDNA3.1 and pcDNA5/FRT/TO. (Reproduced 
from Life Technologies pcDNA3.1 and pcDNA5/FRT/TO manuals). 
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2.11.5	Immunoprecipitation	
Immunoprecipitation experiments were carried out using the Classic IP Kit (Pierce) 
with anti-Flag antibody (Sigma F1804), anti-Myc-tag antibody (9E10, SantaCruz 
sc40) or anti-Cdh1/FZR1 antibody (Life Technologies 34-2000). HeLa and HEK293T 
cells were suspended in IP lysis buffer (Pierce) supplemented with Halt Protease and 
Phosphatase Inhibitor Cocktail (Life Technologies) and transferred into 
microcentrifuge tubes. For each co-transfection (plasmid combination), two 10 cm 
dishes of cells were lysed per IP reaction. Cells were mixed for one hour at 4°C to 
allow cell lysis. The lysates were then passed through a 22 gauge needle, and spun 
down at 13,000 rpm (Beckman Coulter microfuge® 22R) for 15 minutes at 4°C. 80 µL 
of the supernatant was removed and retained as the whole cell lysate (WCL) fraction. 
The rest of the supernatant was added to the Control Agarose Resin. The supernatant 
and resin were mixed for 30 minutes and then the column flow-through was collected 
and 8 µg of antibody was added. The mixture was incubated on ice with occasional 
mixing for two hours and then the antibody-lysate mixture was added to prewashed 
Protein A/G Agarose, and mixed end-to-end for a further hour. The column was then 
washed according to the Classic IP Kit protocol. Anti-Flag antibody-immobilised and 
anti-Myc tag antibody-immobilised proteins were eluted with Flag (M2 peptide, Sigma) 
and Myc (M2435, Sigma) peptides, respectively. Cdh1 antibody-immobilised proteins 
were eluted by addition of 40-60 µL Laemmli sample buffer. 
2.11.5.1	Western	immunoblotting	
Proteins were separated on a 4-20% Criterion gel (Biorad) using SDS-PAGE, and 
then transferred to a polyvinylidene difluoride (PVDF) membrane using Biorad wet 
electroblotting equipment. Blots were blocked in Tris-buffered saline with 0.05% v/v 
Tween 20 (TBST) supplemented with 5% w/v dehydrated milk for one hour. Blots 
were incubated overnight at 4°C with primary antibody in TBST supplemented with 
5% w/v dehydrated milk at a dilution recommended by the manufacturer. Blots were 
washed for a total of 15 minutes in TBST. Stabilised peroxide-conjugated goat anti-
mouse (Dako) or goat anti-rabbit (Dako) antibody was added at a 1:1000 dilution and 
incubated for one hour at 4°C in TBST supplemented with 5% w/v dehydrated milk. 
Blots were washed again for a total of 40 minutes in TBST. Enhanced 
chemiluminescence (ECL, Pierce) was used as the Western blotting developing 
reagent and blots were exposed onto film (Kodak).  
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2.11.6	Antibodies		
Anti-cyclin A2 (BF683, 4656) was purchased from Cell Signalling. Anti-Skp2 (32-
3300) and anti-Cks1 (37-0200) were purchased from Life Technologies. Anti-Cdh1 
(ab3242) was purchased from Abcam. Anti-Flag (F3165) was purchased from Sigma. 
Anti-Myc (05-419) was purchased from Merck Millipore. Anti-CDK2 (sc-6248), anti-
p27 (sc-528) and anti-GAPDH (sc-25778) were purchased from Santa Cruz 
Biotechnology. 
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Chapter	3:	Identification	of	the	cyclin	
A	Skp2	binding	site	
3.1	 Creation	 of	 cyclin	 A	 mutants	 to	 identify	 the	 Skp2-binding	 site																			
on	cyclin	A	
3.1.1	Cyclin	A	is	unique	amongst	cyclins	in	its	interaction	with	Skp2	
CDK2/cyclin A has a role in the ubiquitination of p27 by the SCFSkp2 complex. As 
outlined in Chapter 1, Skp2 binds to cyclin A and this event may help to stabilise the 
interaction between CDK2/cyclin A and the SCFSkp2 complex. However, is not clear to 
what extent the Skp2/cyclin A interaction is required for p27 ubiquitination and whether 
the only function of the Skp2/cyclin A interaction is to assist the ubiquitination of p27. 
It has been demonstrated that the direct interaction between Skp2 and CDK2 is very 
weak (Ji et al., 2006) suggesting that the major interaction between CDK2/cyclin A 
and Skp2 is through the cyclin subunit. The same group demonstrated that Skp2 does 
not interact with CDK2/cyclin E, which, given that the two cyclins are very similar in 
structure (Figure 3.1), suggests surface sequence differences that might define a 
cyclin A-specific Skp2 binding site (Ji et al., 2006, Jeffrey et al., 1995, Honda et al., 
2005). 
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As expected for two cyclins that both partner CDK2 and bind to recruited substrates 
and p21/p27 inhibitors, cyclins A and E share a high degree of sequence similarity at 
the CDK2 interface and recruitment site, respectively (Jeffrey et al., 1995, Honda et 
al., 2005). Outside this region, the N-terminal CBF (N-CBF) is relatively well conserved 
(Figure 3.2). The sequence identity between cyclin E1 and cyclin A N-CBFs (residues 
126-225 and 207-305, respectively) is 42% and the r.m.s.d. in Cα carbons is 0.8 Å for 
100 atoms. The C-terminal CBFs (C-CBFs) of cyclin E1 and cyclin A share a fairly 
high degree of structural homology with an r.m.s.d in Cα of 1.4 Å (PDB 1W98 and 
1JST, respectively). However, the C-CBFs are poorly conserved at the sequence level 
with 13% homology (residues 226-330 of cyclin E1 and residues 306-401 of cyclin A). 
In addition to differences in sequence, CDK2/cyclin E and CDK2/cyclin A differ in their 
relative dispositions of the cyclin subunit. The C-terminal domain of cyclin E makes 
additional contacts with CDK2 particularly in the activation loop. Overall, the interface 
between CDK2 and cyclin E is 14% larger than that between CDK2 and cyclin A. Both 
Figure 3.1: CDK2 with superposed cyclin A and cyclin E. PDB codes 1JST (cyclin 
A) and 1W98 (cyclin E). CDK2 from 1W98 is shown. 
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the cyclin sequence and its interactions with the associated CDK2 subunit might 
contribute to the observed difference in binding affinity between Skp2 and CDK2/cyclin 
A vs CDK2/cyclin E. However both cyclins have similar activating effect on CDK2 
(Honda et al., 2005, Brown et al., 1995, Jeffrey et al., 1995).  
 
 
 
 
 
 
 
Additional insights into where cyclin A might bind Skp2 have been provided by 
competition studies with other known CDK2 regulators. CDK2/cyclin A was found to 
be associated with Skp2 in transformed cell lines, but associated with p21 in 
untransformed cell lines raising the possibility that Skp2 and p21 could be mutually 
exclusive in their binding to CDK2/cyclin A (Xiong et al., 1993b, Zhang et al., 1995). 
Further support for overlapping p21/p27 and Skp2 binding sites on cyclin A came from 
Figure 3.2: Alignment of the sequences of cyclin A and cyclin E showing the 
regions which are in close contact with p27. Orange bars indicate residues 
within 5 Å of p27. Cyclin A is the upper sequence. Adapted from Lacy et al. (2005). 
An asterisk indicates positions which have a fully conserved residue. A colon 
indicates conservation between groups of strongly similar properties, scoring >0.5 
in the Gonnet PAM 250 matrix. A full stop indicates conservation between groups 
of weakly similar properties, scoring =<0.5 in the Gonnet PAM 250 matrix. Figure 
was created using Clustal Omega (Sievers et al., 2011), uniprot codes P20248 
(cyclin A) and P24864 (cyclin E). 
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the discovery that p21 and p27 can both disrupt the CDK2/cyclin A/Skp2 interaction 
(Yam et al., 1999, Ji et al., 2006). However, Skp2 does not contain a solvent-
accessible RXLF motif (Figure 3.3) and a RXLF motif-containing peptide can bind to 
cyclin A in the presence of Skp2 (Ji et al., 2006). Taken together these results suggest 
that Skp2 may bind to a site on the upper surface of the N-CBF (relative to the 
orientation of Figure 3.3). 
	
 
3.1.2	Skp2	is	a	CDK2/cyclin	A	substrate	
CDK2/cyclin A substrates often bind to the RXL recruitment site of cyclin A. Cyclin 
binding to the substrate can confer specificity as changing a CDK’s cyclin partner 
alters the substrates phosphorylated by the complex (Brown et al., 2007, Loog and 
Morgan, 2005). The interaction of Skp2 with cyclin A is not required for Skp2 
phosphorylation (Ji et al., 2006). Skp2 is phosphorylated by CDK2/cyclin A and a Skp2 
mutant that shows decreased binding to cyclin A is still a CDK2/cyclin A substrate.   
 
Figure 3.3: The RXL motif of p27 binds to the cyclin recruitment site. Skp2 
does not contain an RXL motif and is believed to compete with p27 for binding 
to the upper surface of the N-CBF. CDK2 is in ice-blue, cyclin A is in yellow and 
p27 is in coral. 
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3.1.3	Skp2	may	be	a	regulator	of	CDK2/cyclin	A	
Ji and co-workers investigated the activity of a Skp2 blocking peptide, consisting of 
residues 28 to 45 of Skp2 (Ji et al., 2007). They found that this peptide was able to 
block the Skp2/cyclin A interaction, and the peptide was small enough that it did not 
block the p27 interaction. Therefore, the peptide and p27 could bind simultaneously 
keeping CDK2/cyclin A in an inactive state. This observation, together with their earlier 
work that showed that p27 could be competed off CDK2/cyclin A by an increasing 
concentration of Skp2, led to the hypothesis that Skp2 protects CDK2/cyclin A from 
p27 inhibition (Ji et al., 2006). Figure 3.4 shows the possible binding site of the Skp2 
blocking peptide which is predicted to be near the p27 binding site, but does not 
overlap with it. Therefore, other residues of Skp2, not included in this peptide, must 
mediate the interaction with cyclin A which does overlap with p27. 
 
 
In contrast, Yam and colleagues found that binding of the Skp1/Skp2 complex itself to 
CDK2/cyclin A inhibits kinase activity (Yam et al., 1999). In the original paper 
identifying Skp1 and Skp2 as CDK associated proteins, Skp2 was not found to 
Figure 3.4: Structure of CDK2/cyclin A with p27 showing the potential binding 
sites of a peptide of Skp2. Skp2 and p27 compete for binding to cyclin A, however 
a peptide of residues 28-45 of Skp2 is able to bind in combination with p27.  
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significantly affect CDK2/cyclin A kinase activity in vitro (Zhang et al., 1995). These 
differences might be explained by differences in experimental design, as Ji and co-
workers found Skp2 to be protective when p27 is present, whereas the other two 
studies were performed in vitro in the absence of p27. 
3.2	p27	competes	with	Skp2	for	CDK2/cyclin	A	
To confirm the observation that Skp2 and p27 binding to CDK2/cyclin A is mutually 
exclusive in vitro using purified proteins, Nicole Schueller demonstrated that at 
equimolar concentrations, CDK2/cyclin A preferentially partitions into a complex with 
p27 rather than Skp2 (Figure 3.5 (Schueller, 2001)).This observation supports the 
earlier experiments of Sitry and co-workers (Sitry et al., 2002) that demonstrated that 
although Skp2 can remove p27 from the CDK2/cyclin A complex at high 
concentrations, the binding of p27 to CDK2/cyclin A is much tighter than Skp2 to 
CDK2/cyclin A.  
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3.3	Overview	of	chapter	
This chapter describes experiments to identify the Skp2 binding site on cyclin A. A 
mutant cyclin A is described that shows negligible binding to Skp1/Skp2. Structural 
and kinetic analysis was performed on this cyclin A mutant in order to determine 
whether these mutations might affect cyclin A function or binding to other proteins. 
The mutant defines a novel protein binding site on the cyclin A N-CBF that is highly 
conserved across cyclin A orthologues and is not found in other cyclins that regulate 
the cell cycle. 
Figure 3.5: CDK2/cyclin A preferentially binds to p27 over Skp1/Skp2. A) Elution 
profiles of different complexes, as indicated in the key. B) Fractions from the p27 
displacement of Skp1/Skp2 experiment (between black bars of panel A) were run on 
an SDS-PAGE gel. Experiment was carried out by Nicole Schueller. 
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3.4	Characterisation	of	the	Skp2	binding	interface	of	cyclin	A	
3.4.1	Generation	of	cyclin	A	mutants	and	their	incorporation	into	CDK2/cyclin	A	
complexes	
A first set of cyclin A mutants were designed and tested for their interaction with Skp2 
(Appendix A Table A1.2, (Ruddick, 2010)). The mutations encompass the p27 binding 
site but exclude residues at the RXL recruitment site. The residues were mutated from 
the sequence of cyclin A to that of cyclin E as cyclin A but not cyclin E binds to Skp2. 
This approach would decrease the likelihood of large conformational changes 
occurring to cyclin A as a result of mutation. It was also reasoned that mutations to 
alanine might not yield a mutant that blocked Skp2 binding. An alignment of the cyclin 
A and cyclin E sequences (Figure 3.2 and Figure 3.6) showed that the highest levels 
of conservation between cyclin A and cyclin E are within the p27 and CDK2 binding 
regions.  
	
Figure 3.6: Residues conserved between cyclin A and cyclin E are 
predominantly in the p27 and CDK2 binding regions. Cyclin A is coloured 
according to whether the region is conserved, green indicates conserved 
regions, red indicates non-conserved regions and yellow indicates regions that 
are moderately well-conserved. CDK2 is coloured ice-blue and p27 is in coral. 
PDB: 1JSU 
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Building on this work further mutations were made to cyclin A (Table 3.1). The cyclin 
A construct used as a template to generate the mutants encodes the tandem CBFs, 
residues 173-432 in the pET21d vector backbone and is suitable for subsequent cyclin 
A expression in E. coli cells. The structure of this cyclin A fragment (referred to as 
cyclin A hereafter) was first described in Brown et al. (1999) and has since been used 
in a large number of structural studies. Cyclin A mutants (Table 3.1 and Figure 3.7) 
were designed based on the proximity of the residues to p27 (Figure 3.2), the 
conservation of the residues between cyclin A and cyclin E (Figure 3.6) and the 
understanding that Skp2 does not bind to the RXL recruitment site of cyclin A (Ji et 
al., 2006). The position of the mutated regions in relation to p27 are shown in Figure 
3.7. Mutagenesis was carried out using a QIAGEN Quickchange kit according to the 
Manufacturer’s instructions and is described in detail in Chapter 2 Section 2.  
Mutant name Residues mutated Residue changes 
Cyclin A mut 2 284-289 DTYTKK to GACSGD 
Cyclin A mut 3 290-299 QVLRMEHLVL to 
EILTMELMIM 
Cyclin A mut 6 299-305 LKVLTFD to MKALKWR 
Cyclin A mut 7 244-247 SSMS to ATQEN 
 
 
 
 
 
 
 
  
Table 3.1: Cyclin A residues mutated to investigate the Skp2 binding 
interface. The residues mutated and residue changes are shown in the table. A list 
of primers used in the mutagenesis of cyclin A is provided in Appendix A, Table 
A1.2. 
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Figure 3.7: Regions of cyclin A mutated and their proximity to p27. 
CDK2/cyclin A mut 2 (A) mut 3 (B) mut 6 (C) and mut 7 (D) regions where mutations 
were made from a top view (looking down on p27) and from a side view (either front 
or back). CDK2 is in ice-blue, cyclin A is in yellow and p27 is in coral. The regions 
mutated (in red) were in close proximity to the p27 binding site but distant from the 
RXL binding site based on knowledge of the Skp2/cyclin A interaction. PDB: 1JSU. 
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To check that introducing these mutations is not detrimental to the integrity of the cyclin 
A, expression tests were performed. Briefly, constructs were transformed into E. coli 
strain BL21 (DE3) pLysS and cyclin A expression was induced at 30°C for three hours 
upon addition of 1 mM IPTG once the culture had reached an OD600 of between 0.5 
and 0.6. A detailed description of the E. coli transformation and subsequent protein 
expression protocols can be found in Chapter 2, Section 1.2.  
Unlike bovine cyclin A (Brown et al., 1995), human cyclin A is not stable in the absence 
of CDK2. As a result, human cyclin A is purified as a CDK2/cyclin A complex (Brown 
et al., 1999). CDK2 is expressed as a cleavable GST fusion from the pGEX-6P-1 
vector backbone. Alternatively, to generate CDK2 phosphorylated on Thr160, this 
CDK2 expression cassette is co-expressed from the same vector with GST-CAK1 (S. 
cerevisiae CDK-activating kinase (Kaldis et al., 1996, Brown et al., 1999)). Briefly, 
GST-tagged CDK2 expressed from recombinant E. coli cells was affinity purified on a 
glutathione-Sepharose column. This column then acted as an affinity column for the 
untagged cyclin A, exploiting the tight binding between the two proteins (Figure 3.8A). 
The complex was eluted by excess glutathione, cleaved with 3C protease (to remove 
the GST tag from the CDK2) and subsequently purified by size-exclusion 
chromatography (SEC, Figure 3.8B). An excess of CDK2 is sometimes observed in 
the CDK2/cyclin A purification as CDK2 expresses very well. This is illustrated in 
Figure 3.8B where the shoulder on the peak at around 190 ml is excess CDK2. As the 
GST dimer and CDK2/cyclin A co-elute, the major peak was re-applied to a 
glutathione-Sepharose column and the CDK2/cyclin A collected in the flow-through 
(Figure 3.8C).  
Figure 3.8 shows that all cyclin A mutants express well although there is some 
variation, but this is within the margin of variation seen for cyclin A WT expression and 
purifications. Typical yields for CDK2/cyclin A WT and mutants are circa 8 mg/L. This 
analysis also confirms that each of the cyclin A mutants retains the ability to bind to 
CDK2. Authentic and mutant CDK2/cyclin A complexes could be successfully 
concentrated to circa 12 mg/mL and stored in aliquots (400 µL) at -20°C/-80°C. 
However, for isothermal titration calorimetry (ITC) experiments (Sections 3.6 and 
3.7.3), protein samples were freshly prepared.  
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Figure 3.8: Purification of CDK2/cyclin A. A) CDK2/cyclin A WT and mutants 
after glutathione- Sepharose affinity purification and after 3C protease was added 
B) Size-exclusion chromatogram of CDK2/cyclin A WT after 3C cleavage of the 
GST tag on the N-terminus of Skp2. C) SDS-PAGE analysis of CDK2/cyclin A 
selected fractions from the region of the peak indicated by the black bar on the 
chromatogram (B). 
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3.4.2	Generation	of	a	Skp2/Skp2	complex	to	characterise	Skp2	association	with	
CDK2/cyclin	A	
Skp2 is unstable when monomeric, which is thought to be due to the hydrophobic 
nature of the F-box region. To overcome this difficulty, the N-terminal sequence of 
Skp2 that encodes the N-terminal regulatory region and the F-box (residues 1-140, 
Figure 1.9), was co-expressed as a GST fusion with Skp1 (Figure 2.1). 
 E. coli BL21 (DE3) pLysS cells were transformed with the vector pGEX-6P-1-GST-
Skp2-N-Skp1 and the complex was successfully expressed following a 3 hour 
induction at 30°C. It was subsequently purified by GST affinity chromatography, 
cleaved with 3C protease and then loaded onto a size-exclusion column. It was found 
that the Skp1/Skp2-N complex co-elutes with GST (Figure 3.9). Consistent with a 
model in which Skp2 is unstable without Skp1, an excess of Skp2 was not observed. 
The complex expresses well and typical yields were circa 40 mg from 1 L of cell 
culture.  
 
A 
 
B 
 
 
 
 
The Skp1/Skp2-N complex elutes earlier than would be expected from its molecular 
weight. Skp1/Skp2-N co-elutes with CDK2/cyclin A, which is a globular protein 
complex of circa 65 kDa. This result suggests that Skp1/Skp2 might exist as a dimer 
Figure 3.9: Purification of Skp1/Skp2-N. A) Size-exclusion chromatogram of 
Skp1/Skp2-N after 3C cleavage of the GST tag on the N-terminus of Skp2. B) 
SDS-PAGE analysis of Skp1/Skp2-N selected fractions from the region of the 
peak indicated by the black bar on the chromatogram (A). 
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of dimers (Skp1/Skp2-N)2 in solution. To unambiguously assess the Skp1/Skp2-N 
oligomeric state, the complex was analysed by size-exclusion chromatography-multi-
angle laser light scattering (SEC-MALLS, methods described in Chapter 2, Section 
10). This analysis showed that the complex does not oligomerize from which it can be 
inferred that it has a highly asymmetric shape in solution (Figure 3.10). As the structure 
of all but the N-terminal tail of Skp2 has been determined (Figure 1.17) (Schulman et 
al., 2000, Hao et al., 2005), it can be hypothesised that the N-terminal sequence may 
be very elongated causing the apparent molecular weight to be nearly twice its 
calculated molecular weight. 
	
3.5	CDK2/cyclin	A	mutants	identify	a	cyclin	A	surface	that	is	required	for	
stable	association	with	Skp2	
SEC was used to test the binding of the CDK2/cyclin A mutant complexes to 
Skp1/Skp2-N. The chromatograms showed that every cyclin A mutant tested could 
form a quaternary complex with CDK2 and Skp1/Skp2-N on a Superdex 200 10/30 
Figure 3.10: SEC-MALLS data for Skp1/Skp2-N. The calculated molecular 
weight of Skp1/Skp2-N is about 32700 kDa. 
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column, but the chromatograms were difficult to interpret (data not shown). However 
it seemed that the mutants might be weakening the binding to some degree. It is 
possible that Skp2, like p27 binds to a large extended surface of cyclin A and knockout 
of one site might not block binding completely. A mutant cyclin A was therefore 
designed that incorporated all the 4 sets of mutations present in cyclin A mutants 2, 3, 
6 and 7. This cyclin A sequence was gene-synthesized (IDT) and supplied in the 
IDTsmart vector. It was then amplified by PCR and subsequently inserted into the 
pET21d vector by InFusion cloning (Chapter 2, Section 4).  
Figure 3.11 shows that the CDK2/cyclin A global mutant does not form a complex with 
Skp1/Skp2-N that is stable to gel filtration. Each of the complexes was sequentially 
applied to the same column (Superdex 200 10/30). There is a marked shift in the peak 
elution position when CDK2/cyclin A WT is mixed with Skp1/Skp2-N, but there is only 
a slight shift when the CDK2/cyclin A global mutant is mixed with Skp1/Skp2. The 
SDS-PAGE gel shows that the CDK2/cyclin A global mutant and the Skp1/Skp2-N 
complex elute at very similar volumes, to generate a very broad elution profile. The 
CDK2/cyclin A WT/Skp1/Skp2-N peak is not very far shifted from the binary complex 
peaks, so one might infer that Skp1/Skp2-N has become less elongated with the 
quaternary complex being more globular. The CDK2/cyclin A global mutant mixed with 
Skp1/Skp2-N runs as a single peak, but this peak nearly overlays completely with the 
binary Skp1/Skp2-N and CDK2/cyclin A global mutant complex peaks, indicating that 
this a quaternary complex is not being formed or is binding weakly. The small shift in 
the elution profile from what should be a peak to overlay the binary Skp1/Skp2-N and 
CDK2/cyclin A global mutant complexes might be due to non-specific binding caused 
by the proteins co-eluting on this column. 
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CDK2/cyclin A mut 2 and mut 6 were analysed by analytical SEC on a Superdex 75 
10/30 column which gave better resolution of the binary and quaternary complex 
peaks (Figure 3.12). This would show the individual contributions of these CDK2/cyclin 
A mutants to the binding of Skp1/Skp2-N. The elution profile of CDK2/cyclin A mut 6 
is shown as an example in Figure 3.12 (red trace) and compared to that generated 
when authentic CDK2/cyclin A was mixed with Skp1/Skp2 (blue trace). Skp1/Skp2-N 
and CDK2/cyclin A elute at similar volumes on a Superdex 75 26/60 column (compare 
Figure 3.11: CDK2/cyclin A global mut/Skp1/Skp2-N complex is not stable to 
gel filtration. A) The protein complexes were mixed after concentrating and left 
to form a complex for one hour. They were then run on the Superdex 75 10/30 
column. The curves were normalised to the Skp1/Skp2-N/CDK2/cyclin A WT trace 
to account for differences in absorbance and concentration. B) SDS-PAGE gel of 
the CDK2/cyclin A global mutant/Skp1/Skp2-N run. 
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elution volumes of each complex in Figures 3.8B and C and 3.9), such that quaternary 
complex formation would be favoured. There were, however, some indications that 
the mutant cyclin A-containing complex might not be as stable as that containing WT 
cyclin A, indicated by the shoulder on the quaternary complex (red trace, Figure 3.12). 
A more quantitative method of analysing this interaction was sought in order to 
determine the contributions of regions of cyclin A to its interaction with Skp1/Skp2-N. 
 
 
 
 
 
3.6	Use	of	ITC	for	analysis	of	the	Skp2	binding	site	on	cyclin	A	
3.6.1	CDK2/cyclin	A	global	mut	is	unable	to	bind	Skp1/Skp2-N	
Although analytical gel filtration offers several advantages for studying protein-protein 
interactions, there are limitations to this technique. In order to provide a more 
quantitative measure of the interaction between CDK2/cyclin A and Skp1/Skp2-N, 
more sensitive techniques to analyse protein-protein interaction were attempted. Both 
surface-plasmon resonance (SPR) and isothermal titration calorimetry (ITC) were 
Figure 3.12: Analytical gel filtration elution profile of CDK2/cyclin A mut 
6/Skp1/Skp2. The proteins were mixed after concentrating and left to form a 
complex for one hour. They were then run on the Superdex 75 10/30 column. The 
blue trace is CDK2/cyclin A mixed with Skp/Skp2-N. The red trace is CDK2/cyclin 
A mut 6 mixed with Skp/Skp2-N. The curves were normalised to the Skp1/Skp2-
N/CDK2/cyclin A WT trace to account for differences in absorbance and 
concentration. 
Chapter 3: Identification of the cyclin A Skp2 binding site 
 
91 
 
pursued, but ITC gave more reproducible and reliable results. ITC is a useful method 
for analysing binding affinities and thermodynamics of protein-protein interactions. 
Following optimisation of the experimental conditions (described in Chapter 2, Section 
6.2), comparative ITC experiments were performed with CDK2/cyclin A in the cell and 
the Skp1/Skp2-N complex in the syringe as the Skp1/Skp2-N complex proved to be 
more amenable to concentrating. The binding of CDK2/cyclin A global mut to 
Skp1/Skp2-N was determined (Figure 3.13), in order to validate the findings of the 
analytical SEC experiment (Figure 3.11).  
 
 Figure 3.13: CDK2/cyclin A global mutant does not bind to Skp1/Skp2-N 
as determined by ITC. Binding isotherms determined by ITC with 
thermodynamic parameters and binding constant shown below. ITC experiment 
was carried out at 25°C. 20 µM CDK2/cyclin A in the cell and 180 µM 
Skp1/Skp2 in the syringe. 
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3.6.2	Analysis	of	the	contribution	of	individual	cyclin	A	residues	to	the	Skp2/cyclin	
A	interaction	
The interaction between CDK2/cyclin A and Skp1/Skp2-N can be measured by ITC. 
A strong response was seen with little background noise (Figure 3.13). As expected, 
CDK2/cyclin A WT and Skp1/Skp2-N bind tightly and a Kd value of circa 300 nM was 
measured for their interaction. In contrast, the binding of the CDK2/cyclin A global 
mutant to Skp1/Skp2-N was so weak that a Kd value could not be determined (Figure 
3.13).  
These ITC results (Figure 3.13) confirmed that the cyclin A global mutant does not 
bind to Skp1/Skp2-N, from which it was concluded that the authentic residues at these 
positions together make a substantial contribution to the Skp2 binding site on cyclin 
A. Next, the mutants with fewer mutations were assessed for their binding to 
Skp1/Skp2 in order to identify the contributions from the different sites on cyclin A 
(Figure 3.14). 
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Cyclin A residues mutated residue changes Kd (nM) 
WT none none 346 ± 50 
mut 2 284-289  DTYTKK to GACSGD 340 ± 60 
mut 3 290-299  QVLRMEHLVL to EILTMELMIM 
658  ± 
101 
mut 6 299-305  LKVLTFD to MKALKWR 1 690 ± 340 
mut 7 244-247 SSM-S to ATQEN CBD 
 
 
 
 
ITC was used to characterise the contribution of the other cyclin A mutants to the 
Skp1/Skp2-N interaction. The protein samples were analysed by SDS-PAGE after 
each experiment to confirm that a lack of apparent binding between Skp1/Skp2-N and 
the various CDK2/cyclin A complexes was not a result of protein degradation (Figure 
3.15).  
 
Figure 3.14: CDK2/Cyclin A mutants display a range of binding affinities to 
Skp1/Skp2-N. A) Binding isotherms determined by ITC with thermodynamic 
parameters and binding constant shown below. ITC experiment was carried out at 
25°C. 20 µM CDK2/cyclin A in the cell and 180 µM Skp1/Skp2 in the syringe. B) 
Titration plots of the integrated data from (A). C) Table to show residue changes 
made to cyclin A and their resulting effects on binding affinity. 
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The ITC analysis revealed that most of the sites which were modified contribute 
somewhat to the binding. Residues 284-289 (sequence DTYTKK) of cyclin A do not 
interact with Skp2 as CDK2/cyclin A mut 2 is able to bind Skp1/Skp2 with an affinity 
the same as determined for CDK2/cyclin A WT. However, the thermodynamics of the 
CDK2/cyclin A/Skp1/Skp2-N interaction have altered somewhat. For example, the ΔH 
value is greater (less negative) than for the cyclin A WT complex, indicating that there 
is less heat exchanged upon binding. The amino acid changes introduced into cyclin 
A in CDK2/cyclin A muts 3 and 6, significantly reduced the binding affinity to Kd values 
of 0.66 and 1.7 µM, respectively. Mutation of residues 244-247 (mut 7) had the 
greatest effect on the interaction with Skp2- an interaction could not be measured 
between the two proteins (Figure 3.14A and B). These residues are on a loop region 
(Figure 3.7). Whether these residues in the cyclin A sequence make a significant direct 
contribution to the Skp2 interaction, or whether the bulge introduced into the cyclin A 
structure disrupts a larger interface is not known. The ITC experiment was repeated 
Figure 3.15: CDK2/cyclin A WT and mutants before and after ITC 
experiments. Lanes 1-5 show CDK2/cyclin A WT and mutant samples before the 
ITC experiment, lanes 7-9 show samples recovered from the cell after the ITC 
experiment indicating that there was GST contamination from the Skp1/Skp2 
purification. 
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for CDK2/cyclin A global mut and CDK2/cyclin A mut 7 binding to Skp1/Skp2-N using 
new protein preparations (see Appendix A2 for replicate experiments). 
To dissect the effect of this insertion, an intermediate in the construction of this mutant 
in which MS (residues 246 and 247) of the cyclin A sequence were mutated to QEN 
(called mut 5). This mutant was then tested for its binding to Skp1/Skp2-N (Figure 
3.16). Like cyclin A mut 7, cyclin A mut 5 has a much weaker binding affinity than 
cyclin A WT.  
 
 
 
 
The mutations of cyclin A mut 5 have a large effect on the Skp2-cyclin A interaction 
despite being a change of only two residues. It is hypothesised that the extra residue 
is having an effect by ejecting Skp2 from the binding site rather than the loss of key 
interacting residues. A comparison of the molecular surfaces of cyclin A and cyclin E 
at this site highlight the extra bulk present in the cyclin E structure that changes the 
surface shape. When the surface is coloured by electrostatic potential, the region that 
is mutated to create cyclin A mut 7 (circled in Figure 3.17), becomes negatively 
Figure 3.16: The binding between CDK2/cyclin A mut 5 and Skp1/Skp2 is very 
weak. Binding isotherms determined by ITC with thermodynamic parameters and 
binding constant shown below. ITC experiment was carried out at 25°C. 20 µM 
CDK2/cyclin A in the cell and 180 µM Skp1/Skp2 in the syringe. 
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charged due to the introduction a glutamate residue. A charge at this site might be 
incompatible with Skp2 binding. 
 
A 
 
B 
 
 
 
 
Taken together, binding data obtained for these mutants suggests that Skp2 might 
bind across the mut 3, 6 and 7 sites. However, mutation of the mut 7 site alone is 
sufficient to block the interaction. The minimal change to the cyclin A sequence, which 
impairs Skp1/Skp2-N binding, is made in mut 5 where residues 246 and 247 are 
mutated from MS to QEN, introducing an extra residue to the cyclin A sequence. 
Figure 3.18 shows an overlay of the cyclin A and cyclin E structures at this loop region 
where the cyclin A mut 7 mutations were made. The inserted glutamate residue 
derived from the cyclin E sequence protrudes out from the loop into the solvent before 
the sequences return into register at cyclin A residue 249. 
 
 
Figure 3.17: Differences in electrostatic potential between cyclin A and 
cyclin E. A) Cyclin A, PDB: 1JST. B) Cyclin E, PDB 1W98. The region 
mutated to create mut 7 is indicated by the black rings. 
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3.7	Characterisation	of	cyclin	A	mut	7	
The ITC results revealed that the Skp2 interaction can be blocked by making a few 
mutations to a loop region of cyclin A. This region is not known to be involved in any 
other interactions of cyclin A suggesting this a Skp2-specific interaction site. It is 
important to initially validate the structure of the mutant to check that the lack of binding 
to Skp2 is not simply due to a change in the overall secondary structure or loss of 
structure altogether. As very few mutations of cyclin A were required in order to cause 
a loss in binding to Skp2, this mutant could potentially be a useful reagent to 
investigate the Skp2/cyclin A interaction in cell-based assays. 
3.7.1	 CDK2/cyclin	 A	 mut	 7	 exhibits	 similar	 secondary	 structure	 features	 to	
CDK2/cyclin	A	WT	
As cyclin A mut 5 and mut 7 bind very weakly to Skp1/Skp2-N, it is possible that they 
might not be properly folded. In order to confirm their secondary structure content, 
they and cyclin A WT were analysed by circular dichroism (CD). CD results from the 
unequal absorption of right-handed and left-handed circularly polarized light by a 
protein. CD spectra between 260 and 180 nm can be analysed for several secondary 
structure types, such as alpha helices, beta strands, turns and others (Sreerama and 
Figure 3.18: Overlay of the cyclin A and cyclin E structures in the region 
which has been mutated to create cyclin A muts 5 and 7. Cyclin E has an 
extra residue in this loop region. 
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Woody, 1994). The cyclins were analysed in solution in potassium phosphate buffer 
to minimise background absorption at these wavelengths. The CD data obtained show 
that cyclin A mut 7 is folded and has a similar secondary structure to the WT protein 
(Figure 3.19). The spectrum is characteristic of an alpha-helical protein with two 
characteristic negative minima at 208 and 222 nM. The lower minima at 208 nM 
compared to 222 nM for CDK2/cyclin A WT suggests the presence of a significant 
proportion of random coils in the structure (Zhou et al., 1992). The minima values for 
CDK2/cyclin A mut 7 are more similar. The alpha helical content of both WT and 
mutant cyclin A is around 40%. As a further measure of protein integrity, the melting 
temperatures of WT and mutant cyclin A were also determined using differential 
scanning fluorimetry (DSF, Figure 3.19). Melting temperature is an indicator of a 
protein’s native stability (Kumar et al., 2000). Both proteins showed co-operative 
unfolding, whereby the unfolding occurs in a single transition. The melting 
temperatures were similar with a ΔTm of 3.1°C.  
Finally, in order to determine whether these mutations affect the structure of 
CDK2/cyclin A, the CDK2/cyclin A mut 7 structure was determined. Initially, conditions 
which had previously been used to crystallise CDK2/cyclin A (0.8 to 1.35 M ammonium 
sulphate versus 0.6 to 0.95 M potassium chloride in 0.1 M HEPES pH 7.0) were used. 
However, no crystals were obtained from this screen, which usually has a high 
success rate. It was concluded that the mutant cyclin A might not allow for the same 
crystal form as CDK2/cyclin A WT to be created and therefore the CDK2/cyclin A mut 
7 complex was tested against commercial screens. The purity of the CDK2/cyclin A 
mut 7 protein prior to crystallisation trials was confirmed by SDS-PAGE (Figure 3.20). 
The best hit was in a MORPHEUS screen (Molecular Dimensions). The conditions 
were 0.1 M Tris/Bicine pH 8.5, 0.1 M amino acids, 20% v/v glycerol, 10% w/v PEG 4K 
at 4°C. An optimisation screen was then designed and crystals suitable for data 
collection were obtained (Figure 3.21). 
 
Chapter 3: Identification of the cyclin A Skp2 binding site 
 
100 
 
 
Fi
gu
re
 3
.1
9:
 C
D
 d
at
a 
of
 C
D
K
2/
cy
cl
in
 A
 W
T 
an
d 
C
D
K
2/
cy
cl
in
 A
 m
ut
 7
. C
D
K2
/c
yc
lin
 A
 c
om
pl
ex
es
 
w
er
e 
in
 p
ot
as
si
um
 p
ho
sp
ha
te
 b
uf
fe
r 
pH
 7
.0
. L
ef
t 
is
 th
e 
C
D
 s
pe
ct
ra
 a
nd
 o
n 
th
e 
rig
ht
 is
 t
he
 lo
ss
 o
f 
se
co
nd
ar
y 
st
ru
ct
ur
e 
w
ith
 in
cr
ea
se
 in
 te
m
pe
ra
tu
re
. 
Chapter 3: Identification of the cyclin A Skp2 binding site 
 
101 
 
3.7.2	The	crystal	structure	of	CDK2/cyclin	A	mut	7	
 
 
 
 
 
Crystals grown in the conditions described in Figure 3.21 were harvested by Dr 
Mathew Martin. Due to the high glycerol content, cryoprotectant was not required. 
Despite the small size of the crystals, a data set was collected for one of the crystals. 
It diffracted to 3.6 Å with a P31 2 1 space group. This is a different space group to that 
observed with CDK2/cyclin A WT crystals and is at lower resolution than might have 
been expected from previous CDK2/cyclin A WT studies. The dataset was collected 
at the Diamond Light Source (Didcot, UK) on beamline I24, by the Facilities Manager, 
Dr. Arnaud Baslé. Data were collected using a Pilatus3 6M detector with a detector 
Figure 3.21: Crystals of CDK2/cyclin A mut 7. Protein concentration was 5.6 mg/mL 
CDK2/cyclin A mut 7. A) Crystals obtained in Morpheus buffer 3 (Tris/bicine) pH 9.0, 20% 
v/v glycerol, 10% w/v PEG 4k at 4°C. Drop ration 2:1 B) Crystal obtained in Morpheus 
buffer 3 (Tris/bicine) pH 9.0, 22.7% v/v glycerol, 11.3% w/v PEG 4k, 50 mM amino acids 
at 4°C. Drop ratio 1:1 Bars are 200 µm. 
A B 
Figure 3.20: Purity of CDK2/cyclin A 
mut 7 before setting up crystal trays.   
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distance of 61.05 cm and an exposure time of 9 milliseconds. The oscillation range 
was 0.1º, for a total oscillation of 119.9º. Data were processed using Xia2 (Winter, 
2009) and programmes from the CCP4 suite (Winn et al., 2011, 1994) as implemented 
in CCP4i2.  Data collection and processing statistics are given in Table 3.2. 
The data analysis was done with the help of Dr Julie A. Tucker. The structure of 
CDK2/cyclin A mut 7 was solved by molecular replacement (Molrep (Vagin and 
Teplyakov, 1997)) using a high resolution structure of CDK2/cyclin A (PDB code 2C5O 
chains A and B) as a search model after removing the residues that had been mutated.  
The crystal asymmetric unit contains two copies of the CDK2/cyclin A mut 7 
heterodimer.  Chains A, B, and D are well defined, whilst chain C shows very poor 
electron density for the kinase N-terminal lobe. The model was manually completed in 
Coot (Emsley et al., 2010) following an initial refinement in Refmac5 (with map 
sharpening, jelly body restraints, TLS and overall B-factor restraints (Murshudov et al., 
1997), followed by Buster (with TLS and autoNCS restraints (Blanc et al., 2004)). Omit 
maps were calculated using Buster from the final model after removal of residues 244 
to 248 from chains B and D.  Figures were prepared using CCP4MG (Winn et al., 
2011). Details of the refinement statistics and final model quality are given in Table 
3.2. 
The electron density around the mutated region of cyclin A was analysed to determine 
the positions of the residues within the structure (Figure 3.22), and the density is strong 
around the backbone of the chain and around the side chains of most residues. The 
direction of the Gln246 side chain can be determined from the density. However, there 
was little density for Glu247, suggesting that this side chain is in a flexible 
conformation. As would be expected, this mutated region of cyclin A is similar to cyclin 
E (Figure 3.22). An obvious difference between cyclin A WT and mut 7 is the space 
occupied by Glu247. This residue may sterically clash with residues of Skp2, thus 
preventing key interactions of Skp2 with cyclin A. 
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Figure 3.22: Fo-Fc OMIT maps for cyclin A mutated region of mut 7. Maps 
are contoured at 3 σ and are drawn as a green mesh. On the left is chain B and 
on the right is chain D. A) Residues 244-248 of cyclin A mut 7 are shown. B) 
cyclin E (PBD: 1W98) and cyclin A (PDB: 2C5O) are superimposed onto cyclin A 
mut 7 shown in pink and gold, respectively. C) Another view of B. Figure was 
created using CCP4MG. 
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A superimposition of cyclin A WT and cyclin A mut 7 shows good agreement between 
the two structures and the only effect of the mutations to cyclin A are limited to the 
mutated region itself (Figure 3.23). This suggests that Skp2 forms an interaction with 
this region of cyclin A and the decreased binding is not due to loss of structural 
features elsewhere in the protein. 
	
 
 
 
  
Figure 3.23: Superimposed cyclin A WT and cyclin A mut 7. CDK2 is 
in ice-blue, p27 is in coral, cyclin A WT is in turquoise and cyclin A mut 7 
is in gold. CDK2 and p27 are shown to show the orientation of cyclin A. 
Residues 244-248 of cyclin A mut 7, which encompass the mutated region 
of cyclin A are shown in cylinder conformation. Figure was created using 
CCP4MG. 
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Table 3.2: Crystallographic parameters for CDK2/cyclin A mut 7 structure 
Beam-line  Diamond Light Source I24 
Wavelength (Å)  0.979 
Detector type  PILATUS3 6M 
Data collection date  10 May 2015 
Space group  P 31 2 1 
Cell constants a; b; c (Å)  105.6; 105.6; 294.1; 90; 90; 120 
Resolution range (Å) 1  49.47-3.61 (3.9-3.61) 
Completeness overall (%)1  99.6 
Reflections, unique  22577 
Multiplicity1  6.4 
Mean(I)/sd(I)1  4.8 
Rmerge overall 2  0.395 
Rvalue overall (%) 3  21 
Rvalue free (%)1  27 
Non hydrogen protein atoms 
(A;B;C;D) 
 4683; 4148;4706;4107 
Solvent molecules  7 
R.m.s. deviations from ideal values   
Bond lengths (Å)  0.015 
Bond angles (º)  1.7 
Average B values (Å2) 
Average B values for protein 
(Å2 A;B;C;D) 
 32.6; 26.2; 34.5; 30.6 
Average B values for water 
(Å2) 
 31.9 
Φ, Ψ angle distribution for residues 4    
In favoured regions (%)  95.4 
In allowed regions (%)  3.9 
In outlier regions (%)  0.64 
  1 Values in parentheses refer to the outer resolution shell 
2 Rmerge = Shkl [( Σi |Ii - ‹I›| )/ Σi Ii] 
3 Rvalue = Shkl ||Fobs| - |Fcalc|| / Shkl |Fobs| 
Rfree is the cross-validation R factor computed for the test set of 
5% of unique reflections 
4 Ramachandran statistics as defined by Coot  
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3.7.3	p27	binds	to	cyclin	A	mut	7	with	similar	affinity	to	WT	cyclin	A	
As the cyclin A surface identified by mut 7 has not been reported as a site of cyclin A-
protein interaction, this mutant might be useful as a probe to investigate the functional 
significance of the Skp2/cyclin A interaction. Before exploiting the mutant in this way, 
its ability to bind to other cyclin A partners was investigated. From the SEC analysis, 
the cyclin A mutations do not affect their interaction with CDK2.  
One of the criteria for designing the cyclin A mutations was proximity to the p27 binding 
site as Skp2 and p27 compete for binding to CDK2/cyclin A. However, it was mutation 
of the more distant residues that produced a CDK2/cyclin A complex that was unable 
to bind Skp1/Skp2-N. Therefore, it was hypothesised that by disrupting the Skp2 
interaction through mutation of residues 244-247, the interaction of cyclin A with p27 
might not be affected. ITC was again used to test whether this is the case. Two p27 
fragments were expressed in E. coli and purified by Dr Martyna W. Pastok (Figure 
3.24). p27S consists of amino acids 23-106 and p27XS is slightly smaller and includes 
residues 34-106. These two fragments were chosen as p27S includes the RXLF 
sequence at residues 30-33 and so binds to the cyclin A recruitment site, whereas 
p27XS does not (Russo et al., 1996b).  
 
The binding of p27 to CDK2/cyclin A mut 7 was determined in order to assess whether 
these mutations have affected the ability of cyclin A to carry out its known functions. 
Figure 3.25 shows that the binding affinities were only very slightly weaker for both 
Figure 3.24: Purity of the p27 peptide 
fragments p27S and p27XS. These 
fragments were expressed in E. coli and 
purified by Martyna W. Pastok. 
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p27S and the smaller fragment, p27XS. The difference in the binding affinities 
between WT and mut 7 were within the error of the ITC experiment. This large error is 
commonly seen for very tight interactions as they are difficult to accurately measure 
by ITC. Due to limited amounts of proteins and time restraints, the binding of p27 to 
CDK2/cyclin A WT and CDK2/cyclin A mut 7 was not optimised. The thermodynamic 
parameters for the interaction are also similar for cyclin A WT and mut 7. Therefore, 
the introduction of these mutations should be able to provide a readout of the 
Skp2/cyclin A interaction and any effects on p27 will not be directly due to the binding 
of p27 to cyclin A. The calculated Kd values are higher than those reported by the 
Kriwacki group (Lacy et al., 2004). Again, using ITC, this group measured the Kd of a 
peptide of residues 22-105 of p27 to be 3.5 nM ± 1.2 nM (Lacy et al., 2004). This could 
possibly be due to the experimental conditions as the concentrations in the cell and 
syringe were kept at a ratio of about 1:10 (as they were for the CDK2/cyclin A 
Skp1/Skp2-N experiments). However, this interaction might be better analysed with a 
lower ratio as it is a very tight interaction. The enthalpy (ΔH) associated with this 
interaction is very large and this is most likely due to the amount of hydrogen bonds 
created over the large surface area of CDK2/cyclin A contacted by p27. The enthalpy 
observed is consistent with what has been observed in previous investigations (Ou et 
al., 2011). 
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Figure 3.25: CDK2/cyclin A WT and mut 7 interaction with p27 peptides. Binding 
affinity and thermodynamic data shown underneath calorimetry data. A) CDK2/cyclin 
A WT binding to p27S. B) CDK2/cyclin A mut 7 binding to p27S. C) CDK2/cyclin A 
WT binding to p27XS. D) CDK2/cyclin A mut 7 binding to p27XS. ITC experiment 
was carried out at 25°C. 20 µM CDK2/cyclin A in the cell and 180 µM p27 peptide in 
the syringe. 
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p27, p21 and p57 are well conserved in their CDK2/cyclin A binding domains (Figure 
3.26), so it would be expected that they would bind in a similar way to p27 and 
therefore the interaction of p21 and p57 with CDK2/cyclin A is unlikely to be affected 
by the mutations. The relative binding affinities of Skp2 and p27 to CDK2/cyclin A are 
in agreement with the analytical gel filtration data which showed that p27 can displace 
Skp2 from CDK2/cyclin A/Skp1/Skp2 (Figure 3.5). 
 
 
 
 
 
 
3.7.4	CDK2/cyclin	A	global	mut	and	mut	7	are	catalytically	active	
Cyclin A is involved in the recruitment of substrates to CDK2. These substrates 
include, Skp2 (Rodier et al., 2008), p53 (Wang and Prives, 1995), pRb (Mittnacht et 
al., 1994), Histone H1b (Contreras et al., 2003), and BRCA1 (Ruffner et al., 1999). 
Substrates are selected by binding to the cyclin protein (Roberts, 1999), therefore it is 
important that when mutating cyclin A, its role as a substrate recruiter has not been 
compromised. CDK2/cyclin A activity was tested against two substrates, histone H1 
and Rb. Histone H1 is not part of the nucleosomal core, however, it is important for 
maintaining chromatin higher-order structure. CDK2 phosphorylates histone H1 during 
the G1-S transition and S-phase (Talasz et al., 1996). Phosphorylation increases or 
Figure 3.26: Sequence alignment of the kinase inhibitory domains of p27, p21 and 
p57. Within the domains of p27 that bind to CDK2/cyclin A there is good conservation 
with other CDK2 inhibitory proteins. Adapted from Lacy et al. (2004). An asterisk 
indicates positions that are fully conserved. A colon indicates conservation between 
groups of strongly similar properties, scoring >0.5 in the Gonnet PAM 250 matrix. A full 
stop indicates conservation between groups of weakly similar properties, scoring =<0.5 
in the Gonnet PAM 250 matrix. Figure was created using Clustal Omega (Sievers et al., 
2011). 
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decreases transcription of certain genes (Bhattacharjee et al., 2001, Dou and 
Gorovsky, 2000). Phosphorylation occurs on the N- and C-terminal tails of histone H1 
with the consensus sequences K [S/T]PXK and K[S/T]PK being recognised by CDK1 
and CDK2 (Meijer et al., 1989, Maller et al., 1989). Phosphorylation of histone H1 was 
assayed by a radiometric phosphorylation assay (methods are described in Chapter 
2, Section 5.2). The results showed that CDK2/cyclin A global mutant and mut 7 are 
able to phosphorylate histone H1 with an activity similar to CDK2/cyclin A WT (Figure 
3.27). 
 
 
 
The C-terminal domain of Rb is phosphorylated at many sites by CDK2/cyclin A during 
the G1-S transition (Zarkowska and Mittnacht, 1997). This phosphorylation inactivates 
Rb leading to transcription factors such as E2F1 being released from repression by 
Rb and is required for the cell to pass through the restriction point (Weinberg, 1995). 
CDK2 phosphorylation can be visualised on an SDS-PAGE gel as the phosphorylation 
causes the Rb to migrate more slowly (Chapter 2, Section 5.1). Figure 3.28 shows 
that the global mutant and mut 7 are able to phosphorylate the C-terminal domain of 
Rb as effectively as the authentic complex. 
Figure 3.27: CDK2/cyclin A mutant 7 is able to phosphorylate histone H1.  A 
radioactive in vitro kinase assay was carried out by Lan-Zhen Wang. Values are 
derived from one experiment. The control is the reaction solution without any 
CDK2/cyclin A added. 
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Many of the substrates of CDK2/cyclin A are also substrates of CDK2/cyclin E, 
including Rb and histone H1. Therefore, it might be expected that mutating cyclin A 
residues to the cyclin E sequence would not have an effect on substrate binding. By 
exploiting the difference in the Skp2-binding abilities between these two cyclins, the 
other interactions of cyclin A have not been affected. 
  
Figure 3.28: CDK2/cyclin A mut 7 is able to phosphorylate Rb. CDK2 with 
indicated cyclin A variants were incubated with a C-terminal construct of Rb for 
the indicated times. The reaction was stopped by adding SDS loading buffer and 
boiling. Samples were subjected to SDS-PAGE and phosphorylation monitored 
by mobility shift. The band at circa 90 kDa is a contaminant protein. 
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3.8	Discussion	
Deletion of cyclin A2 in mice is lethal with mice dying at E5.5. This phenotype suggests 
that other cyclins are not able to compensate for loss of cyclin A2 during early 
embryogenesis (Murphy et al., 1997). It is interesting, therefore, to determine the 
features of the cyclins which make them unique. This investigation has determined the 
answer to how Skp2 is specific for cyclin A, but the question of why it is specific to 
cyclin A requires more investigation. 
A novel cyclin A protein interaction site located on the cyclin A N-terminal CBF has 
been identified. This site is required for CDK2/cyclin A to form a stable complex with 
Skp1/Skp2-N and does not affect the association of CDK2/cyclin A with other known 
regulators. Work in this chapter also confirms the earlier observations that Skp2 
binding to CDK2/cyclin A is mutually exclusive with p27 and that the association of 
p27 with CDk2/cyclin A is tighter than that of Skp2. Mutation of cyclin A residues 244-
247 is not injurious to other cyclin A functions as it is folded properly; it does not affect 
the kinase activity of CDK2/cyclin A against Rb (C-terminal domain) or Histone H1; 
and cyclin A mut 7 is able to interact with CDK2, p107 and p27. Therefore, the cyclin 
A residues identified here as required for the binding of Skp1/Skp2-N will be a very 
useful tool to identify the function of the Skp2/cyclin A interaction in cell-based assays. 
3.8.1	Conservation	of	the	cyclin	A	mut	7	site	
Analysis of the conservation of the region which was mutated to create cyclin A mut 7 
indicates that there is high sequence conservation in this region (Figure 3.29). The N-
CBF of cyclin A is well conserved, indicating the essential role of this lobe in mediating 
protein-protein interactions. 
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3.8.2	 The	 Skp1/Skp2-N	 structure	 is	 elongated	 producing	 a	 higher	 apparent	
molecular	weight	when	analysed	by	SEC	
This investigation determined that the Skp1/Skp2-N complex is a single heterodimer. 
When Skp1/Skp2-N binds to CDK2/cyclin A, the quaternary complex runs at a similar 
elution volume as the two binary complexes. This suggests that the large apparent 
molecular weight of Skp1/Skp2-N by SEC is a shape effect and is due to the elongated 
and unstructured N-terminus of Skp2. The non-additive effect when Skp1/Skp2-N 
binds to CDK2/cyclin A suggests that the N-terminus of Skp2 binds along the surface 
of cyclin A to create a more compact and globular complex.  
Figure 3.29: Sequence conservation across species of cyclin A. Cyclin A is 
coloured according to whether the region is conserved, green indicates conserved 
regions, red indicates non-conserved regions and yellow indicates regions that are 
moderately well-conserved. CDK2 is coloured ice-blue and p27 is coral. PDB: 
1JST. A black ring indicates residues 244-247 of cyclin A, which have been shown 
to be involved in its interaction with Skp2. Uniprot codes P20248 (Homo sapian), 
P51943 (Mus musculus), P30274 (Bos taurus), P43449 (Gallus gallus), P47827 
(Xenopus laevis) and P37881 (Mesocricetus auratus) were used for the sequence 
alignment. 
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3.8.3	 Regulation	 of	 CDK/cyclin	 complexes	 through	 interactions	 with	 the	 N-
terminal	and	C-terminal	CBFs	of	the	cyclin	
The Zhu lab demonstrated that Skp2 in excess is able to compete p27 from 
CDK2/cyclin A and protect CDK2/cyclin A from inhibition by p27 (Ji et al., 2006). In 
contrast, a former member of the Endicott lab, Nicole Schueller, was able to show that 
CDK2/cyclin A preferentially binds to p27 over Skp2 (Figure 3.5, (Schueller, 2001)). 
The ITC data shown here are in agreement with the latter finding. p27 was found to 
bind to CDK2/cyclin A about tenfold tighter than Skp1/Skp2-N, suggesting that Skp2 
would not be able to compete p27 from CDK2/cyclin A unless it were in great excess 
over p27. As p27 binds more weakly to CDK2/cyclin A after phosphorylation on Tyr74 
and Tyr88, which partially activates CDK2/cyclin A, it is possible that Skp2 is then the 
preferred binding partner (Chu et al., 2007, Grimmler et al., 2007).  If this were the 
case, then you would expect that the full activation of the CDK2/cyclin A complex 
would result from binding to Skp2, perhaps in the context of the SCFSkp2 complex.  
Investigations into cyclin substrate recruitment have found that the cyclin recruitment 
site which binds to RXL motifs present in substrates is required for docking. Rb, p53, 
p107, p21, p27 are substrates of CDK2/cyclin A which bind to the recruitment site on 
the N-terminal CBF (Lowe et al., 2002). This recruitment site is shared with cyclins A, 
B, D and E that regulate the cell cycle. Cyclins C, H and T bind to CDK8, CDK7 and 
CDK9, respectively and collectively regulated early events in the initiation of eukaryotic 
transcription (reviewed in (Loyer et al., 2005)). These cyclins do not share sequence 
features with the cell cycle cyclins in the region of the recruitment site and in the case 
of the cyclin H structure, the recruitment site location is obscured by an extended C-
terminal sequence (Kim et al., 1996, Lolli, 2010). These observations suggest that the 
substrate recruitment function of the N-CBF is not conserved in the transcriptional 
CDKs.  
Recent reports have shown that the cyclin T C-CBF is involved in binding regulatory 
proteins, such as human immunodeficiency virus 1 (HIV-1) Tat protein. Through 
binding CDK9/cyclin T1 (P-TEFb), HIV Tat (Zhu et al., 1997) and AFF4 (Schulze-
Gahmen et al., 2013) promote the synthesis of viral transcripts. The binding of the 
inhibitory protein hexamethylene bisacetamide-inducible protein (HEXIM) 1 is 
mutually exclusive with HIV Tat binding, and it has been recently shown (S. Baumli, 
A. Hole and R. Heath, unpublished results) that HEXIM1 and BRD4 bind to the cyclin 
Chapter 3: Identification of the cyclin A Skp2 binding site 
 
115 
 
T C-CBF. Taken together these observations suggest that cyclin T has a novel 
substrate and regulatory protein binding site that can accommodate multiple 
interactions on the C-CBF rather than the N-CBF. This emerging view of cyclins 
promotes the idea that the cyclin is not only for substrate recognition and docking, but 
that there are regulatory interactions occurring at multiple sites offering the possibility 
of cross-talk between signalling pathways. This model is an extension of the 
established model of CDK activation by the cyclin and cyclin recruitment at one 
specific site. The implications for this work might be that this would suggest a 
regulatory role for Skp2 binding to cyclin A. The finding from the Zhu lab that the 
Skp2/cyclin A interaction is not required for Skp2 phosphorylation at Ser64 (Ji et al., 
2006), suggests this novel binding site is not an alternative substrate recruitment site 
and therefore it might be to allow for regulatory interactions.
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Chapter	4:	Identifying	residues	of	Skp2	
which	mediate	its	interaction	with	
Cyclin	A	
4.1	The	Skp2	N-terminal	regulatory	region	
The N-terminus of Skp2 is unstructured with multiple residues subject to post-
translational modification and involved in protein-protein interactions. A disordered 
structure is typical of a region with multiple binding and post-translational modification 
sites, as it can allow for flexibility and folding-upon-binding (Dyson and Wright, 2005). 
Over the past decade, multiple studies have been published describing the complex 
regulatory networks that are involved in modification of, and protein interactions made 
within the first 80 residues of Skp2. There have been accounts of phosphorylation and 
acetylation in this region (Figure 4.2B) leading to cytoplasmic localisation and 
influencing the migration-inducing potential of Skp2 (Gao et al., 2009, Inuzuka et al., 
2012); Skp2 stabilisation through phosphorylation (Rodier et al., 2008, Cen et al., 
2010, Inuzuka et al., 2012); and Skp2 ubiquitination through interaction with the 
APCCdh1 complex, and subsequent degradation (Bashir et al., 2004, Lin et al., 2009). 
Skp2 was first identified as part of a CDK2/cyclin A/Skp1/Skp2/Cks1 complex (Zhang 
et al., 1995). However, since this discovery, little further knowledge has been gained 
as to whether this interaction is an important mechanism in the function of Skp2. Cyclin 
A interacts with the disordered N-terminal region of Skp2.  A SDM study in 2006 aimed 
to determine the function of the Skp2/cyclin A interaction (Ji et al., 2006). Skp2 
mutations were made within the N-terminal region and tested for their ability to bind to 
cyclin A through co-immunoprecipitation experiments. WT Skp2 and mutated Skp2 
were also overexpressed in cell lines and cell cycle analysis was carried out. Due to 
the study design, where Skp2 WT or mutant was being overexpressed, they were 
determining how well the mutations made to Skp2 countered the effects of Skp2 
overexpression. They reported that disruption of the Skp2/cyclin A interaction did not 
have an effect on p27 or p21 expression, however, a higher proportion of cells entered 
G1 arrest. They also showed using recombinant proteins that GST-Skp2 does not pull 
down CDK2 (Ji et al., 2006). In agreement with this observation, Skp2 was shown not 
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to bind CDK2/cyclin E suggesting that the specificity is primarily driven by cyclin A. 
Although CDK2 cannot form a stable complex with Skp2 on its own, it might bind to 
Skp2 in the context of a ternary CDK2/cyclin A/Skp2 complex. The role of Skp1 in 
complex formation with CDK2/cyclin A is less controversial. Despite the proximity of 
Skp1 to cyclin A in the proposed SCF-Skp2-Cks1-CDK2-cyclin A model (Figure 4.1), 
there is no evidence to support a direct interaction between Skp1 and CDK2/cyclin A 
(Ji et al., 2006). 
It is possible to superpose the Skp1/Skp2/Cks1 structure with that of CDK2/Cks1 and 
CDK2/cyclin A/p27 (Figure 4.1). This structure reveals that the furthest N-terminal 
residue which has been structurally characterised, residue 97, is distant from the 
proposed Skp2 binding site, consistent with the data suggesting this N-terminal tail is 
extended and unstructured (see Chapter 3, Section 4.2). 
 
 Figure 4.1: Model of the Skp1/Skp2/CDK2/cyclin A/Cks1/p27 complex. 
The N-terminus of Skp2 is modelled to show the possible routes that it could 
take to reach the proposed Skp2 binding site which overlaps with part of the 
p27 binding site. 
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Due to the predicted disordered structure of the Skp2 N-terminus (Figure 4.2), 
determination of the structure of this region by X-ray crystallography may not be 
possible, and there are no crystal structures that include this region of Skp2 to date. 
Computational methods, such as secondary structure prediction, can provide an 
estimation of secondary structure. Secondary structure prediction algorithms take into 
account the preference of amino acids for α-helices or β-sheets. For example, 
alanines and leucines have high α-helical propensity, whereas tryptophans and 
threonines prefer to form beta sheet structures. The PSIPRED secondary structure 
prediction server (Buchan et al., 2013) suggests the Skp2 N-terminus has very few 
structural elements, with no secondary structure predicted within the cyclin A binding 
site (Figure 4.2, (Ji et al., 2006)). 
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4.2	Overview	of	this	chapter	
Figure 4.2: The Skp2 N-terminal regulatory region. A) Secondary structure 
prediction for Skp2 residues 1-100 using PSIPRED server (Buchan et al., 2013). B) 
Binding sites within the Skp2 N-terminus. Akt, 14-3-3β and many other proteins 
have been found to bind to this region of Skp2. Residues 32, 33, 39 and 41 have 
been shown to be required for cyclin A binding (Ji et al., 2006, Chan et al., 2013). 
The D-box motif of Skp2 which binds Cdh1 comprises residues 3-7 of Skp2, 
however Cdh1 binding is also believed to involve additional residues further along 
the sequence, and phosphorylation of residues 64, 72 and 75 has been shown to 
compromise Skp2 binding to Cdh1 (Rodier et al., 2008, Lin et al., 2009, Hao et al., 
2005). Residues subject to phosphorylation are shown in red, and residues subject 
to acetylation are shown in green. Residues 66-72 comprise the Skp2 nuclear 
localisation signal (Hu et al., 2011). 
A 
B 
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In the preceding Chapter, details of the Skp2-binding site of cyclin A were presented. 
This chapter describes experiments to determine the cyclin A-binding site of Skp2. A 
model for the binding of Skp2 to cyclin A is presented, and the possible functions of 
this interaction are discussed. Identifying residues of Skp2 which are involved in this 
interaction might allow for crystallisation of the CDK2/cyclin A/Skp1/Skp2 complex. 
4.3	The	cyclin	A-binding	site	is	located	towards	the	Skp2	N-terminus	
4.3.1	Skp2	4A	is	impaired	in	its	binding	to	CDK2/cyclin	A	
A Skp2 construct containing residues 1-140 was mutated to alanine at residues Leu32, 
Leu33, Ser39 and Leu41, (hereafter referred to as Skp2-N 4A), in order to confirm the 
finding of Ji et al. (2006) that these residues are required for binding cyclin A. These 
residues are not part of a structured region (Figure 4.2), therefore, changing this 
sequence would not be expected to create structural changes. The primers for this 
mutagenesis are listed in Appendix A, Table A1.2. The SEC elution profile of this 
mutant looks very similar to that of Skp1/Skp2 WT (compare Figures 3.8 and 4.3) 
indicating that the mutations have not had a detrimental effect on protein stability or 
binding to Skp1.  
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Skp1/Skp2-N 4A expressed well and ITC was used again to assess its interaction with 
CDK2/cyclin A (Figure 4.4). Skp1/Skp2-N 4A was found to form a weak interaction 
with CDK2/cyclin A. This result was repeated and a similar binding affinity of 5.5 ± 
0.61 µM was measured. 
Figure 4.3: Purification of Skp1/Skp2-N 4A A) Skp1/Skp2-N 4A gel filtration 
chromatogram. B) SDS-PAGE gel showing whole-cell lysate (WCL), the unbound 
fraction from the glutathione-Sepharose column, eluate after 3C protease 
treatment and fractions from the regions of the peaks indicated by the black bars. 
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4.3.2	 Residues	 between	 Phe20	 and	 Ser30	 of	 Skp2	 also	 contribute	 to	 the	
interaction	with	cyclin	A	
The binding affinity of the Skp2-N 4A mutant for CDK2/cyclin A is over 10-fold weaker 
than that of WT Skp2 (Figure 4.4). Ji and co-workers confirmed this binding site by 
immunoprecipitation from a HEK293T WCL, and it has been shown here in an in vitro 
reconstituted system that mutating these residues has a direct effect on complex 
formation (Ji et al., 2006). The predicted secondary structure (PSIPred (Buchan et al., 
2013)) for Skp2-N 4A is the same as for the WT sequence (data not shown) suggesting 
that these residues are directly involved in the cyclin A interaction rather than 
contributing to the integrity of the secondary structure. Skp2-N 4A still retained some 
ability to bind to CDK2/cyclin A, suggesting that the cyclin A-binding site of Skp2 might 
be a fairly extended one. Previous work in the Endicott lab found through pull-down 
Figure 4.4: Binding isotherms for Skp2-N WT and 4A binding to 
CDK2/cyclin A. ITC experiment was carried out at 25°C. 20 µM CDK2/cyclin A 
in the cell and 180 µM Skp1/Skp2 in the syringe. 
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experiments that Skp2 residues 20-48 are required for binding to cyclin A (Schueller, 
2001). In order to determine whether residues 20-30 are involved in a direct interaction 
with cyclin A, constructs consisting of Skp2 residues 20-140 (Skp220-140) and residues 
30-140 (Skp230-140) were created. Both constructs include all of the residues mutated 
to create the Skp2-N 4A mutant. Skp2 residues 1-19 and 1-29 were removed in a 
deletion mutagenesis reaction using primers that annealed to either side of the deleted 
region. The truncations were not injurious to Skp2 and protein yields and the elution 
profiles following SEC were similar to Skp2-N (1-140) (Figure 4.5). 
 
A 
 
B 
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The association of these two truncated Skp2-N complexes with CDK2/cyclin A was 
also tested by ITC (Figure 4.6) These experiments revealed that residues within the 
range Phe20 to Ser30 are required for binding to CDK2/cyclin A. Removing the first 
19 residues did not have an effect on binding affinity, however, removing the first 29 
residues decreased the binding affinity from around 300 nM to 5.8 µM. 
Figure 4.5: Purification of Skp1/Skp220-140 and Skp1/Skp230-140. A) SEC 
elution profile of Skp1/Skp220-140. B) SDS-PAGE gel of fractions from the SEC 
elution of Skp1/Skp220-140. C) SEC elution profile of Skp1/Skp230-140. D) SDS-
PAGE gel of fractions from the SEC elution of Skp1/Skp230-140. 
Chapter 4: Identifying residues of Skp2 which mediate its interaction with Cyclin A 
 
124 
 
	
 
 
 
 
There is a large decrease in binding affinity for Skp1/Skp2-N30-140 binding to 
CDK2/cyclin A considering the Skp2 fragment still contains the four residues 
previously shown to be involved in the interaction with cyclin A (residues 32, 33, 39 
and 41 (Ji et al., 2006)). One explanation for these observations could be that there is 
a mechanism of folding-upon-binding which creates a secondary structure which 
requires residues within the range Phe20 to Ser30 for stabilisation. Alternatively, Skp2 
might form part of its interaction with cyclin A through residues within the range Phe20 
to Ser30. Within this sequence, there are charged and hydrophobic residues which 
might be involved in the interaction with CDK2/cyclin A. Residues within this region 
are fairly well conserved across species (Figure 4.7), some of which might be involved 
in the interaction with cyclin A.  
Figure 4.6: Analysis of the binding of Skp1/Skp220-140 and Skp1/Skp230-140 
to CDK2/cyclin A. ITC analysis was carried out using the same stock of 
CDK2/cyclin A for both binding analysis of Skp1/Skp220-140 and Skp1/Skp230-140. 
For comparison, the Kd for CDK2/cyclin A binding to Skp1/Skp2 (1-140) was 346 
nM. ITC experiment was carried out at 25°C. 20 µM CDK2/cyclin A in the cell 
and 180 µM Skp1/Skp2 in the syringe. 
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4.3.3	Mutation	of	 residues	22	and	24	weakens	 the	binding	affinity	of	 Skp2	 for	
CDK2/cyclin	A.		
To identify which residues within this sequence might be important for the Skp2/cyclin 
A interaction, two double mutants were created, and paired due to proximity to one 
another. These mutants were W22A W24A and D25A K28A. They were subsequently 
expressed and purified from recombinant E. coli cells (Figure 4.8).  
	
 
 
Residues Trp22 and Trp24 of Skp2 were found to contribute to its interaction with 
cyclin A (Figure 4.9). Their individual contribution to the binding affinity was not tested. 
The cyclin A binding surface on Skp2 is therefore extensive with a stretch of over 20 
Figure 4.7: Sequence alignment of Skp2 residues 21-30 
across species. Highly conserved residues are shown in red. 
Figure 4.8: Purified CDK2/cyclin A WT and Skp1/Skp2 WT and mutants 
before ITC. SDS-PAGE gel of CDK2/cyclin A and Skp1/Skp2 complexes before 
ITC. Small amounts of GST were still present in the purified samples. 
Chapter 4: Identifying residues of Skp2 which mediate its interaction with Cyclin A 
 
126 
 
residues contributing to the interaction. This might suggest that Skp2 extends over the 
surface of cyclin A in a similar way to p27. Alternatively, Skp2 could fold-upon-binding 
to create a globular domain in this region. The two tryptophans are part of a region of 
Skp2 predicted to form a short beta-sheet (Figure 4.2A).  
	
 
 
 
4.3.4	Further	mutation	of	Skp2	4A	to	include	W22A	and	W24A	mutations	leads	to	
loss	of	binding	
Taken together, the experiments to test the binding of Skp1/Skp2-N 4A and Skp2 
truncations to CDK2/cyclin A WT suggested that Skp2 residues Trp22 and Trp24 
contribute to its interaction with cyclin A. Skp2 4A was further mutated to include the 
W22A and W24A mutations. This mutant (hereafter referred to as Skp2-N 6A) was 
Figure 4.9: Binding isotherms for Skp2 double mutants D25A, K28A and 
W22A, W24A binding to CDK2/cyclin A WT. ITC experiment was carried out 
at 25°C. 20 µM CDK2/cyclin A in the cell, and 180 µM Skp1/Skp2-N in the 
syringe. 
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expressed and purified and found to be stable and able to associate with Skp1 (Figure 
4.10). A comparison of the relative mobilities of the different Skp1/Skp2-N mutant 
complexes by SDS-PAGE shows that the introduction of different mutants can make 
a substantial change in their electrophoretic properties (Figure 4.10). When running 
Skp2-N 6A on an SDS-PAGE gel, the introduction of the six mutations causes a 
change in the electrophoretic mobility of Skp2 (Figure 4.10). The Skp2-N 4A mutation 
also causes a less noticeable shift in electrophoretic mobility. Comparing the mobilities 
of the various Skp2 mutants indicates that there is a band shift when mutating Leu32 
and Leu33 to alanines and a further band shift when Trp22 and Trp24 are mutated to 
alanines (Figure 4.10). This could be due to Skp2-N 4A and 6A not being able to bind 
as much SDS as the WT protein causing a slower migration through the acrylamide 
gel (Rath et al., 2009). The change in electrophoretic mobility could also be due to 
insufficient unfolding upon boiling of Skp2 when certain residues are mutated. Mass 
spectrometry could be used to determine whether Skp2-N 4A and 6A are being 
modified by enzymes in E. coli, thus increasing their molecular weight. 
	
 
 
Skp1/Skp2-N 6A was analysed for its binding to CDK2/cyclin A and binding was found 
to be unable to bind CDK2/cyclin A (Figure 4.11). For this experiment, the binding of 
CDK2/cyclin A WT to Skp1/Skp2-N WT was measured again using the same stock of 
CDK2/cyclin A for the experiments shown in 4.11 and 4.12). The Kd obtained was 45 
Figure 4.10: SDS-PAGE analysis of purified CDK2/cyclin A WT, Skp1/Skp2 
WT and Skp1/Skp2-N mutants. SDS-PAGE of protein complexes before ITC. 
Mutation of some residues causes a change in electrophoretic mobility of Skp2. 
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nM, which is a much higher binding affinity than previously determined (Kd of 346 nM, 
Figure 3.14). The samples for this ITC experiment were purer than the last one 
(compare Figures 3.15 and 4.10) suggesting that this is a reliable experiment. 
However, the binding affinity would not be affected by the presence of contaminants 
as this would merely change the concentration and alter the binding stoichiometry. 
The error measurements shown with the binding affinity are errors of the fit of the 
curve to the data. This is at the lower end of all binding affinities measured for 
CDK2/cyclin A WT binding to Skp1/Skp2-N, a binding affinity of around 200 nM is the 
average for all measurements (see appendix A, section A2). 
	
4.3.5	Analysing	the	contributions	of	the	cyclin	A-binding	regions	on	Skp2	to	overall	
binding	affinity	
The observation that the cyclin A-binding region of Skp2 is extended over 19 residues 
suggests that these sites might have secondary structure. To test this hypothesis, a 
Figure 4.11: Skp1/Skp2-N 6A is unable to bind to CDK2/cyclin A. ITC 
experiment was carried out at 25°C. 20 µM CDK2/cyclin A in the cell, and 180 µM 
Skp1/Skp2-N 6A in the syringe 
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Skp2 peptide of residues 21-43 was synthesised and tested using CD (Chapter 2, 
Section 8). It was found that to have no secondary structure (data not shown). 
However, this region could be folding-upon-binding, or require more of the sequence 
in order to form a stable secondary structure.  
Three clusters of residues have been identified as forming the Skp2 interaction site 
with cyclin A. The individual contributions of each of these three sites were then 
interrogated in order to determine whether these sites bind co-operatively or whether 
they act independently. From the ITC experiments that tested the interactions of the 
Skp2 double mutants with CDK2/cyclin A (Section 4.3.3), it was clear that Trp22 and 
Trp24 together contribute to the interaction with cyclin A. The contribution of L32A and 
L33A; and W22A, W24A, S39A and L41A to the observed loss of binding, were then 
assessed for their binding to determine the contribution of the three clusters of binding 
sites (Figure 4.12 and Appendix A, Section A2).  
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Figure 4.12: Binding isotherms for CDK2/cyclin A binding to Skp1/Skp2-N 
mutants with various mutations within the cyclin A-binding region. 
CDK2/cyclin A WT binding to Skp1/Skp2-N WT; L32A, L33A; W22A, W24A, S39A, 
L41A; and W22A, W24A, L32A, L33A, S39A, L41A (6A). The same stock of 
CDK2/cyclin A was used for all four experiments. See Figure 4.9 for sample purity.  
ITC experiment was carried out at 25°C. 20 µM CDK2/cyclin A in the cell, and 180 
µM Skp1/Skp2 in the syringe.  
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Within the Skp2 N-terminus, three clusters of residues (Trp22 and Trp24; Leu32 and 
Leu33; and Ser39 and Leu41) were identified as being involved in the interaction with 
cyclin A (Figure 4.4 and 4.11). All sites seem to be contributing to the interaction. The 
ITC experiment of Skp1/Skp2-N 6A binding to CDK2/cyclin A was repeated and is 
shown in Appendix A2. Knocking out any one site reduces the cyclin A-binding 
capacity of Skp2 and knocking all out causes near complete loss of binding, 
suggesting that the three sites bind independently of one another. Alternatively, one 
of the sites may dock to cyclin A making it easier for other parts of Skp2 to 
subsequently bind. Mutation of cyclin A residues 244 to 247 to residues of the cyclin 
E sequence caused loss of Skp2 binding (Chapter 3). The mutations included an 
insertion of a glutamate residue, and analysis of the cyclin E structure shows that the 
glutamate points out into solution (Chapter 3, Section 3.7.2). Although an extended 
region of Skp2 was found to bind cyclin A, this sequence can be displaced by this 
insertion suggesting that the bulge in the surface of cyclin A caused by the mutations 
prevents docking of the three binding sites by extending the area of the cyclin A 
surface which Skp2 residues 22 to 41 spans. 
4.4	CDK2	does	not	form	an	interaction	with	Skp1/Skp2		
4.4.1	Role	of	CDK2	in	the	interaction	of	CDK2/cyclin	A	with	Skp2	
The finding that the cyclin A-binding site of Skp2 is fairly extended opens up the 
possibility that CDK2 may contribute to the interaction with Skp2. There is some 
discrepancy in the literature as to whether CDK2 contributes to the CDK2/cyclin A 
interaction with Skp2. Yam and co-workers found that Skp1 and Skp2 are pulled down 
by CDK2 in an in vitro GST pull-down assay, where CDK2 was GST tagged (Yam et 
al., 1999). However, Ji and co-workers were unable to pull down CDK2 in a similar 
GST pull-down assay, where Skp2 was GST tagged (Ji et al., 2006). An explanation 
for this might be found by considering the binding of p27 to CDK2/cyclin A and 
CDK2/cyclin E. p27 binds to CDK2/cyclin A and CDK2/cyclin E through a sequential 
mechanism which involves an initial interaction with the cyclin at the RXL recruitment 
site, and then folding of the p27 around cyclin A/E onto CDK2 (Lacy et al., 2004). Skp2 
might, therefore, bind to CDK2/cyclin A in a similar manner. However, as CDK2/cyclin 
E does not bind to Skp2, it seems unlikely that Skp2 forms a significant interaction 
with CDK2 without cyclin A.  
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Figure 4.13 shows the CDK2/cyclin A surface structure with p27 in coral and the region 
of cyclin A identified as contributing to the interaction with Skp2 (Chapter 3) in yellow 
with a red surface. Skp2 also binds to the p27 binding site of cyclin A as p27 and Skp2 
binding to cyclin A is mutually exclusive. In order to determine the role of CDK2 in 
binding of the CDK2/cyclin A complex to Skp1/Skp2-N, monomeric CDK2 was 
expressed in E. coli and purified by Dr Mathew P. Martin. 
 
 
 
4.4.2	Monomeric	CDK2	does	not	bind	to	Skp1/Skp2-N	
ITC was used to quantitate the interaction between CDK2 and Skp1/Skp2-N (Figure 
4.14). The ITC experiment showed that monomeric, unphosphorylated CDK2 does not 
bind to Skp1/Skp2-N. 
Figure 4.13: Mutated residues of cyclin A mut 7 are in close proximity 
to CDK2. CDK2 is in ice-blue, cyclin A is in yellow with mutated region in 
red (cyclin A mut 7), p27 in coral. PDB: 1JSU 
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This result could arise if the CDK2 were unstable and had aggregated in the cell. When 
the contents of the cell were recovered after the experiment, there were no signs of 
cloudy precipitate. SDS-PAGE analysis of the proteins after the experiment showed 
that CDK2 was intact and had the expected stoichiometry with Skp1/Skp2-N (Figure 
4.15). 
Another control which could have been done would be to use cyclin E1 as a surrogate 
for cyclin A to determine the contribution of CDK2 to the binding of Skp2 as cyclin E 
cannot bind Skp2. This would ensure CDK2 was stable and in a conformation which 
supports protein-protein interactions. However, in contrast to cyclin A, cyclin E does 
not express well in E. coli and a protocol had not been established in the lab for 
producing cyclin E recombinantly, so it was not possible at the time to do this 
experiment. Other temperatures and conditions could have been used to establish 
Figure 4.14: Binding isotherms of CDK2/cyclin A binding to Skp1/Skp2-N 
compared with monomeric CDK2 binding to Skp1/Skp2-N. ITC experiment 
was carried out at 25°C. 20 µM CDK2 or CDK2/cyclin A in the cell, and 180 µM 
Skp1/Skp2-N in the syringe. 
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whether CDK2 does bind slightly as the conditions used were those used for 
CDK2/cyclin A binding to Skp1/Skp2-N.  
 
 
The Skp2 construct used in this experiment comprised residues 1-140. Ji and co-
workers also used an N-terminal construct of Skp2 in their study, whereas Yam and 
co-workers used full-length Skp2. Full-length phosphorylated Skp2 binds to CDK2 
indirectly through Cks1, an interaction which is mediated through the C-terminus of 
Skp2 (Hao et al., 2005). This difference in Skp2 constructs could explain the 
discrepancy in the published studies. In agreement with Ji and co-workers, our results 
confirm that monomeric CDK2 does not form an interaction with the Skp2 N-terminus. 
4.4.3	Thermodynamics	of	binding	are	different	between	CDK2/bovine	cyclin	A	and	
bovine	cyclin	A	binding	to	Skp1/Skp2-N	
In order to investigate the binding of CDK2/cyclin A to Skp1/Skp2-N further, bovine 
cyclin A was expressed as a surrogate for monomeric human cyclin A. Bovine cyclin 
A was used in these experiments as human cyclin A is not stable in a monomeric form, 
Figure 4.15: SDS-PAGE analysis of 
CDK2 and Skp1/Skp2-N before and 
after the ITC experiment. On the left 
are the individual protein samples 
before the ITC experiment, and on the 
right is the protein mixture recovered 
from the ITC cell. 
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and must be co-purified with CDK2. Bovine and human cyclin A are similar in 
sequence (Figure 4.16) and structure (Brown et al., 1995, Jeffrey et al., 1995). The 
sequence is identical between residues 164 and 302 of human cyclin A, which 
encompasses the Skp2 binding site identified around residues 244 to 247 of human 
cyclin A. Therefore, it would be expected that binding of Skp2 to bovine cyclin A and 
human cyclin A would be equivalent. 
 
 
Bovine cyclin A was purified using nickel affinity purification (Figure 4.17A), through 
binding of a C-terminal hexahistidine tag to the nickel resin. SEC was then used as a 
Figure 4.16: Sequence alignment of human and bovine cyclin A2 to 
illustrate sequence conservation between the two cyclin orthologues.  
Uniprot accession numbers P20248 (Homo sapian) and P30274 (Bos taurus). 
An asterisk indicates positions that are fully conserved. A colon indicates 
conservation between groups of strongly similar properties, scoring >0.5 in the 
Gonnet PAM 250 matrix. A full stop indicates conservation between groups of 
weakly similar properties, scoring =<0.5 in the Gonnet PAM 250 matrix. Figure 
was created using Clustal Omega (Sievers et al., 2011). 
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final purification procedure (Figure 4.18). CDK2/bovine cyclin A was purified following 
the same protocol as used to purify CDK2/human cyclin A (Figure 4.17B). 
	
	
 
Figure 4.17: Affinity purification of bovine cyclin A (A) and CDK2/bovine 
cyclin A (B). A) His-tagged bovine cyclin A was purified using nickel-affinity 
chromatography. The column was washed with 15 mM imidazole in mHBS. Bovine 
cyclin A was eluted by increasing the imidazole concentration. Only the final fraction 
was used for the subsequent SEC purification. B) CDK2/bovine cyclin A was 
purified using the protocol for purification of CDK2/human cyclin A (see Chapter 2, 
Sections 1.7 to 1.9). WCL (whole cell lysate) was derived from the bovine cyclin A 
E. coli cell lysate. 
A 
B 
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Bovine cyclin A expresses well in E. coli under the same conditions as are used to 
successfully express human cyclin A (Figure 4.17). Only the last fraction shown in 
Figure 4.17A was concentrated and loaded onto the size-exclusion column for further 
purification (Figure 4.18) as high amounts of contaminating proteins co-eluted with 
bovine cyclin A at the lower imidazole concentrations. 
	
	
 
Figure 4.18: Purification of bovine cyclin A was achieved by nickel-affinity 
chromatography followed by SEC. Fractions corresponding to the parts of the 
chromatogram with the black bars underneath were analysed by SDS-PAGE. A high 
level of purity of bovine cyclin A was achieved after nickel-affinity purification and 
SEC. 
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Monomeric bovine cyclin A was then tested for binding to Skp1/Skp2-N20-140 by ITC 
(Figure 4.19). Bovine cyclin A binds tightly to Skp1/Skp2-N, with a measured Kd of 192 
± 36 nM. This value compares to the affinity of Skp1/Skp2-N20-140 to CDK2/bovine 
cyclin A of 741 ± 101 nM. The relatively tight association suggests that the complex is 
sufficiently stable for crystallisation trials. It might, therefore, be possible to obtain the 
structure of bovine cyclin A bound to a Skp2 peptide or Skp1/Skp2-N. Interestingly, 
the Kd for CDK2/bovine cyclin A binding to Skp1/Skp2-N was weaker than bovine 
cyclin A binding to Skp1/Skp2-N by about fourfold (Figure 4.19). However, the 
enthalpy (ΔH) was much greater for CDK2/bovine cyclin A than monomeric bovine 
cyclin A binding to Skp1/Skp2-N20-140. Bovine cyclin A and human cyclin A are very 
similar, and therefore, it would be expected that the Skp1/Skp2 binding affinities would 
be similar. However, the binding to bovine cyclin A could be weaker as this is not the 
physiological binding partner of Skp2. In this case, you would expect that monomeric 
human cyclin A would then also bind tighter than CDK2/human cyclin A, which is 
around 200 nM binding affinity.  
Figure 4.19: Binding isotherms for bovine cyclin A and CDK2/bovine cyclin 
A binding to Skp1/Skp2-N20-140. The ITC experiment was carried out at 25°C. 20 
µM CDK2 or CDK2/cyclin A in the cell and 200 µM Skp1/Skp2 in the syringe. 
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The bovine cyclin A versus CDK2/bovine cyclin A binding to Skp1/Skp2-N experiment 
(Figure 4.19) and the monomeric CDK2 versus CDK2/human cyclin A experiment 
(Figure 4.14) have given similar results; they both show that Skp1/Skp2-N does not 
make a significant interaction with monomeric CDK2. But the two experiments are 
slightly different and the binding profiles of CDK2/bovine cyclin A and CDK2/human 
cyclin A look slightly different (compare Figure 4.19, right panel, to Figures 3.13 and 
4.11, left panels), with a weaker Kd for CDK2/bovine cyclin A-Skp1/Skp2-N. Hence, 
the binding might be altered by the subtle differences in either the way CDK2 binds 
bovine cyclin A compared to human cyclin A; or the way CDK2/bovine cyclin A 
compared to CDK2/human cyclin A binds to Skp1/Skp2-N.  
4.5	Stoichiometry	of	the	CDK2/cyclin	A	interaction	with	Skp1/Skp2-N	
ITC experiments described in Chapters 3 and 4 revealed an unexpected N-value for 
CDK2/cyclin A binding to Skp1/Skp2. This value was expected to be 1, indicative of a 
1:1 stoichiometry, however, the N-value has been found to be around 0.6 for the 
CDK2/cyclin A interaction with Skp1/Skp2-N (Figure 4.4 left panel and 4.11, left panel). 
This suggests either an overestimation of the protein concentration in the cell or an 
underestimation of the protein concentration in the syringe. When this result was first 
noticed, protein concentrations were re-calculated rigorously. However, the N-value 
remained around 0.6. Therefore, it is possible that a proportion of CDK2/cyclin A is in 
a state which cannot undergo an interaction. For some of the ITC experiments, there 
was a proportion of contamination from GST in the sample (see Figures 3.15 and 4.8). 
The initial ITC experiments on the cyclin A mutants gave an N-value of about 1 for 
CDK2/cyclin A WT binding to Skp1/Skp2-N. However, this sample contained some 
GST (Figure 3.15). Repeating the ITC experiment with no GST gave an N-value of 0.6 
(Figure 4.11). Therefore, it appears that GST is not causing the N-value to differ from 
its expected value. It would appear, therefore, that a proportion of the CDK2/cyclin A 
in these experiments is unable to form an interaction with Skp1/Skp2-N. This 
stoichiometry has also been observed for CDK1 binding to cyclin B, and therefore 
might be something inherent to the CDK (Brown et al., 2015). Another change in the 
ITC binding isotherm when GST had been fully removed, was that the affinity of 
Skp1/Skp2 for CDK2/cyclin A was measured at about 10-fold tighter than for previous 
experiments (compare Figures 3.13 and 4.11). As the samples were very pure for the 
ITC experiment shown in Figure 4.11 (compare Figures 3.15 and 4.10), the result 
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seems to be the more reliable experiment. However, the binding affinity should not be 
affected by the purity of the sample. The binding affinity of CDK2/cyclin A and 
Skp1/Skp2-N has been measured several times (See Appendix Section A2) and this 
high binding affinity appears to be unusually tight. 
In this chapter and the previous one, the binding interfaces of the Skp2/cyclin A 
interaction have been described and the literature suggests that inhibition of this 
interaction might prevent tumour growth. It would be useful to build on the current 
literature describing small molecule drug developments which target Skp2. As Skp2 
has been found to be upregulated in many cancers and to have many roles in cancer 
(see Chapter 1, Section 9), it has been widely accepted as a valid target for drug 
development. The crystallisation of the SCFSkp2 complex has helped this drug 
discovery effort. Addition of structural information for the Skp2/cyclin A interaction 
would also aid drug discovery efforts to inhibit the SCFSkp2 complex. The following 
section describes efforts to obtain a structure of CDK2/cyclin A bound to Skp1/Skp2 
or a Skp2 peptide. 
4.6	Structural	investigations	of	the	Skp1/Skp2/CDK2/cyclin	A	complex	
Taken together, the data outlining the binding site of cyclin A on Skp2 show that there 
are about 55 residues between the N-terminus of Skp2, which is visible in the 
Skp1/Skp2-C crystal structure (Figure 1.17), and the region of Skp2 that mediates the 
interaction with cyclin A. It is likely that these residues form an elongated structure to 
bridge the interaction of Skp2 with cyclin A. The first 19 residues of Skp2 were shown 
to be external to the cyclin A binding site (Figure 4.6). Using the biophysical data 
indicating the Skp2 N-terminal residues involved in the interaction with cyclin A, 
peptides were synthesised with the aim of obtaining a co-crystal structure with 
CDK2/cyclin A. The synthesised peptides are shown in Table 4.1. 
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Peptide 
number 
Residues of 
human Skp2 Sequence 
1 31-43 ELLSGMGVSALEK 
2 21-43 TWGWDSSKTSELLSGMGVSALEK 
3 18-43 TSFTWGWDSSKTSELLSGMGVSALEK 
 
 
Crystal trays were initially set up using peptide 1 at 1.8 mM mixed with 5.8 mg/mL 
CDK2/cyclin A WT, and hits were obtained in a MORPHEUS screen (Molecular 
Dimensions). Large flat plate crystals were obtained in condition G7 (0.1 M buffer 
system 2 (Sodium HEPES, MOPS (acid)) pH 7.5, 0.1 M carboxylic acids, 50% v/v 
precipitant mix 3 (40% v/v glycerol, 20% w/v PEG 4000), with a 1:1 drop ratio of protein 
to well solution. The crystals were cryocooled and taken to Diamond Light Source 
(Didcot, UK) for data collection. When the data were analysed and the structure 
solved, the peptide was found to be absent from the structure.  
It appeared that the lack of success with the co-crystallisation of peptide 1 with 
CDK2/cyclin A could have been due to two factors. The first is that the crystal contacts 
don’t accommodate the Skp2 peptide. And secondly the peptide might not be binding 
tight enough. Peptide 2, which is more extended than peptide 1 and contains Trp22 
and Trp24 which were identified as contributing to the interaction with cyclin A (Figure 
4.9), was designed. Crystal trays were set up using peptide 2 as with peptide 1. The 
MORPHEUS screen was not used as CDK2/cyclin A crystallises readily from this 
screen in a crystal form incompatible with peptide binding, and new conditions more 
optimal for the growth of the peptide-bound complex were desired. In order to disrupt 
the crystal contacts observed in the CDK2/cyclin A crystal lattice and allow the peptide 
to bind within an alternative lattice, a key leucine residue of CDK2 (Leu25) was 
mutated to an aspartate. Commercial screens were set up using peptide 2 with CDK2 
WT/cyclin A and CDK2 L25D/cyclin A. Crystals with CDK2/cyclin A WT, but not CDK2 
L25D/cyclin A formed after one month at 4°C from an Index screen condition 
(Hampton Research) with CDK2/cyclin A WT rather than the CDK2 L25D mutant 
(Figure 4.20). Data collection was carried out at Diamond Light Source (Didcot, UK) 
Table 4.1: Skp2 peptides synthesised for co-crystallisation with 
CDK2/cyclin A. 
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and the crystals diffracted to 2.8 Å. The data were analysed and structure solved, and 
it was found again that the peptide was not present. The crystallization trials of the 
Skp2 peptides with the CDK2 L25D/cyclin A mutant complex did not yield any crystals. 
This result suggests that CDK2/cyclin A does not crystallise readily in alternative 
lattices, but confirms the importance of the Leu25 contact. This work did, however, 
identify alternative conditions which yield CDK2/cyclin A crystals. 
	
 
Finally, peptide 3 was purchased. This peptide contains an additional three residues 
at the N-terminus to encompass a potentially structured region around residue 20 
(Figure 4.2) which is required for proper orientation of Skp2 to the cyclin A binding 
site. In addition, the greater number of residues might increase the binding affinity, 
albeit, it might increase the flexibility. Peptide 3 has not yet been put into crystallisation 
trials. Due to the lack of success with peptides 1 and 2, the binding of peptide 3 to 
CDK2/cyclin A should be confirmed before continuing with the crystallisation trials. 
 
Figure 4.20: Crystals obtained by co-crystallisation of CDK2 (WT)/cyclin A 
with Skp2 peptide 2. Crystals grew in Index screen condition C12 (15% v/v 
Tacsimate pH 7.0, 0.1 M HEPES pH 7.0, 2% w/v PEG 3350). Drop shown is 2:1 
protein: mother liquor.  
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4.7	Discussion	
4.7.1	Model	of	the	cyclin	A	binding	site	of	Skp2	
These data have allowed for a clearer understanding of the interactions within the 
CDK2/cyclin A/Skp1/Skp2/Cks1 complex. There are 56 residues between the N-
terminus of Skp2 which has been structurally characterised (residues 97 to 424) and 
the sequence of Skp2 identified here as being involved in the interaction with cyclin A 
(Trp22 to Leu41). This result is represented in Figure 4.21, which is a superimposed 
structure of Skp1/Skp2/Cks1 (PDB: 2AST), CDK2/Cks1 (PDB: 1BUH) and 
CDK2/cyclin A/p27 (PDB: 1JSU), created by Dr Julie A Tucker. The Figure 
hypothesises that the N-terminus of Skp2 loops around cyclin A to dock at the Skp2-
binding site. Further interactions cannot be used to map the binding as the residues 
of Skp2 that compete with p27 for binding to cyclin A are not known, and therefore 
which region of Skp2 might bind along the top (relative to figure orientation of Figure 
3.3) of cyclin A cannot be located. It might be possible to obtain a crystal structure of 
CDK2/cyclin A/Skp1/Skp2-N with the Skp2 region which spans the gap from the N-
terminus to the identified binding site of cyclin A truncated such that only the minimum 
amount of residues required to cross this gap were present. This might be more 
amenable to crystallisation as it would mean that this region would be less flexible. 
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4.7.2	Hydrophobic	residues	of	Skp2	are	key	to	its	interaction	with	cyclin	A	
The Skp2-binding site on cyclin A does not have features suggestive of a binding 
pocket. Five of the six residues shown in this Chapter to influence Skp2 binding to 
cyclin A are hydrophobic. The separation of the residues along the Skp2 sequence 
would be compatible with them adopting a helical structure that might form a 
hydrophobic face that could dock on cyclin A. The p27 structure is helical as it binds 
to the upper surface of the cyclin A N-CBF and a number of residues are hydrophobic. 
A comparison of this region of the p27 sequence with that of Skp2 between residues 
Figure 4.21: Structural model of the CDK2/cyclin A/Skp1/Skp2/Cks1 
complex. A dashed line illustrates the N-terminus of Skp2 which has not been 
structurally characterised. The loop region of cyclin A which has been identified as 
being involved in the interaction with Skp2 is shown in green (cyclin A mut 7). The 
superimposed structure was created by Dr Julie A. Tucker using CCP4MG. 
Skp1/Skp2/Cks1 (PDB: 2AST), CDK2/Cks1 (PDB: 1BUH) and CDK2/cyclin A/p27 
(PDB: 1JSU). 
Chapter 4: Identifying residues of Skp2 which mediate its interaction with Cyclin A 
 
145 
 
22 to 41 shows little homology between the two (Figure 4.22), suggesting that Skp2 
and p27 do not share many cyclin A residue interactions. Rather than following the 
same path along the ‘top’ of cyclin A, perhaps Skp2 crosses the path of the p27 binding 
site causing their mutually exclusive binding. This upper region of the cell cycle cyclins 
may be able to mediate diverse interactions. On cyclin A, this site is involved in its 
interaction with p27 and it was recently reported that the upper region of cyclin B can 
support helix binding. The CDK1 C-terminal tail forms an amphipathic helix and this 
helix was identified in the CDK1/cyclin B structure to bind to a symmetry-related cyclin 
B molecule at the site which on cyclin A is the upper p27 binding site. This helix mimics 
interactions which p27 makes with cyclin A. It is probable that it is at this site that Skp2 
and p27 compete for binding to cyclin A. 
	
As many of the Skp2 residues identified as contributing to the interaction with cyclin A 
are hydrophobic, the hydrophobic surface of cyclin A was analysed. There is a 
hydrophobic groove next to the cyclin A loop which was identified as involved in the 
interaction with Skp2. The hydrophobic side chain of Met246 of cyclin A points out 
towards this groove (Figure 4.23). The structure of CDK2/cyclin A mut 7 revealed that 
Gln246 of cyclin A mut 7 points out towards this groove (Chapter 3, Section 7.2). As 
glutamine is polar, this would be expected to decrease the hydrophobicity of this 
groove (Figure 4.23B). Glu247 of cyclin A mut 7 points out into solution and might 
sterically clash with residues of Skp2.  
  
Figure 4.22: Comparison of cyclin A binding regions of Skp2 and p27. Skp2 
residues W22, W24, L32, L33, S39 and L41 were identified as contributing to the 
interaction with cyclin A. The cyclin A-binding region (with the exception of the RXL 
motif at residues 30-32) of p27 is shown. Hydrophobic residues are in red. Skp2 
contains many hydrophobic residues within this region including many residues 
involved in the interaction with cyclin A, whereas p27 has a higher proportion of 
charged residues. 
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4.7.3	 Identification	 of	 Skp2	 residues	 which	 contribute	 to	 its	 interaction	 with				
cyclin	A	
Mutations made to cyclin A in order to disrupt the Skp2 interaction (Chapter 3) lie on 
a loop region that is not believed to be involved in any other interaction of cyclin A. 
Figure 4.23: Hydrophobic residues of Skp2 which contribute to its 
interaction with cyclin A might bind to a hydrophobic groove on cyclin A. 
CDK2/cyclin A WT (A) and CDK2/cyclin A mut 7 (B and C) are shown with cyclin 
A in surface representation with hydrophobic regions shown in dark fawn with 
polar and charged regions shown in blue. A) Cyclin A residues 244-247 which 
contribute to the interaction with Skp2 are in close proximity to a hydrophobic 
groove. C) Gln246 of cyclin A mut 7 is shown in gold to illustrate its position in 
this groove. CDK2 is coloured ice-blue. 
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This cyclin A mutant might therefore be useful as a probe to investigate the function 
of the Skp2/cyclin A interaction and to gain further insights into whether it would be 
beneficial to inhibit this particular interaction. Reports from other labs using the Skp2 
4A mutant, which is impaired for binding to cyclin A, suggest that the Skp2/cyclin A 
interaction is important for Skp2 function, and that blocking this interaction could lead 
to G1 cell cycle arrest or apoptosis (Ji et al., 2006, Ji et al., 2007, Lu et al., 2014). By 
identifying the Skp2 interaction site on cyclin A, it will be possible to determine whether 
the effects of the mutations made to Skp2 are due to inhibition of the cyclin A 
interaction specifically. The mutations made to Skp2 are in a region involved in 
multiple protein-protein interactions, and thus this site may not function exclusively in 
the binding of cyclin A and it would be useful to tease out the exact role. Identifying 
the significance of this interaction might also allow for the explanation of the role that 
cyclin A plays in protecting or promoting Skp2 interactions with other proteins. 
The Skp2/cyclin A interaction has been shown by the Zhu group to be a useful target 
for therapy through the engineering of a Skp2 peptide (Ji et al., 2007). The peptide 
comprised residues 28-45 of Skp2 and thus included the four residues Ji and co-
workers identified as mediating the interaction of Skp2 with cyclin A in their earlier 
paper (Ji et al., 2006). This peptide was tagged with HIV Tat to allow for its entry into 
cells. Using an MTS cell proliferation assay, they found that introducing this peptide 
blocked the Skp2/cyclin A interaction and decreased the proliferation of U20S cells, 
with an IC50 of 35 µM. They also found that the peptide was able to bind to cyclin A in 
the presence of p27, suggesting that the overlap of the Skp2 and p27 binding sites on 
cyclin A lies outside Skp2 residues 28-45 and therefore the tryptophan residues at 22 
and 24 might share a binding site with p27.  
4.7.4	Might	Skp2	act	as	a	regulator	of	CDK2/cyclin	A?	
Regulators of CDK/cyclin complexes tend to bind to both the CDK and cyclin subunits. 
Examples include, p27 binding to CDK2/cyclin A/E and HIV-Tat binding to CDK9/cyclin 
T1 (Chapter 1, Section 1.4 (Russo et al., 1996a, Gu et al., 2014)). As Skp1/Skp2-N 
does not interact with monomeric unphosphorylated CDK2, and Skp1/Skp2-N binds 
equivalently to monomeric bovine cyclin A and CDK2/human cyclin A (Figures 4.14 
and 4.19), it is likely that CDK2 does not make a contribution to the interaction of 
CDK2/cyclin A with Skp2. Therefore, it seems unlikely that Skp2 would be able to 
regulate CDK2 activity in a similar way to other regulators of CDK/cyclin complexes.  
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4.7.5	Implications	of	the	work	described	in	this	chapter	
In this investigation, Skp2 residues within the region of Trp22 to Leu41 were identified 
as being involved in the interaction of Skp2 with cyclin A (specifically residues Trp22, 
Trp24, Leu32, Leu33, Ser39 and Leu41). The residues identified in this work have not 
been directly linked to binding of any other proteins to Skp2, however, they are within 
a region implicated in many protein-protein interactions, and cyclin A binding to Skp2 
might have an effect on the binding of other proteins. Therefore, it is likely that this site 
is not solely involved in the cyclin A interaction. Being able to study the Skp2/cyclin A 
interaction from both sides in functional studies will allow for the specificity of either 
site for this interaction to be determined. 
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Chapter	5:	Functional	
characterisation	of	the	Skp2/cyclin	A	
interaction	
5.1	Overview	of	chapter	
This chapter describes cell-based experiments to validate the mutations identified in 
Chapters 3 and 4 that block the interaction of Skp2 with cyclin A. Cyclin A mut 7 has 
been shown to be properly folded; the mutations do not cause any structural 
rearrangements in distal parts of the protein; it is able to bind CDK2, p107 and p27; 
and is equivalent to WT cyclin A in its ability to activate CDK2. Cyclin A was shown to 
bind to an extended region of the Skp2 N-terminus. It was also found that Skp1/Skp2-
N does not bind to monomeric CDK2. Cyclin A mut 5 and mut 7, and Skp2 4A and 6A 
were tested in the following in cellulo experiments (Figure 5.1). 
A cyclin A mutant, which cannot bind Skp2, will allow for the specificity of any 
phenotypic effects to be assessed, due to the specificity of the interaction site for 
Skp2. The mutations made to Skp2 are within a region involved in multiple protein-
protein interactions and therefore might give rise to off-target effects. In contrast, the 
Skp2-binding site on cyclin A appears to be in a region not known to be involved in 
any other interactions of cyclin A. It would, therefore, be expected that the phenotype 
associated with the cyclin A mutations would be cleaner than that associated with the 
Skp2 mutants.  
It has been demonstrated that mutation of residues 244 to 247 on a loop of cyclin A 
causes a complete loss of cyclin A binding to Skp2 with a Kd too low to be determined 
by ITC (Figures 3.14 and 3.16). Skp1/Skp2-N 4A retained some binding to cyclin A, 
with a Kd value about 10 times weaker than WT (Figure 4.4). Skp2 4A will be used in 
in cellulo experiments to confirm the experiments of Ji and co-workers (Ji et al., 2006). 
Skp1/Skp2-N 6A showed very weak binding to CDK2/cyclin A (Figure 4.11). 
Therefore, both Skp2 6A and cyclin A mut 7 would be expected to be mutants which 
would cause a noticeable phenotype when assayed in cellulo (binding affinity are 
summarised in Figure 5.1B). 
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A 
 
B Interaction Kd 
Skp1/Skp2 WT binding to CDK2/cyclin A WT 346 ± 50 nM 
Skp1/Skp2 WT binding to CDK2/cyclin A mut 5 19 ± 11.5 µM 
Skp1/Skp2 WT binding to CDK2/cyclin A mut 7 unable to determine 
Skp1/Skp2 4A binding to CDK2/cyclin A WT 5.5 ± 0.61 
Skp1/Skp2 6A binding to CDK2/cyclin A WT unable to determine 
 
 
 
 
5.2	Putative	functions	of	the	Skp2/cyclin	A	interaction	
5.2.1	Role	of	the	Skp2/cyclin	A	interaction	in	degradation	of	p27	
The finding that CDK2/cyclin A binds to the SCF complex and that there is a non-
catalytic role of CDK2/cyclin A in the ubiquitination of p27 has led to additional 
research into the Skp2/cyclin A interaction. Using the Skp1/Skp2/Cks1 (Hao et al., 
Figure 5.1: Mutations made to Skp2 and cyclin A. A) Partial Skp2 and cyclin A 
sequences and mutated regions are shown. B) Summary table of binding affinities 
determined by ITC. 
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2005, Rodier et al., 2008) and CDK2/Cks1 (Bourne et al., 1996) structures, 
CDK2/cyclin A can be superimposed onto the SCF complex. This model reveals that 
the Skp2/cyclin A interaction would be expected to be intact in the SCF-Skp2-Cks1-
CDK2-cyclin A complex due to the predicted proximity of the N-terminus of Skp2 to 
cyclin A (Figure 4.21). Seeliger and co-workers used ITC to determine that the binding 
affinity of p27 for Skp2/Cks1/CDK2 is 150 nM, whereas the binding affinity for 
Skp2/Cks1 is 470 nM, showing that CDK2 enhances the binding affinity of p27 to the 
SCFSkp2 complex (Seeliger et al., 2003). When the structure of Cks1 bound to 
Skp1/Skp2 was solved two years later, it was apparent that CDK2 has no role in 
contacting the C-terminus of p27. Therefore, any effect it might have on the binding 
affinity would be allosteric or through the anchoring of the p27 N-terminus. The 
structure of CDK2/Cks1 revealed no change in Cks1 structure upon CDK2 binding. 
Further investigations are therefore required to determine whether this difference is 
significant, and if so, why p27 binds tighter to Skp2/Cks1/CDK2 than Skp2/Cks1. 
Despite expectations that the Skp2/cyclin A interaction might be important for p27 
ubiquitination, Ji and co-workers found that p27 levels were unaffected by the 
introduction of the 4A mutations to Skp2 (Ji et al., 2006). However, this might have 
been due to the presence of the endogenous Skp2 and therefore knocking down the 
endogenous Skp2 might achieve an effect. This could be achieved by transiently 
knocking down Skp2 or cyclin A and transfecting in relevant Skp2 or cyclin A 
functional mutant constructs.  
There are several possible roles for CDK2/cyclin A within the SCF complex to 
contribute to the ubiquitination of p27. One is the recruitment of p27 to the complex. 
Secondly, CDK2/cyclin A could have a role in the stabilisation of the complex. And 
finally, perhaps the role of CDK2/cyclin A is to retain p27 within the SCFSkp2 complex 
until it is competed off of CDK2/cyclin A by Skp2. Previous investigations into the role 
of the Skp2/cyclin A interaction indicate a role for the Skp2/cyclin A interaction in 
regulation of the cell cycle and apoptosis. Increased levels of p27 could lead to cell 
cycle arrest at G1 phase, however, it is unclear whether increased p27 levels might 
lead to apoptosis.  
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5.2.2	Role	of	the	Skp2/cyclin	A	interaction	in	Skp2	phosphorylation	
CDK2/cyclin A phosphorylates Skp2 at Ser64 (Yam et al., 1999). Phosphorylation at 
Ser64 leads to stabilisation of Skp2 by interfering with its interaction with Cdh1. Skp2 
is dephosphorylated by Cdc14B during M phase and early G1 phase (Rodier et al., 
2008). Ji and co-workers investigated whether the association of Skp2 with cyclin A 
is required for phosphorylation of Skp2 and found that Skp2 4A can be 
phosphorylated by CDK2/cyclin A at Ser64 (Ji et al., 2006). They concluded that a 
stable interaction between Skp2 and cyclin A is not required for Skp2 phosphorylation.  
5.2.3	Role	of	the	Skp2/cyclin	A	interaction	in	Cdh1	association	
Cdh1 is a substrate recognition component of the APC/C, involved in the 
ubiquitination of Skp2 which leads to its degradation via the 26S proteasome (Bashir 
et al., 2004, Wei et al., 2004). It was established that phosphorylation of Skp2 at 
Ser64, Ser72 and Ser75 by CDK2/cyclin A, Akt, Pim1, casein kinase I (CKI) and 
possibly other kinases protects Skp2 from binding to Cdh1 and therefore stabilises 
Skp2 (Rodier et al., 2008, Cen et al., 2010, Inuzuka et al., 2012, Gao et al., 2009). 
The findings of Gao et al. (2009) were conflicting as they found that although these 
phosphorylation events stabilise Skp2 levels, they do not directly block Cdh1 binding. 
Gao and co-workers also reported that the Skp2/cyclin A interaction is required for 
recruitment of Skp2 to the APCCdh1 complex. They transfected a Skp2 4A construct 
into HEK293T and found that as well being unable to bind cyclin A, it was also unable 
to pull down Cdh1. This result suggests that Skp2 binds to Cdh1 in complex with 
cyclin A (Gao et al., 2009). However, this seems contradictory as Skp2 was found to 
be stabilised by phosphorylation by CDK2/cyclin A and hence the Skp2/cyclin A 
interaction would be believed to promote stabilisation of Skp2 (Rodier et al., 2008). 
5.3	Mutagenesis	and	sub-cloning	to	create	Skp2	and	cyclin	A	mutant	
constructs	in	mammalian	vectors	
A pcDNA3 plasmid containing the Skp2 gene sequence was purchased from 
Addgene (Plasmid number 19947). The Skp2 6A mutant sequence with 3’UTR was 
synthesised by IDT. A SDM reaction was used to mutate Ala22 and Ala24 back to 
tryptophans, thus creating the 4A mutant. After sequencing the insert, both the Skp2 
4A and Skp2 6A mutants were then PCR amplified and inserted into a pcDNA3 vector 
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from Addgene from which WT Skp2 had been removed by EcoRI and HindIII 
restriction digestion. The primers for the InFusion cloning are shown in Appendix A, 
Table A1.3. 
A pcDNA5/FRT/TO/NEO plasmid containing the cyclin A gene sequence was provide 
by Keiko Yata (Gurdon Institute, Cambridge). Mutations were made to the plasmid 
sequence to create cyclin A mut 5 and mut 7 and these constructs were then 
confirmed by sequencing. The cyclin A sequences were then PCR amplified and re-
inserted via InFusion cloning into a non-mutated vector stock which had been 
digested with HindIII and BamH1. This step was to control for the possibility of the 
vector backbone being altered during the mutagenesis reaction. Primers for the 
InFusion cloning are shown in Appendix A, Table A1.3. Different methods were used 
to make the Skp2 and cyclin A mutant plasmids because of a delay in delivery of the 
synthetic Skp2 6A sequence. The plasmids generate Myc-tagged Skp2 and Flag-
tagged cyclin A, respectively. 
5.4	Validating	the	Skp2	and	cyclin	A	mutants	in	HeLa	cells	
5.4.1	Cyclin	A	and	Skp2	test	expression	in	HeLa	cells	
HeLa cells were chosen to transiently express the mutant cyclin A and Skp2 
constructs as a HeLa cell line in which the CDKN1B gene that encodes p27 had been 
replaced with a gene to express p27 T187D mutant protein, was available in the lab. 
This cell line would be useful in distinguishing any possible effects of the Skp2/cyclin 
A interaction on phosphorylation of p27. 
Initially, a co-transfection was done with varying concentrations of the Skp2 and cyclin 
A plasmids to determine their expression levels (Figure 5.2). All of the constructs were 
expressed well, even at the lowest concentration of 0.375 µg plasmid DNA per well. 
0.75 µg/well was chosen as an appropriate concentration for subsequent transfection 
experiments. For the subsequent co-immunoprecipitation experiments, cells were 
seeded onto 10 cm dishes. 4.5 µg/dish of each plasmid were used for these 
experiments (scaled up from 6-well plates according to the Mirius Bioscience LT-1 
transfection protocol). 
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5.4.2	Analysis	of	Skp2	and	cyclin	A	mutants’	binding	capabilities	in	HeLa	cells	
A co-immunoprecipitation experiment was then carried out (Figure 5.3) using anti-
Flag antibodies to pull-down cyclin A interacting proteins and using anti-Myc and anti-
Skp2 to detect Myc-Skp2 in the eluate. This and the following co-immunoprecipitation 
experiments were carried out as described in Chapter 2, Section 12.5. The co-
immunoprecipitation data seemed to suggest that the Skp2 and cyclin A mutants 
retain their ability to bind to each other (Figure 5.3). However, there was no change 
in the electrophoretic mobility of Skp2 4A and 6A in the immunoblot whilst there was 
a mobility change in the whole-cell lysate (WCL) sample. It is possible that the anti-
Myc antibody could be binding to endogenous c-MYC, but a c-MYC/cyclin A 
interaction has not been reported. As Skp2 was originally identified in an anti-cyclin A 
immunoprecipitation in HeLa cells (Zhang et al., 1995), one would assume that the 
CDK2/cyclin A/Skp2 complex is the principal cyclin A containing complex particularly 
when Skp2 is overexpressed. The lysate was incubated with control agarose resin for 
30 minutes as per the Pierce classic IP protocol (Thermo Fisher) in order to remove 
any agarose binding proteins before the immunoprecipitation experiment. You would 
not expect, therefore, that Myc-Skp2 was being co-immunoprecipitated non-
specifically. 
Figure 5.2: Expression of Flag-cyclin A and Myc-Skp2 constructs in HeLa cells. 
Flag-cyclin A and Myc-Skp2 were transiently co-transfected into HeLa cells using the 
indicated amounts of DNA. Cells were seeded in a 6-well plate. Cells were lysed after 
24 hours, and 20 ng total protein was loaded into each well of the gel. GAPDH was used 
as a loading control. 
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Figure 5.4 shows that Skp2 is being co-immunoprecipitated by cyclin mut 5 and mut 
7 and Skp2 4A and Skp2 6A are being co-immunoprecipitated with WT cyclin A. The 
weak binding to one another might be sufficient for complex formation in this 
experiment. In order to test this hypothesis further, both Skp2 6A and cyclin A mut 7 
were co-transfected together in order to further decrease the stability of the complex 
(Figure 5.4). 
Figure 5.3: The mutations made to Skp2 and cyclin A do not appear to block 
their interaction in HeLa cells. HeLa cells were transfected with the indicated 
Myc-Skp2 and Flag-cyclin A constructs. Cells were lysed 24 hours after 
transfection.  
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5.4.3	Determining	the	role	of	Cks1	in	CDK2/cyclin	A/Cks1/Skp2	complex	formation	
5.4.3.1	Generation	of	a	Skp2	mutant	deficient	in	Cks1	binding		
A second co-immunoprecipitation experiment was carried out in HeLa cells. The most 
effective Skp2 mutant (Skp2 6A) was co-transfected with the most effective cyclin A 
mutant (cyclin A mut 7) in order to see if the combined effect of knocking out binding 
sites on both interacting partners would block the interaction. Again, no reduction in 
binding was observed between Skp2 and cyclin A (Figure 5.4). Furthermore, cyclin A 
and Skp2 were probed using anti-cyclin A and anti-Skp2 antibodies and this confirmed 
that Skp2 was being pulled down. It is possible that the interaction between Skp2 and 
cyclin A is being bridged via CDK2 and Cks1 (Figure 5.5). Cks1 was probed in the 
co-immunoprecipitation-Western blots and bands were visible in all lanes at 
Figure 5.4: Blocking the Skp2/cyclin A interaction by mutation of both Skp2 and 
cyclin A does not appear to disrupt CDK2/cyclin A/Skp2 complex formation in 
HeLa cells. HeLa cells were transfected with the indicated Myc-Skp2 and Flag-cyclin 
A constructs. Cells were lysed 24 hours after transfection.  
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approximately 25 kDa (data not shown). This value is an unexpectedly high molecular 
weight for Cks1 which has a calculated molecular weight of 9 kDa. A search of Cks1 
antibodies led to the finding that many of the antibodies available against Cks1 also 
bind to a protein of about 25 kDa, but the antibody suppliers identify Cks1 as a lower 
molecular weight band. As there were no bands on the Western blot below that at 25 
kDa, it seemed that Cks1 was not in fact being pulled down in the HeLa cell co-
immunoprecipitations.  
	
 
 
 
5.4.3.2	Use	of	a	HTRF	assay	to	assess	the	interactions	between	Skp2	mutants	and	Cks1	
In order to further test whether the interaction with Cks1 bridges Skp2 and cyclin A, a 
mutant of Skp2 was identified which is unable to bind to Cks1. A Homogenous Time 
Resolved Fluorescence (HTRF) assay was developed to test the effect of mutations 
Figure 5.5: Model of the Skp1/Skp2/CDK2/cyclin A/Cks1 complex. Pairwise 
interactions which form this complex are Skp1-Skp2, Skp2-Cks1, Cks1-CDK2, 
CDK2-cyclin A and Skp2-cyclin A. This is a superimposed structure of 
Skp1/Skp2/Cks1 (PDB: 2AST), CDK2/Cks1 (PDB: 1BUH) and CDK2/cyclin A/p27 
(PDB: 1JSU), created by Dr Julie A Tucker. 
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on the Skp2/Cks1 interaction (Figure 5.6). This work was carried out by Judith Reeks, 
who developed the assay, carried out the site-directed mutagenesis, purified the 
protein and ran the assay. A GST-tagged C-terminal construct of Skp2 (residues 96-
424, N-terminally GST-tagged) was used without cleavage of the GST tag. This C-
terminal Skp2 fragment (Skp2-C) is only soluble when bound to Skp1, so again the 
two proteins were co-expressed in E. coli. The GST tag binds to a terbium-labelled 
anti-GST antibody. Cks1 was N-terminally Avi-tagged, which allows for its 
biotinylation. A dye-labelled streptavidin binds to Cks1-biotin. When Skp2 and Cks1 
are in close proximity due to interaction between them, fluorescence energy transfer 
is observed and fluorescence is emitted at 665 nm.  
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The binding affinity of Skp2 WT for Cks1 was measured at around tens of nanomolar 
(Figure 5.6), which is in close agreement with the published Kd of 14 nM (Seeliger et 
al., 2003). Analysis of the Skp2/Cks1 interface suggested that Phe393 might be 
required for Cks1 binding and mutation might block the Skp2/Cks1 interaction (Figure 
5.7). Mutation of Phe393 to arginine or aspartate did not affect binding (data not 
shown). Mutation of Phe393 to glycine and serine, however, resulted in total loss of 
binding (Figure 5.6). This is perhaps through a similar mechanism as seen with cyclin 
Figure 5.6: Use of an HTRF assay to identify a mutation which leads to 
inhibition of the Skp2/Cks1 interaction. The assay format is shown in the upper 
panel. Skp2 binds to Cks1 with a Kd in the 10s of nanomolar range. When Phe393 
of Cks1 is mutated to Gly and Ser, the interaction with Skp2 is lost. 
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A mut 5 and mut 7, where the introduction of an extra residue creates a bulge which 
blocks the interaction. 
	
 
5.4.3.3	 Blocking	 both	 cyclin	 A	 and	 Cks1	 binding	 to	 Skp2	 does	 not	 appear	 to	 block	
Skp2/CDK2/cyclin	A	complex	formation	in	HeLa	cells	
The F393GS mutation was made in the Skp2 WT and Skp2 6A constructs in order to 
investigate the role of Cks1 in mediating the binding interaction between Skp2 and 
cyclin A. However, the CDK2/cyclin A/Skp2 complex was still formed (Figure 5.8). 
There are two bands in lane 2 of the anti-Skp2 blot. The lower band is likely to be 
endogenous Skp2 which does not have a Myc-tag. Skp2 6A + F393GS might 
therefore show slightly reduced binding as it might be binding less WT cyclin A, 
allowing WT endogenous Skp2 to be co-immunoprecipitated. The lack of a band for 
endogenous Skp2 in lane 3 suggests that the mutants might be working somewhat 
Figure 5.7: Phe393 of the C-terminal tail of Skp2 sits in a pocket of Cks1. 
Phe393 is shown as sticks with carbon atoms in green and interacts with a pocket 
on the surface of Cks1. The Cks1 surface is colour coded according to 
hydrophobicity. PDB:2AST, figure created using CCP4MG. 
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as predicted from the in vitro work (Chapter 3). Flag-cyclin A mut 7, which is 
immobilised on the beads in this case, does not bind any endogenous Skp2 (no lower 
band for Skp2 in lane 3). Although the F393GS mutant of Skp2 did not provide an 
unambiguous answer as to whether Cks1 plays a role in the maintenance of the 
Skp2/cyclin A interaction in HeLa cells, it provides an additional tool mutation to 
investigate the potential effect of blocking the Skp2/Cks1 interaction in cell-based 
assays. 
	
 
 
5.5	Validating	the	Skp2/cyclin	A	interaction	in	HEK293T	cells	
5.5.1	Cyclin	A	and	Skp2	test	expression	in	HEK293T	cells	
As the results obtained from the HeLa co-immunoprecipitation experiments were 
unexpected from the published results (Ji et al., 2006) and in vitro characterisation of 
the Skp2 and cyclin A mutants (Chapter 3 and 4), other cell lines were explored in 
Figure 5.8: Introducing the Skp2 F393GS mutation to Skp2 6A does not 
disrupt the CDK2/cyclin A/Skp2 interaction in HeLa cells. HeLa cells were 
transfected with the indicated Myc-Skp2 and Flag-cyclin A constructs. Cells were 
lysed 24 hours after transfection.  
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order to validate the in vitro results. As the Skp2 4A mutation had been validated in 
cell-based assays using HEK293T cells (Ji et al., 2006), a co-immunoprecipitation 
experiment was carried out in these cells in an effort to reproduce the literature and 
validate cyclin A mut 5 and 7 and Skp2 6A. An expression test was first carried out, 
and again there were good expression levels (Figure 5.9). Again, 4.5 µg/10 cm dish 
of each plasmid were transfected.  
 
5.5.2	Mutation	of	Skp2	and	cyclin	A	at	 the	 identified	binding	sites	blocks	 their	
interaction	in	HEK293T	cells	
In contrast to what was seen in HeLa cells, when co-immunoprecipitation was carried 
out in HEK293T cells, using anti-Flag antibody to pull down Flag-cyclin A interacting 
proteins, there was a marked reduction in the binding of Skp2 4A and 6A to WT cyclin 
A and cyclin A mut 5 and 7 to WT Skp2 (Figure 5.10). Despite the apparent lack of 
effect of binding interface mutations on formation of the Skp2/cyclin A complex in 
HeLa cells, in HEK293T cells, the blot clearly shows reduced complex formation 
(Figure 5.10). Here, a change in the electrophoretic migration for Skp2 4A and 6A is 
observed in both the WCL and the immunoprecipitates.  Lanes 2 and 3 show that 
there is some endogenous Skp2 binding to the Flag-cyclin A WT. This is not seen in 
Figure 5.9: Expression levels of Flag-cyclin A and Myc-Skp2 constructs in 
HEK293T cells. Flag-cyclin A and Myc-Skp2 were transiently co-transfected into 
HEK293T cells using the indicated amounts of DNA. Cells were seeded in a 6-well 
plate. Cells were lysed after 24 hours. GAPDH was used as a loading control. 
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lanes 4 and 5 as Flag-cyclin A mut 7, which is deficient in Skp2-binding, is immobilised 
on the beads. There is less Skp2 4A and Skp2 6A being immunoprecipitated with 
cyclin A WT, which is in agreement with the literature (Ji et al., 2006) and with the ITC 
results (Chapter 4).  
	
 
 
5.6	Cyclin	A	binding	to	Skp2	is	not	required	for	Skp2	recognition	by	the	
APCCdh1	complex	
As the effect of the binding interface mutations on Skp2/cyclin A complex formation 
has been validated in HEK293T cells, the functional significance of the interaction 
Figure 5.10: In HEK293T cells, the Skp2/cyclin A interaction is blocked by 
introduction of mutations at the putative Skp2/cyclin A binding interface. 
HEK293T cells were transfected with indicated Myc-Skp2 and Flag-cyclin A constructs. 
Cells were lysed 24 hours after transfection.  
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could then be probed. Initially, another co-immunoprecipitation was carried out in 
order to investigate the effects of the mutations on the ability of Skp2 to bind to Cdh1. 
In this investigation, the most effective mutants were used, Skp2 6A and cyclin A mut 
7. Endogenous Cdh1 was immobilised onto beads via an anti-Cdh1 antibody. It was 
found that Skp2 does not require cyclin A in order to bind to Cdh1 (Figure 5.11). This 
immunoprecipitation experiment suggests that Skp2 and cyclin A bind to Cdh1 
independently of one another.  The levels of Cdh1 immobilised in lane 3 are less than 
in the other lanes in Figure 5.11. Cdh1 was too dilute in the WCL to be detected and 
therefore it couldn’t be determined whether this was due to lower total levels of Cdh1 
for this sample compared to the others. The levels of Skp2 appear to be decreased 
in this sample, and cyclin A levels appear to be decreased when probing with an anti-
Flag antibody, but not when probed with an anti-cyclin A antibody. 
	
 
 
Figure 5.11: Skp2 does not require cyclin A to bind Cdh1. Cdh1 antibody was 
immobilised on agarose resin. HEK293T cells were transfected with the indicated 
Myc-Skp2 and Flag-cyclin A constructs. Cells were lysed 24 hours after 
transfection.  
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5.7	Discussion	
5.7.1	Validation	of	mutations	at	the	Skp2/cyclin	A	interface	
Using the mutants of Skp2 and cyclin A defective in complex formation as judged by 
in vitro experiments (see Chapters 3 and 4) a co-immunoprecipitation was carried out 
in order to determine whether disruption of these sites are sufficient to disrupt complex 
formation in cellulo. As the constructs which were expressed in cell lines were of the 
full-length proteins, this validates that other regions of Skp2 (C-terminus) and cyclin 
A (N-terminus) are not contributing towards the interaction with each other. 
Co-immunoprecipitation was used to determine the effectiveness of the cyclin A and 
Skp2 mutations at disrupting complex formation in HeLa and HEK293T cells. The 
Skp2/cyclin A interaction appeared to be intact in HeLa cells when the mutants were 
introduced. Despite further investigations into the potential role of Cks1, which binds 
to both Skp2 and CDK2 and therefore could allow for complex formation, an 
explanation for this result has not been found as Cks1 could not be detected in the 
samples. One explanation is that the Cks1 antibodies used in the immunoprecipitation 
experiments are not very efficient. One way of overcoming this difficulty with the Cks1 
antibody would be to transfect in exogenous tagged Cks1 and probe for the tag. When 
the co-immunoprecipitation experiment was carried out in HEK293T cells, the Skp2 
and cyclin A mutants did show reduced binding to one another and the amount of 
protein pulled down was consistent with the in vitro ITC data. These data are 
consistent with that of Ji et al. (2006). 
The high level of expression in HeLa cells could mean that the concentrations of the 
interacting partners were so high that they were still able to form an interaction when 
either binding partner were mutated. In order to control for this, Skp2 6A was 
cotransfected with cyclin A mut 7 such that the binding sites on either protein would 
be deficient for binding to each other. This should disrupt the interaction even in the 
context of overexpression. However, the interaction between Skp2 6A and cyclin A 
mut 7 appeared to be intact (Figures 5.3 and 5.4). Alternatively, the antibody could 
bind non-specifically to the overexpressed proteins. A control such as a non-specific 
isotype control antibody would allow for any non-specific background binding to be 
detected. 
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5.7.2	 Role	 of	 cyclin	 A	 in	 Skp2	 recognition	 and	 ubiquitination	 by	 the	 APCCdh1	
complex	
The interaction between Skp2 and Cdh1 was then investigated in HEK293T cells. 
Gao and co-workers found that Skp2 requires cyclin A for binding to Cdh1 in 
HEK293T cells (Gao et al., 2009). However, the data presented here show that a 
Skp2 mutant which is unable to bind cyclin A, can bind to Cdh1. Equal amounts of 
Skp2 6A and Skp2 WT were pulled down, and similarly cyclin A mut 7 can be pulled 
down just as effectively as WT cyclin A (Figure 5.11). However, this method is unable 
to show whether Skp2 and cyclin A bind simultaneously or mutually exclusively to 
Cdh1.  
There is considerable interplay between Cdh1 and cyclin A. Cyclin A contains a D-
box motif which interacts with Cdh1 (Geley et al., 2001) and cyclin A has a role in 
dissociating Cdh1 from the APC/C complex. Cdh1 binds to cyclin A through the RXL 
motif within the Cdh1 C-terminal domain (Sørensen et al., 2001, Mitra et al., 2006). 
By mutating the RXL site of Cdh1, its interaction with the APC is stabilised. 
CDK2/cyclin A is able to phosphorylate Cdh1, and this phosphorylation is inhibitory 
and may serve to release Cdh1 from the APC/C core (Lukas et al., 1999, Sorensen 
et al., 2000). Phosphorylation of Cdh1 is an additional mechanism which could lead 
to the stabilisation of Skp2 by CDK2/cyclin A. Cdh1 is also involved in the ubiquitin-
mediated degradation of cyclin A (Sørensen et al., 2001). In summary, there are many 
mechanisms which could lead to the discrepancy between the results presented here 
and that of Gao and co-workers, such as the phosphorylation status of Cdh1 and/or 
Skp2. There are also differences in the way in which this experiment was done 
compared to the study reported by Gao and co-workers (Gao et al., 2009). Firstly, 
they used an anti-Flag antibody which would recognise their Flag-Skp2 constructs as 
the immobilised ‘bait’, whereas here an anti-Cdh1 antibody and endogenous Cdh1 
was the immobilised ‘bait’. Secondly, in the published investigation, only Skp2 
constructs were transfected whereas here Skp2 and cyclin A constructs were co-
transfected such that both proteins would be overexpressed. 
It is reported in this chapter that the Skp2/cyclin A interaction is not required for 
binding of Skp2 to Cdh1. There is controversy in the literature over the role of 
CDK2/cyclin A in the recognition of Skp2 by the APCCdh1 complex. It was reported that 
Ser64 phosphorylation by CDK2/cyclin A stabilises Skp2 suggesting that 
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phosphorylation can protect Skp2 from degradation via the APCCdh1 complex. Others 
have reported, however, that phosphorylation of Ser64 might not block the direct 
Skp2/Cdh1 interaction as incubation of Skp2 with Pim1 which phosphorylates Skp2 
on Ser64, Ser72 and Ser417 did not disrupt the Skp2/Cdh1 interaction (Cen et al., 
2010).  
There may be many routes of indirect CDK2/cyclin A stabilisation of Skp2. For 
example through CDK2/cyclin A activity on Akt. Akt phosphorylation, but not Akt 
abundance, fluctuates throughout the cell cycle. A recent report from the Pandolfi and 
Wei groups (Liu et al., 2014) found that Akt phosphorylation mirrors the expression 
pattern of cyclin A. Decreased CDK2/cyclin A, but not cyclin E, results in decreased 
Akt phosphorylation and Akt1 was identified as a CDK2/cyclin A substrate. 
Phosphorylation of Akt by CDK2/cyclin A is mediated through the RXL motifs of Akt. 
Phosphorylation of Akt by CDK2/cyclin A at Ser477 and Thr479 leads to increased 
Ser72 phosphorylation of Skp2, Skp2 stabilisation and increased proliferation. They 
further showed that Akt phosphorylation at Ser477 and Thr479 triggers Ser473 and 
Thr308 phosphorylation by mTORC2 and PDK1, respectively, leading to full activation 
of Akt, and therefore increased phosphorylation of Ser72 of Skp2 (Liu et al., 2014). 
Therefore it is possible that an increased CDK2/cyclin A activity would lead to 
increased stabilisation through Akt rather than directly through Ser64 
phosphorylation. Another route to Skp2 stabilisation by CDK2/cyclin A is through 
CDK2/cyclin A phosphorylation of Cdh1 at Ser36, Ser40 and Thr121 which promotes 
β-TrCP-mediated ubiquitination and subsequent degradation of Cdh1 (Fukushima et 
al., 2013).  
5.7.3	Final	comments	
Due to time constraints, the effects on ubiquitination of p27 when Skp2 and cyclin A 
are replaced with binding interface mutants were not investigated. Ji and co-workers 
tested whether their Skp2 4A mutant retained its ability to ubiquitinate p27 (Ji et al., 
2006). They found that p27 ubiquitination was unaffected by the introduction of these 
mutations. Their assay involved the use of proteins purified from HEK293T cell lysates 
and an in vitro ubiquitination assay. Other investigations which would be useful for 
identifying the functional significance of the Skp2/cyclin A interaction are discussed in 
Chapter 6. 
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Validation in HEK293T cells of the mutations that block the Skp2 and cyclin A 
interaction is a starting point from which to investigate the functional significance of 
this interaction. 
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Chapter	6:	Concluding	remarks	and	
future	directions	
6.1	The	Skp2/cyclin	A	interaction	
Mutation of cyclin A residues 244 to 247 is sufficient to block the Skp2/cyclin A 
interaction. The mutations do not cause structural rearrangements as determined by 
X-ray crystallography and circular dichroism; do not destabilise the CDK2/cyclin A 
complex as shown by thermal stability analysis; do not affect CDK2/cyclin A kinase 
activity; and do not disrupt its interaction with CDK2 or p27. Taken together, these 
results show that this is a novel interaction site on cyclin A. This result is also in 
agreement with the finding that Skp2 does not bind to the RXL recruitment site of 
cyclin A (Ji et al., 2006).  
This work has built on the findings of Ji and colleagues, who identified four residues 
of Skp2 which contribute to the interaction with cyclin A (Ji et al., 2006) with two 
additional tryptophan residues of Skp2 being shown to contribute to the interaction of 
Skp2 with cyclin A (Chapter 4). Mutating all six residues leads to nearly complete loss 
of binding. Monomeric CDK2 was shown not to bind to Skp2, showing that although 
the physiological complex incorporates CDK2, cyclin A alone interacts with Skp2.  
The Skp2 and cyclin A mutations have been created in Skp2 and cyclin A constructs 
in mammalian vectors (Chapter 5), and therefore, this interaction is primed to be 
interrogated in cellulo. Analysis will include characterising the effects of the mutations 
on cellular localisation of Skp2, cell cycle and p27 ubiquitination. Ji and co-workers 
characterised the effect of Skp2 4A overexpression in U2OS cells and found that this 
caused a higher proportion of cells to accumulate in G1 phase. The authors also 
reported an unexpected finding that there was no change in p27 ubiquitination and 
degradation upon Skp2 4A overexpression (Ji et al., 2006). Future work will aim to 
confirm this observation in a wider range of cell lines and to extend it to characterise 
the functions of Skp2 6A. 
Cyclin A acts as a substrate recruiter for CDK2. It is required for CDK2 activation and 
certain substrates are selected by cyclin A through binding to the RXL recruitment 
site, however, Skp2 is not recruited to CDK2/cyclin A through the RXL site. It has 
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been shown that Skp2 does not need to bind cyclin A in order to be phosphorylated 
on Ser64 by CDK2/cyclin A, through use of the Skp2 4A mutant (Ji et al., 2006). This 
finding could be confirmed using cyclin A mut 7 in a kinase assay against Skp2. A 
kinase assay could also be employed to determine whether Skp2 might have a 
regulatory role when it binds to CDK2/cyclin A. For example, Skp2 might affect the 
phosphorylation of other substrates of CDK2/cyclin A. 
Cyclin A is closely related to cyclin E and both are involved in the activation of CDK2, 
however Skp2 cannot bind to cyclin E (Ji et al., 2006). There is disagreement in the 
literature as to whether CDK2/cyclin E and CDK2/cyclin A are equivalent in their ability 
to stimulate p27 ubiquitination. Zhu and co-workers have found that CDK2/cyclin A 
stimulates the ubiquitination of p27 to a greater extent than CDK2/cyclin E when p27 
is already phosphorylated (Zhu et al., 2004). Whereas, Montagnoli and co-workers 
found that there is no difference in the ability of CDK2/cyclin A and CDK2/cyclin E to 
stimulate the ubiquitination of unphosphorylated p27 (Montagnoli et al., 1999). This 
experiment measured both the ability of CKD2/cyclin A to phosphorylate p27 and 
stimulate its ubiquitination, which may be the cause of the discrepancy in the findings. 
Phosphorylation of p27 at Thr187 is often attributed to CDK2/cyclin E rather than 
CDK2/cyclin A, due to this event primarily occurring in G1 phase. A further 
understanding of the roles of CDK2/cyclin E and CDK2/cyclin A in the ubiquitination 
of p27 would be aided by knowing whether cyclin A binds to the Skp2 N-terminus in 
order to facilitate ubiquitination of p27 or whether there is an alternative role of the 
Skp2/cyclin A interaction. Therefore, the cyclin A and Skp2 mutants described in this 
thesis could be used to further investigate the role of cyclin A in p27 ubiquitination. 
6.1.1	The	functional	significance	of	the	Skp2/cyclin	A	interaction	
The Skp2 and cyclin A mutants described in this thesis are reagents which can be 
used to probe the functional significance of the Skp2/cyclin A interaction in cells. 
Some studies have hypothesised that cyclin A has a role in p27 ubiquitination within 
the SCFSkp2 complex through its interaction with Skp2 (Sitry et al., 2002, Zhu et al., 
2004, Montagnoli et al., 1999);, which is consistent with CDK2/cyclin A, and not 
CDK2/cyclin E, having a kinase-independent role in p27 ubiquitination. whereas 
others have suggested that the Skp2/cyclin A interaction is not required for the 
ubiquitination of p27. Instead it has been proposed that this interaction is required for 
proper cell cycle progression, and that attenuation of this interaction leads to 
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dysregulation of the cell cycle and apoptosis in Rb-deficient cells (Ji et al., 2006, Ji et 
al., 2007, Lu et al., 2014). The role of the CDK2/cyclin A complex in the ubiquitination 
of p27 could be deciphered using the cyclin A and Skp2 mutants described in our 
investigation. The mutants could additionally be used to determine whether 
attenuation of the Skp2/cyclin A interaction causes a G1 block or leads to apoptosis. 
As the cellular distribution of Skp2 is regulated by its N-terminus, it would also be 
possible to see whether cyclin A binding might affect the subcellular distribution of 
Skp2 in the cell.  
6.2	 Is	 Skp2	 and	 p27	 mutually	 exclusive	 binding	 to	 CDK2/cyclin	 A	
functional?	
p27 is able to bind to cyclin A mut 7 and the mutations do not have an effect on the 
kinase activity of the CDK2/cyclin A complex (Chapter 3, Sections 7.3 and 7.4). Ji and 
co-workers reported that Skp2 is able to protect CDK2/cyclin A from p27-mediated 
inhibition (Ji et al., 2006). However, p27 was found to bind more tightly than Skp2 to 
CDK2/cyclin A (Chapter 3, Sections 6 and 7.3). Taken together, these results suggest 
that only when Skp2 is in large excess can the inhibition of CDK2/cyclin A by p27 be 
disrupted by Skp2. 
p27 is phosphorylated by oncogenic tyrosine kinases on Tyr74 and Tyr88, such as 
cSrc, prior to Thr187 phosphorylation by CDK2/cyclin A (Grimmler et al., 2007). 
Tyrosine phosphorylation of p27 weakens the binding of p27 to CDK2/cyclin A, and 
leads to its partial activation. Skp2 and p27 compete for binding to cyclin A, and this 
investigation has found that p27 binds about 10 times stronger than Skp2 (compare 
Figures 3.13 and 3.25 and see Appendix A, Section A2 for replicates of this 
experiment). Furthermore, the binding of p27 might be measured at a stronger binding 
affinity with optimisation, as the Kd has previously been reported at 3.5 nM (Lacy et 
al., 2004). Both Tyr74 and Tyr88 are in the region of p27 which contacts CDK2, with 
Tyr88 occupying the ATP-binding pocket. p27 would be expected to bind to the 
SCFSkp2 complex when phosphorylated at Tyr74, Tyr88 and Thr187 as the interaction 
of p27 with cSrc occurs predominantly during G1 phase (Chu et al., 2007). Tyr88 
phosphorylation is also expected to precede phosphorylation of p27 at Thr187 and 
p27 ubiquitination as mutation of Tyr88 of p27 to phenylalanine leads to stabilisation 
of p27 in mouse embryonic fibroblasts (MEFs) (Grimmler et al., 2007). It might be 
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possible, therefore, that Skp2 can compete p27 off the CDK2/cyclin A complex after 
p27 is phosphorylated at Tyr74 and Tyr88 and recruited to the SCFSkp2 complex. One 
way of testing whether Skp2 can compete off Tyr74 and Tyr88 phosphorylated p27 
would be through creation of a phosphomimetic mutant and assessing whether this 
mutant binds to CDK2/cyclin A less tightly than WT Skp2. If p27 binding to 
CDK2/cyclin A were reduced to the point it was weaker than Skp2, this would suggest 
that when p27 is recruited to the SCFSkp2 complex, there is a handover of CDK2/cyclin 
A. Competition binding assays such as pull-down assays or biophysical methods, 
such as ITC, could be employed in order to determine whether Skp2 is able to 
compete off Tyr74 and Tyr88-phosphorylated p27. 
6.3	 Role	 of	 Ser72	 phosphorylation	 in	 Skp2	 regulation	 and	 cyclin	 A	
binding	
Studies over the past seven years have increasingly pointed towards the importance 
of the phosphorylation and acetylation state of Skp2 within and around the NLS 
(PRKRLKS, residues 66-72, Figure 6.1) being important for its activity and regulation 
(Gao et al., 2009, Inuzuka et al., 2012, Rodier et al., 2008, Lin et al., 2009). These 
models would suggest that Skp2 activity may be attenuated by inhibition of the 
kinases responsible. A number of Akt substrates interact with 14-3-3 proteins after 
Akt-mediated phosphorylation, which in turn results in a change in phosphoprotein 
localisation (Brunet et al., 2002, Fujita et al., 2003, Sekimoto et al., 2004). Skp2 
interacts with 14-3-3β and Akt phosphorylation of Skp2 significantly enhances this 
interaction (Lin et al., 2009, Gao et al., 2009). Gao and colleagues found that 
suppression of Akt led to increased levels of p27, but observed that this resulted from 
reduction in Skp2 Ser72 phosphorylation which would otherwise stabilise Skp2 
through reducing its binding to Cdh1 (Gao et al., 2009). Lin and co-workers reported 
that Ser72 phosphorylation promoted SCFSkp2 complex formation and enhanced the 
ubiquitination of p27 (Lin et al., 2009). The result from Lin and colleagues is surprising 
as it has been shown that the Skp2 N-terminus is dispensable for SCFSkp2 complex 
formation as assessed by SEC (Hao et al., 2005). Furthermore, they found that 
suppression of the Akt pathway led to impaired SCFSkp2 complex formation and 
although Skp2 WT and Skp2 S72D readily complex with endogenous Skp1 and Cul1, 
the binding of Skp2 S72A was found to be significantly impaired. Inhibition of PI3K by 
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LY294002 also prevented SCFSkp2 formation. In contrast to Akt inhibition, however, 
PI3K inhibition also prevented Skp1 binding to Cul1 suggesting that this is a broad 
effect on Cul1-containing SCF complexes (Lin et al., 2009).  
Determining whether these phosphorylation events affect the interaction of Skp2 with 
Cdh1 or affect the stability of Skp2 through another mechanism could be relevant to 
identifying alternative routes of inhibition of Skp2. For example, upregulation of Akt 
results in stabilisation of Skp2 and increased degradation of p27 (Gao et al., 2009), 
and therefore Akt inhibitors might be indicated for tumours with increased levels of 
Skp2. 
 
 
 
The question of the role of Ser72 phosphorylation in the regulation of SCFSkp2 activity 
is discussed by Ecker and Hengst (2009) and they proposed that Ser72 
phosphorylation might induce a structural rearrangement which permits SCF 
assembly. On the other hand, Rodier and colleagues have shown that mutation of 
Ser64 and Ser72 to alanines did not affect SCF complex assembly or activity. They 
showed that unphosphorylated Skp2 was able to bind to cyclin A with a Kd in the range 
of a few hundreds of nM. If Ser72 phosphorylation were required for complex 
Figure 6.1: Schematic representation of Skp2. The F-box and LRRs are 
required for the ubiquitin ligase function of Skp2. Skp2 is regulated through its N-
terminal domain which contains many sites subject to post-translational 
modification or involved in interactions with other regulatory proteins of which a 
subset are indicated. Adapted from Ecker and Hengst (2009). 
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assembly, it would therefore not be expected to act by mediating the binding of cyclin 
A. This prediction could be confirmed through the use of a phosphomimetic Skp2 
mutant (for example, the S72D mutation), in order to determine whether cyclin A 
binding is altered or whether p27 ubiquitination is affected. 
There are additional suboptimal Akt consensus phosphorylation sites in Skp2, 
including Thr21 (Gao et al., 2009, Lin et al., 2009), the phosphorylation of which could 
affect SCFSkp2 complex formation through effects on cyclin A binding (Figure 6.1). In 
the study by Lin and colleagues, Akt was overexpressed and the effect on SCF 
formation were determined through pull-down experiments (Lin et al., 2009). 
Therefore, in this study, Thr21 could have been phosphorylated as well as Ser72. Lin 
and co-workers then investigated whether Thr21 is phosphorylated by Akt, and 
determined that a Skp2 T21A mutation lead to reduced phosphorylation of Skp2 upon 
incubation with Akt. The Skp2 T21A mutant is somewhat deficient in its formation of 
a complex with SCF in an in vitro assay. The tryptophan residues of Skp2 at positions 
22 and 24 were identified in this investigation as important for its interaction with cyclin 
A, and therefore phosphorylation of Thr21 by Akt could conceivably affect cyclin A 
binding. 
6.4	The	Skp2/Cdh1	interaction	
As well as investigating how the phosphorylation status of Skp2 affects its stability 
and ability to bind Cdh1, Gao and co-workers found that the Skp2 4A mutant is unable 
to pull down Cdh1 suggesting that Skp2 is presented to the APCCdh1 complex in 
association with cyclin A (Gao et al., 2009). In contrast, this investigation has found 
that Skp2 mutants, that are unable to bind cyclin A, can bind Cdh1 and the ability of 
Skp2 to bind Cdh1 was not compromised by mutations in either Skp2 or cyclin A 
(Figure 5.11). WT and Skp2-binding deficient cyclin A were also pulled down by Cdh1 
indicating that cyclin A binds to both Cdh1 and Skp2, and that cyclin A might compete 
with Skp2 for binding to Cdh1. It is unclear whether phosphorylation of Skp2 directly 
or indirectly protects Skp2 from binding to Cdh1. Further investigation is warranted to 
determine whether Skp2 is required to be unphosphorylated or part of a specific 
complex in order to be ubiquitinated by the APCCdh1 complex. Test expressions of 
recombinant human Cdh1 in E. coli generated very low to negligible levels of proteins 
(Appendix B). Yeast Cdh1 is routinely expressed by other labs, using an insect cell 
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expression system (He et al., 2013, da Fonseca et al., 2011). Therefore, human Cdh1 
might also be amenable to recombinant expression in insect cells for future 
experiments.  
6.5	The	role	of	Spy1	in	the	ubiquitination	of	p27	
Spy1 is a cell cycle regulator involved in activating CDKs (Porter et al., 2002). It 
associates with p27 and inhibits p27-induced cell cycle arrest (Porter et al., 2003). 
Spy1 has been found to be involved in tumourigenesis of breast cancer (Al Sorkhy et 
al., 2012), it is a critical factor in the stem-like properties of neuroblastoma (Lubanska 
and Porter, 2014) and has a role in the development of hepatocellular carcinoma 
(HCC, (Ke et al., 2009)). It was found that Spy1 can phosphorylate p27 on Thr187 
when in complex with CDK2 and it can also promote p27 ubiquitination and increased 
degradation (McAndrew et al., 2007). Spy1 is not closely related to the cyclins, 
however it is most similar to cyclin A2. This together with its role in degradation of p27 
opens up the possibility that Spy1 might be able to bind Skp2 and perhaps aid the 
ubiquitination of p27 in a non-catalytic fashion as observed with CDK2/cyclin A (Zhu 
et al., 2004). One way of testing this hypothesis would be to phosphorylate p27 or use 
a phosphomimetic mutant and then assess whether a kinase dead CDK2/Spy1 
complex might be able to enhance the ubiquitination of p27. 
6.6	Structural	studies	of	Skp2	
The structure of all but the N-terminal 97 residues of Skp2 has been characterised. 
The flexibility of the Skp2 N-terminus means it is not amenable to crystallisation, at 
least in the absence of other proteins that might order the sequence. Identifying the 
region of Skp2 which is involved in the interaction with cyclin A has led to attempts to 
crystallise a Skp2 N-terminal peptide with CDK2/cyclin A. The finding that the first 20 
residues of Skp2 are not required for binding to cyclin A also prompted attempts to 
crystallise a truncated Skp2 (20-140) with CDK2/cyclin A. Despite more detailed 
knowledge of the cyclin A binding site, the Skp2 N-terminus has hitherto remained 
refractory to crystallisation. Alternative CDK2/cyclin A crystallisation conditions have 
been identified but did not yield a ternary CDK2/cyclin A/Skp2 peptide structure. 
Deletion of the residues between the cyclin A binding site and the F-box of Skp2 might 
help to generate a less flexible structure. SAXS data was collected for the 
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CDK2/cyclin A/Skp1/Skp2-N complex, but further analysis is required to reconcile it 
with the crystal structures of its constituent sub-complexes.  
With the increased interest in the N-terminal regulatory region of Skp2 and its 
interaction with Cdh1 shown by literature publications (see Appendix B), it would also 
be of interest to crystallise a peptide of Skp2 with Cdh1. Recently, yeast Cdh1 has 
been co-crystallised with an Acm1 peptide which inhibits Cdh1 activity (He et al., 
2013). The structure revealed the mechanism of binding between Cdh1 and a D-box 
motif. Only the WD40 domain of yeast Cdh1 was used and this should be sufficient 
for binding to Skp2.  
6.7	Final	conclusions	
This investigation has set out to characterise protein-protein interactions of Skp2 
which could be targeted for drug design. The Skp2/cyclin A interaction was 
interrogated using mutagenesis and in vitro biophysical assays. The binding sites on 
either protein were identified in an in vitro system and futher tested in cellulo. The 
Skp2 and cyclin A mutants created are useful reagents to probe this interaction 
further. Investigating the phenotypic effect of the mutations to Skp2 and cyclin A in 
cellulo will provide insights into functional mechanisms of Skp2 and what effect would 
be achieved by inhibition of the Skp2/cyclin A interaction. The cyclin A-binding site on 
Skp2 has guided crystallisation experiments, and despite the lack of success in 
crystallisation of CDK2/cyclin A with Skp2 to date, knowledge has been gained as to 
what might be successful in future crystallisation trials. 
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Appendix	A	
Table A1.1: Recipes for common lab reagents 
Modified HEPES-buffered saline 
(mHBS) 
40 mL 1 M HEPES stock 
20 mL 5 M NaCl stock 
Make solution up to just less than 1 L 
and adjust pH with 5 M NaOH to pH 7.0 
1 mL of 1 M DTT stock 
10 x Tris-glycine running buffer (for 
Biorad gels used for Western blotting) 
Buffer was made up to 1 x with dH2O 
144 g Glycine 
30 g Tris base 
10 g SDS 
Make solution up to 1 L 
Tris-Glycine transfer buffer 40 mL Novex transfer buffer solution 
(Life Technologies) 
40 ml methanol 
Make up to 1 L ddH2O 
Tris-buffered saline with Tween 20 
(TBST) 
6.06 g Tris base 
30 mL 5 M NaCl stock 
500 µL Tween 20 
Make up to just less than 1 L and adjust 
pH with concentrated HCl to pH 7.6 
1% (w/v) agarose gels 0.5 g agarose (Ultrapure from 
Invitrogen) 
Make up to 50 mL in 1 x TAE 
(Invitrogen) 
Microwave for 1 ¾ minutes 
Add 5 µL of SYBR safe (Life 
Technologies) once cooled and pour gel 
 
SDS running buffer (TEO-Tricine-SDS) for running Expedeon gels was purchased from 
Expedeon. 
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Table A1.2: Oligonucleotide primer sequences for mutagenesis of cyclin A, Skp2 
and CDK2, respectively 
Primer 
name 
strand template 
plasmid 
Primer sequence 5' to 
3' 
%GC 
content 
length 
(N) 
% 
mismatch 
Tm 
(°C) 
Mut9 forward WT cyclin 
A 
ACC AAG AAA CAA 
GTT CTG ACA ATG 
GAG CAT CTA GTT 
TTG 
38 39 2.6 77.2 
Mut 9 reverse WT cyclin 
A 
CAA AAC TAG ATG 
CTC CAT TGT CAG 
AAC TTG TTT CTT 
GGT 
38 39 2.6 77.2 
Mut10 forward WT cyclin 
A 
GAG CAT CTA GTT 
TTG AAA GTC CTT 
AAG TTT AGG TTA 
GCT GCT CCA ACA 
GTA AAT CAG 
39 57 8.8 76.8 
Mut10 reverse WT cyclin 
A 
CTG ATT TAC TGT 
TGG AGC AGC TAA 
CCT AAA CTT AAG 
GAC TTT CAA AAC 
TAG ATG CTC 
39 57 8.8 76.8 
Mut5 forward WT cyclin 
A 
GAT AGG TTC CTG 
TCT TCC CAG GAA 
AAT GTG CTG AGA 
GGA AAA CTT CAG 
46 45 8.9 76.5 
Mut5 reverse WT cyclin 
A 
CTG AAG TTT TCC 
TCT CAG CAC ATT 
TTC CTG GGA AGA 
CAG GAA CCT ATC 
46 45 8.9 76.5 
Mut 101 forward WT cyclin 
A 
CAGATGATACCTACA
GCGGGGACCAAGTT
CTGAGAATGG 
51 39 12.8 68.7 
Mut 101 reverse WT cyclin 
A 
CCATTCTCAGAACTT
GGTCCCCGCTGTAG
GTATCATCTG 
51 39 12.8 68.7 
Mut102 forward Mut 101 GTACATTACAGATGG
TGCCTGCAGCGGGG
ACCAAGTTCTGAG 
55 42 7.1 71.3 
Mut102 reverse Mut 101 CTCAGAACTTGGTCC
CCGCTGCAGGCACC
ATCTGTAATGTAC 
55 42 7.1 71.3 
Mut103 forward Mut 104 GTTCTGACAATGGAG
CTTATGATTATGAAA
GTCCTTACTTTTGAC 
36 45 11.1 64.5 
Mut103 reverse Mut 104 GTCAAAAGTAAGGAC
TTTCATAATCATAAG
CTCCATTGTCAGAAC 
36 45 11.1 64.5 
Mut104 forward Mut 9 GATACCTACACCAAG
AAAGAAATTCTGACA
ATGGAGCTTATG 
38 42 4.8 64.5 
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Primer 
name 
strand template 
plasmid 
Primer sequence 5' to 
3' 
%GC 
content 
length 
(N) 
% 
mismatch 
Tm 
(°C) 
Mut104 reverse Mut 9 CATAAGCTCCATTGT
CAGAATTTCTTTCTT
GGTGTAGGTATC 
38 42 4.8 64.5 
Mut105 forward Mut 10 GAATGGAGCATCTA
GTTATGAAAGCCCTT
AAGTTTAGGTTAGCT
G 
40 45 4.4 66.4 
Mut105 reverse Mut 10 CAGCTAACCTAAACT
TAAGGGCTTTCATAA
CTAGATGCTCCATTC 
40 45 4.4 66.4 
Mut106 forward Mut 105 CTAGTTATGAAAGCC
CTTAAGTGGAGGTTA
GCTGCTCCAAC 
46 41 9.8 67.5 
Mut106 reverse Mut 105 GTTGGAGCAGCTAA
CCTCCACTTAAGGG
CTTTCATAACTAG 
46 41 9.8 67.5 
Mut107 forward Mut 5 CATTGATAGGTTCCT
GGCTACCCAGGAAA
ATGTGCTGAGG 
50 40 5 68.6 
Mut107 reverse Mut 5 CCTCAGCACATTTTC
CTGGGTAGCCAGGA
ACCTATCAATG 
50 40 5 68.6 
    
 
 
 
    
Primer 
name 
strand template 
plasmid 
Primer sequence 5' to 
3' 
%GC 
content 
length 
(N) 
% 
mismatch 
Tm 
(°C) 
Skp2 
AA1 
forward Skp2 WT TCC AGC AAG ACT 
TCT GAA GCG GCG 
TCA GGC ATG GGC 
GTC TCC 
62.0 42 9.5 81 
Skp2 
AA1 
reverse Skp2 WT GGA GAC GCC CAT 
GCC TGA CGC CGC 
TTC AGA AGT CTT 
GCT GGA 
62.0 42 9.5 81 
Skp2 
AA2 
forward Skp2AA1 GTC AGG CAT GGG 
CGT CGC CGC CGC 
GGA GAA AGA GGA 
GCC 
72 39 10.3 83 
Skp2 
AA2 
reverse Skp2AA1 GGC TCC TCT TTC 
TCC GCG GCG GCG 
ACG CCC ATG CCT 
GAC 
72 39 10.3 83 
Skp2 
F20 
forward Skp2 WT GGAGTTCTGTTCCAG
GGCCCCTTCACGTG
GGGATGGGATTCCA
G 
61 44  N/A 90.4 
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Primer 
name 
strand template 
plasmid 
Primer sequence 5' to 
3' 
%GC 
content 
length 
(N) 
% 
mismatch 
Tm 
(°C) 
Skp2 
F20 
reverse Skp2 WT CTGGAATCCCATCCC
CACGTGAAGGGCCC
CTGGAACAGAACTC
C 
61 44  N/A 90.4 
Skp2 
S30 
forward Skp2 WT GGAGTTCTGTTCCAG
GGGCCCTCTGAACT
GCTGTCAGGCATGG
G 
61 44   90.4 
Skp2 
S30 
reverse Skp2 WT CCCATGCCTGACAG
CAGTTCAGAGGGCC
CCTGGAACAGAACT
CC 
61 44   90.4 
Skp2 
W22AW
24A 
forward Skp2 WT 
and 
Skp2AA2 
CACCAGCTTCACGG
CGGGAGCGGATTCC
AGCAAG 
65 34 11.7 76.6 
Skp2 
W22AW
24A 
reverse Skp2 WT 
and 
Skp2AA2 
CTTGCTGGAATCCG
CTCCCGCCGTGAAG
CTGGTG 
65 34 11.7 76.6 
Skp2 
D25A 
K28A 
forward Skp2 WT 
and 
Skp2AA2 
GTGGGGATGGGCTT
CCAGCGCGACTTCT
GAACTGC 
63 35 8.5 79.5 
Skp2 
D25A 
K28A 
reverse Skp2 WT 
and 
Skp2AA2 
GCAGTTCAGAAGTC
GCGCTGGAAGCCCA
TCCCCAC 
63 35 8.5 79.5 
Skp2 
K68L 
K71L 
forward Skp2 WT GAGCCCGCCACGGC
TACGGCTGCTGAGC
AAAGGGAGTGAC 
68 40 20 72.5 
Skp2 
K68L 
K71L 
reverse Skp2 WT GTCACTCCCTTTGCT
CAGCAGCCGTAGCC
GTGGCGGGCTC 
68 40 20 72.5 
Skp2 
S72E 
forward Skp2 WT CACGGAAACGGCTG
AAGGAGAAAGGGAG
TGACAAAGAC 
53 38 7.9 77.4 
Skp2 
S75E 
forward Skp2 WT CGGCTGAAGAGCAA
AGGCGAAGACAAAG
ACTTTGTGATTGTCC 
49 43 9.3 76.6 
Skp2 
S72E 
reverse Skp2 WT GTCTTTGTCACTCCC
TTTCTCCTTCAGCCG
TTTCCGTG 
53 38 7.9 77.4 
Skp2 
S72A 
S75A 
forward Skp2 WT GAAACGGCTGAAGG
CCAAAGGGGCTGAC
AAAGACTTTGTG 
53 40 10 76.3 
Skp2 
S72A 
S75A 
reverse Skp2 WT CACAAAGTCTTTGTC
AGCCCCTTTGGCCTT
CAGCCGTTTC 
53 40 10 76.3 
Skp2 
S64A 
forward Skp2 
S72A 
S75A 
CTGGGACACCCGGA
GGCACCACCACGGA
AACGG 
70 33 11 78.7 
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Primer 
name 
strand template 
plasmid 
Primer sequence 5' to 
3' 
%GC 
content 
length 
(N) 
% 
mismatch 
Tm 
(°C) 
(phosph
o-null) 
Skp2 
S64A 
(phosph
o-null) 
reverse Skp2 
S72A 
S75A 
CCGTTTCCGTGGTG
GTGCCTCCGGGTGT
CCCAG 
70 33 11 78.7 
        
Primer 
name 
strand template 
plasmid 
Primer sequence 5' to 
3' 
%GC 
content 
length 
(N) 
% 
mismatch 
Tm 
(°C) 
CDK2 
L25D 
forward CDK2 
WT 
GAGTTGTGTACAAAG
CCAGAAACAAGGAC
ACGGGAGAGGTG 
51 41 7.3 78.6 
CDK2 
L25D 
reverse CDK2 
WT 
CACCTCTCCCGTGTC
CTTGTTTCTGGCTTT
GTACACAACTC 
51 41 7.3 78.6 
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Table A1.3: Oligonucleotide primer sequences for InFusion sub-cloning of Skp2, 
cyclin A and Cdh1 
primer 
name strand 
cloning 
site 
15 bp 
overhangs 
insert-specific 
sequence 
%GC 
content 
length 
(N) 
Tm 
(°C) 
Cyclin A 
AE mut 
forward  BamHI AGCAAAT
GGGTCGC
G 
GAGTCCCAGA
CTATCACGAA
GATATCCACA
CC 
50 32 62 
Cyclin A 
AE mut 
reverse EcoRI TGTCGAC
GGAGCTC
G 
AATCACAGGT
TCAGGGTTTC
CGGCGGGTTC
AG 
56 32 68 
Cdh1 FL 
POPIN  
forward  KpnI AAGTTCTG
TTTCAGG 
GCCCGCGGAA
ACCCACCCGC
AAGATCTC 
68 28 70 
Cdh1 FL 
POPIN  
reverse HindIII ATGGTCTA
GAAAGCT 
TTACGAACGG
GTTTTGCTAAA
GACGTTCCAG 
45 31 62 
Cdh1 
WD40 
POPIN 
forward  KpnI AAGTTCTG
TTTCAGG 
CCCGCGGAAA
CCCACCCGCA
AGATCTC 
67 27 68 
Cdh1 
WD40 
POPIN 
reverse HindIII ATGGTCTA
GAAAGCT 
TTACGAACGG
GTTTTGCTAAA
GACGTTCCAG 
45 31 62 
pcDNA3 
myc-
Skp2 
forward  EcoRI GGAAGAT
CTGGAATT 
CCCGGGGATC
CCCATGGAC 
74 19 63 
pcDNA3 
myc-
Skp2 
reverse HindIII CATGCTC
GAGAAGC
T 
TACATTTTATG
TTAGCTGGTG
GACTGACGC 
43 30 60 
pcDNA5 
flag-
cyclin A 
forward  HindIII GTTTAAAC
TTAAGCT 
TGAGGAGATA
GAACCATGG 
47 19 51 
pcDNA5 
flag-
cyclin A 
reverse BamHI CTGGACT
AGTGGAT
C 
CTTACTTGTCA
TCGTC 
44 16 43 
 
 
 
Gene sequences were synthesised by IDT, subcloned into IDTsmart vectors, 
PCR amplified using the above primers, and then inserted into pET21d for 
cyclin A global mutant, POPIN J/M for Cdh1 constructs, pcDNA3 for Skp2, or 
pcDNA5 for cyclin A after restriction digestion using the indicated restriction 
enzymes. 
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Table A1.4: Summary of constructs used for in vitro experiments 
Protein  Residue numbers Vector backbone Tag 
Skp1 1-163 with ‘loops out’* pGEX-6P-1 none 
Skp2-N 1-140 pGEX-6P-1 N-terminal GST 
Skp2-C 89-424 Not determined GST 
CDK2 1-298 pGEX-6P-1 N-terminal GST 
Cyclin A 174-432 pET21d C-terminal His  
Cdh1 1-496 (FL) POPIN J/ POPIN M N-terminal GST/ 
MBP 
Cdh1 165-478 POPIN J/ POPIN M N-terminal GST/ 
MBP 
RbCT 792-928 pGEX-2T GST 
 
*Skp1 ‘loops out’ is lacking residues 38-43; and 67-81 is replaced with DGGSG (single 
letter amino acid code) as these loops are susceptible to protease-sensitive (Schulman 
et al., 2000). 
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A2:	Replicate	ITC	experiments	
The following ITC data are replicates of ITC data not shown in the main body of this 
thesis. 
CDK2/cycllin A (WT) interaction with Skp1/Skp2-N (WT) 
The interaction between CDK2/cyclin A and Skp1/Skp2-N has been tested with 
multiple protein preparations. The replicate experiment shown here between 
CDK2/cyclin A global mut and mut 7 with Skp1/Skp2-N was carried out using a different 
protein preparation to that shown in the main body of the thesis. The replicate 
experiments shown here of CDK2/cyclin A mut 5 with Skp1/Skp2-N and CDK2/cyclin 
A with Skp1/Skp2-N 6A were carried out with the same protein preparation as that 
shown in the main body of the thesis.  
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CDK2/cyclin A global mut interaction with Skp1/Skp2-N 
 
CDK2/cyclin A mut 7 interaction with Skp1/Skp2-N 
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CDK2/cyclin A mut 5 interaction with Skp1/Skp2-N 
 
CDK2/cyclin A interaction with Skp1/Skp2-N 6A 
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Appendix	B	
This appendix describes experiments designed to investigate the binding of Skp2 to 
Cdh1. These experiments are related to those in the main body of the thesis and due 
to time restraints, were not able to be completed.  
B1	 Regulation	 of	 Skp2	 by	 Cdh1	 binding,	 and	 post-translational	
modification	of	the	N-terminus	of	Skp2	
Skp2 is degraded by the APCCdh1 complex in mitosis and early G1. Cdh1 is itself 
degraded by the SCFβTrCP1 complex in S and G2 phases of the cell cycle. It was found 
that CDK2/cyclin A phosphorylates Cdh1, and this promotes its degradation. 
CDK2/cyclin A is required to phosphorylate Cdh1 to prime it for subsequent 
phosphorylation by Plk1 (Fukushima et al., 2013). Plk1 plays important roles in mitotic 
entry and exit, and in cytokinesis (Bahassi, 2011).  Cyclin A binds to a conserved RXL 
motif at the C-terminus of Cdh1. Sorensen et al. (2000) observed that mutation of the 
RVL motif of Cdh1 stabilises its interaction with the APC/C complex. Interestingly, the 
Cdh1 RXL to AAA mutant lost its capability to promote ubiquitination of cyclin A 
suggesting that this motif is required for cyclin A ubiquitination, as well as CDK2/cyclin 
A-mediated phosphorylation of Cdh1 (Sorensen et al., 2000). Cdh1 can be inactivated 
by binding of the inhibitory proteins Acm1 (APCCdh1 modulator 1) and Emi1 (early 
mitotic inhibitor 1), which act as pseudosubstrates binding to Cdh1 through D-box and 
KEN motifs to block Cdh1 interaction with substrates (Ostapenko et al., 2008, 
Machida and Dutta, 2007). The structure of Cdh1 in complex with Acm1 was 
published in 2013 by the Barford group (Chan et al., 2013), and the structure revealed 
the mechanism of binding of D-box and KEN motifs. Substrates interact with the 
WD40 β-propeller domain of Cdh1 (Chan et al., 2013). The D-box binds to an inter-
blade groove of this domain. Skp2 contains a D-box at the extreme N-terminus, 
however, a KEN box motif has not been identified within Skp2. 
Acetylation of Skp2 by p300 at Lys68 and Lys71 has been shown to promote its 
nuclear export (Inuzuka et al., 2012). Lys68 and Lys71 are adjacent to the Akt 
phosphorylation site at Ser72. p300 is an adenoviral E1A-binding protein with a role 
in histone acetylation and transcriptional co-activation. It is involved in the p53 and 
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Rb pathways, and may be a factor in the ability of Skp2 to further drive cancer 
progression of Rb- and p53-deficient tumours (Iyer et al., 2004). Elevated levels of 
p300 have been reported to be correlated with proliferation, and predict poor outcome 
in prostate cancer (Debes et al., 2003). p300 was also found to be subject to androgen 
regulation. Androgen deprivation results in up-regulation of p300. Truncating 
mutations of p300 (Gayther et al., 2000) and loss of heterozygosity (Iyer et al., 2004) 
have also been reported in human cancers.  
Cdh1 is unable to bind to Skp2 when Skp2 is acetylated at Lys68 and Lys71, further 
confirming that Cdh1 binds to the Skp2 N-terminus. Mimicking the acetylation through 
mutagenesis leads to increased oncogenicity through increased cytoplasmic 
localisation of Skp2 and increased ubiquitination of E-cadherin by Skp2, leading to its 
degradation. The degraded E-cadherin results in increased migration as determined 
by in vitro wound healing assays (Inuzuka et al., 2012). SIRT3 was identified as a 
deacetylase capable of removing the acetylation from Skp2 and hence, restores the 
nuclear localisation of Skp2 (Inuzuka et al., 2012).  
Acetylation of Skp2 at Lys68 and Lys71 was reported to cause Skp2 dimerisation. 
The potential of Skp2 to dimerise upon acetylation was investigated because p300-
mediated acetylation has been reported to induce dimerization of other substrates 
(Tang et al., 2007, Yuan et al., 2005, Inuzuka et al., 2012). Inuzuka and co-workers 
showed that an acetylation-mimetic mutant of Skp2 was able to pull down other Skp2 
molecules and, when chemically crosslinked, a proportion of the acetylated Skp2 runs 
at twice the expected molecular weight on an immunoblot. 
Increased Akt- and p300-mediated modification of Skp2 leads to increased stability 
of Skp2 and increased oncogenicity. Skp2 could therefore act as a receptor for Akt 
and p300 activity and through Skp2, Akt and p300 could orchestrate their oncogenic 
roles. The role of Skp2, and its oncogenic potential appears to be dependent on 
acetyl- and phosphorylation status, cellular localisation and regulator-bound status. 
B1.1	Establishing	a	method	of	human	Cdh1	purification	
In order to investigate the binding of Skp2 to Cdh1 in in vitro experiments, a method 
of expressing and purifying large quantities of Cdh1 must be established. There is an 
established protocol for recombinant production of yeast Cdh1, however, there are no 
reports in the literature for human Cdh1. Cdh1 is about 55 kDa, and is predicted to 
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have an unstructured N-terminal sequence of about 180 residues preceding a 7-
bladed β-propeller fold known as a WD40 domain. 
A codon optimised human Cdh1 gene sequence was synthesised by IDT. It was sub-
cloned into POPIN J and POPIN M vectors from the Oxford Protein Production Facility 
(OPPF). The advantage of these vectors is that they are compatible with expression 
in E. coli, insect cells and HEK293 cells. POPIN J encodes an N-terminal His tag and 
GST tag upstream of the protein of interest, and POPIN M encodes an N-terminal His 
tag and MBP tag. 
Cdh1 in both POPIN M and J vectors were transformed into a three E. coli strains for 
test expression. The test expression was done with an undergraduate student, Robert 
Bloxham. The E. coli cells were grown to an OD600 of 0.5 and then the temperature 
was reduced to 18°C and expression was initiated with addition of 100 µM IPTG. 
Expressing proteins at low temperatures can be favourable for protein folding and 
stability as it decreases the rate of protein synthesis. Cdh1 was expressed overnight 
at 18°C as robust expression can often lead to formation of inclusion bodies 
composed of insoluble aggregates of the expressed protein. The cells were harvested 
and lysed using BugBuster reagent (Merck Millipore). GST and MBP beads were used 
to capture any tagged protein which had been expressed. Samples were taken at 
every stage to track which band corresponded to Cdh1. Unfortunately, it appeared 
that no Cdh1 was expressed (data not shown).  
With the additional GST or MBP tags, the Cdh1 fusion protein is about 80 and 98 kDa 
in size, respectively. E. coli generally does not express large proteins very well, and 
therefore expression levels might be improved by truncating the protein. Residues 1-
164 of Cdh1 were removed in order to obtain a construct similar to the yeast Cdh1 
sequence, which has been expressed in insect cells and subsequently crystallised 
(Figure B1) (Chan et al., 2013). 
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The truncated Cdh1 sequences in the POPIN J vector was transformed into E. coli 
Arctic Express (Agilent) and E. coli BL21 Star (DE3) (Life Technologies) strains in 
order to test expression. E. coli Arctic Express cells are optimised for expression of 
proteins at low temperatures, and co-express cold-adapted chaperonins. E. coli BL21 
Star (DE3) cells are optimised for high-level expression of proteins.  The cells were 
grown, induced and purified as described for the full-length Cdh1. Results are shown 
in Figure B2. 
 
Figure B1: Sequence alignment of the structurally characterised yeast 
Cdh1 WD40 domain with full-length human Cdh1. The structurally 
characterised S. cerevisiae Cdh1 sequence is from da Fonseca et al. (2011). 
Uniprot codes P53197 (S. cerevisiae Cdh1), Q9UM11 (human Cdh1). 
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The E. coli chaperone protein, GroEL, which is involved in helping protein folding is 
about 60 kDa. GroEL could be the upper band of lanes 4, 5, 9 and 10. GroEL forms 
an oligomeric complex around proteins, and if a protein is associated with GroEL, 
there is a 14 to 1 molar ratio of GroEL to protein (Braig et al., 1994). As the GroEL 
binds to the glutathione-Sepharose beads, this might suggest that there is some Cdh1 
being expressed. Extra bands appear after 3C protease is added. The band around 
55 kDa is likely to be GST-3C protease. The middle band could be the Cdh1 WD40 
domain, which is about 37 kDa in size, or the extra bands could be contaminants from 
the 3C protease stock solution.  
Human Cdh1 might not be amenable to expression in E. coli. Insect cells offer the 
advantage of increasing the likelihood of correct folding and they support post-
translational modifications. Test expressions in E. coli were not continued with the 
Figure B2: Cdh1 WD40 domain test expression in Arctic Express and BL21 Star 
(DE3) E. coli strains. Lanes 1 and 7 are the WCLs, lanes 2 and 8 are the unbound 
proteins which have passed through the column, lanes 3 and 9 are the eluates and 
lanes 4 and 10 are the eluates with 3C protease added. 3C protease is about 46 kDa 
but runs at about 52 kDa. 
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aim of continuing work in Sf9 insect cells. However, due to time constraints, this work 
was not further pursued. 
B2	Analysis	of	the	Skp2	N-terminal	post-translational	modification	sites	
In order to test the effect of N-terminal post-translational modifications of Skp2 on 
Cdh1-binding in in vitro experiments, a set of mutants were created with residue 
changes designed to mimic these modifications. The mutagenesis reactions were 
performed by two summer students, Robert Bloxham and Hannah Fuller. These 
mutants are shown in Table B1 and primers used in the mutagenesis reactions are 
shown in Appendix A, Table A1.2. 
Skp2 mutants: 
S64A S72A S75A 
S72E 
S75E 
K68L K71L 
 
As recombinant Cdh1 was not available, it was decided to test the hypothesis that 
acetylation of Skp2 residues 68 and 71 leads to dimerization. On SEC columns, the 
Skp1/Skp2-N complex runs at an unusually high apparent molecular weight, and at a 
similar elution volume to the CDK2/cyclin A complex and the GST dimer which are 65 
kDa and 52 kDa in size, respectively. As the Skp1/Skp2-N complex is about 33 kDa 
in size, it is possible that Skp1/Skp2-N exists as a dimer. An acetylation-induced 
dimerization event might lead to formation of an alternate dimer forming or a dimer of 
dimers. Analytical gel filtration was initially carried out in order to see if the Skp2 K68L 
K71L mutant elutes at a different volume than the WT protein. 
Skp2 K68L K71L was purified according to the standard Skp2 expression protocol, 
and the mutations did not seem to affect the stability of the protein. The results of the 
subsequent SEC experiment were not definitive as Skp1/Skp2 WT and the acetylation 
mimetic mutant run at similar elution volumes. The small shift to a higher molecular 
weight observed would not warrant the conclusion that the Skp1/Skp2-N K68L K71L 
complex dimerises (Figure B3). One cannot exclude, however, the possibility that 
rather than forming a dimer of dimers, an alternate dimer has been formed. This result 
Table B1: Mutants of Skp2 created to 
test effects of phosphorylation and 
acetylation on binding of Skp2 to Cdh1. 
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was inconclusive and therefore size-exclusion chromatography-multi-angle laser light 
scattering (SEC-MALLS) was utilised in order to further determine the oligomeric 
state, and whether dimerization occurs upon acetylation.  
 
B3	Analysis	of	the	oligomeric	state	of	Skp1/Skp2-N	K68L	K71L	by	SEC-
MALLS	
It was decided to analyse the absolute molecular weights of Skp2 WT and K68L K71L 
so as to establish whether acetylation does induce dimerisation. SEC-MALLS is a gel 
filtration-based method of obtaining robust data on the oligomeric states of proteins. 
This technique is described in Chapter 2 Section 9. 
Figure B3: Analytical SEC chromatograms for Skp1/Skp2 WT and 
Skp1/Skp2-N K68L K71L using a Superdex 200 10/30 column. Protein 
complexes were fully purified prior to this experiment. The Skp1/Skp2-N WT trace 
is normalised to the Skp1/Skp2-N K68L K71L trace to account for differences in 
concentration. 
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The SEC-MALLS instrument was calibrated with BSA immediately prior to this 
experiment. The instrument was run at 0.5 mL/minute in mHBS pH 7.0 (Figure B4). 
	
	
 
Figure B4: SEC-MALLS data for Skp1/Skp2-N WT and Skp1/Skp2-N 
K68L K71L. The calculated molecular weight of Skp1/Skp2-N WT is about 
32 700 kDa. Experiment was run at room temperature. 1 mL fractions of the 
eluate were collected. 
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The SEC-MALLS data show that both the Skp1/Skp2 WT and acetylation mimetic 
mutant are heterodimers in solution with no tendency to form oligomeric states. The 
elution profile shown in Figure B3 indicates a small shift to a lower elution volume in 
the elution profile of the Skp1/Skp2-N K68L K71L complex compared to the WT Skp2 
complex. This might result from a change in conformation of N-terminus, with a more 
elongated protein running at a higher molecular weight than expected. SEC elution 
profiles are dependent on the shape as well as the size of a protein, suggesting that 
there might be a structural rearrangement of the Skp2 N-terminal region upon 
acetylation. SEC-MALLS is not affected by the shape of a protein, and therefore 
provides an absolute value for the size of a protein, or complex. 
The Skp1/Skp2-N complexes showed some degradation during the SEC-MALLS 
experiment as shown by the tail on both peaks in Figure B4, and the emergence of 
the lower molecular weight bands in Figure B5. The reason for the degradation is not 
clear, as Skp1/Skp2-N is usually stable at room temperature for a few hours.  
Figure B5: SDS-PAGE analysis of Skp1/Skp2-N input and eluate 
fractions from the SEC-MALLS experiment. Fractions shown cover the 
eluted peak.  
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B4	Discussion	
This chapter has detailed the Cdh1 constructs and Skp2 mutants created in order to 
test the effect of post-translational modification of Skp2 on Cdh1 binding in in vitro 
assays. This investigation has shown that mimicking Skp2 acetylation using K to L 
mutations did not induce dimerization. This investigation does not rule out, however, 
that the dimerization observed in cells may occur ‘end-to-end’ with the C-terminus of 
one Skp2 monomer binding to the acetylated residues of a second. The Skp2 
construct used in this work is truncated and starts at residue 140. As the K to L 
mutation was used in the paper by Inuzuka and co-workers who reported 
dimerization, it is reasonable to assume that this mutation would have a similar effect 
in vitro as in vivo (Inuzuka et al., 2012). However, there could be an additional post-
translational modification which follows the acetylation in vivo which induces the 
dimerization, and this would only be observed in cell-based assays. 
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